

Consensus proposals for a unified system of nomenclature

Hepatology

42, 962-973

DOI: [10.1002/hep.20819](https://doi.org/10.1002/hep.20819)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Basic Residues in Hypervariable Region 1 of Hepatitis C Virus Envelope Glycoprotein E2 Contribute to Virus Entry. <i>Journal of Virology</i> , 2005, 79, 15331-15341.	3.4	74
2	Comparative analysis of hepatitis C virus phylogenies from coding and non-coding regions: the 5' untranslated region (UTR) fails to classify subtypes. <i>Virology Journal</i> , 2006, 3, 103.	3.4	25
3	Evidence of recombination in quasispecies populations of a Hepatitis C Virus patient undergoing anti-viral therapy. <i>Virology Journal</i> , 2006, 3, 87.	3.4	26
4	Evidence of structural genomic region recombination in Hepatitis C virus. <i>Virology Journal</i> , 2006, 3, 53.	3.4	38
5	Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 2310-2315.	7.1	338
6	Identification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 Binding. <i>Journal of Virology</i> , 2006, 80, 8695-8704.	3.4	232
8	Effect of Ribavirin in Genotype 1 Patients With Hepatitis C Responding to Pegylated Interferon Alfa-2a Plus Ribavirin. <i>Gastroenterology</i> , 2006, 131, 1040-1048.	1.3	183
10	Chronic hepatitis C virus infection: genotyping and its clinical role. <i>Future Microbiology</i> , 2006, 1, 103-112.	2.0	50
11	Peginterferon and Ribavirin for Chronic Hepatitis C. <i>New England Journal of Medicine</i> , 2006, 355, 2444-2451.	27.0	433
12	Hepatitis C virus in elderly cancer patients. <i>European Journal of Internal Medicine</i> , 2006, 17, 325-329.	2.2	30
13	Virology of hepatitis B and C viruses and antiviral targets. <i>Journal of Hepatology</i> , 2006, 44, S10-S13.	3.7	33
14	Preparation of hepatitis C virus structural and non-structural protein fragments and studies of their immunogenicity. <i>Protein Expression and Purification</i> , 2006, 50, 43-48.	1.3	12
15	Hepatitis C Virus Serologic and Virologic Tests and Clinical Diagnosis of HCV-Related Liver Disease. <i>International Journal of Medical Sciences</i> , 2006, 3, 35-40.	2.5	90
17	Eighth Major Clade for Hepatitis Delta Virus. <i>Emerging Infectious Diseases</i> , 2006, 12, 1447-1450.	4.3	180
18	Risk factors and prevalence of hepatitis virus B and C serum markers among nurses at a tertiary-care hospital in Mexico City, Mexico: a descriptive study. <i>Annals of Hepatology</i> , 2006, 5, 276-280.	1.5	23
19	Clinical virology of hepatitis C virus. <i>Future Virology</i> , 2006, 1, 649-657.	1.8	0
21	Diversity and origin of hepatitis C virus infection among unpaid blood donors in the Netherlands. <i>Transfusion</i> , 2006, 46, 1719-1728.	1.6	28
22	Safety Pharmacology, Toxicology and Pharmacokinetic Assessment of Recombinant Human omega-Interferon Produced from CHO-SS Cells. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006, 99, 62-70.	2.5	11

#	ARTICLE	IF	CITATIONS
23	Using maximum likelihood method to detect adaptive evolution of HCV envelope protein-coding genes. <i>Science Bulletin</i> , 2006, 51, 2236-2242.	1.7	0
24	Genotypic variations around the world: Is hepatitis C virus evolving?. <i>Current Hepatitis Reports</i> , 2006, 5, 142-149.	0.3	4
25	Study of a novel hypervariable region in hepatitis C virus (HCV) E2 envelope glycoprotein. <i>Virology</i> , 2006, 352, 357-367.	2.4	50
26	A target on the move: Innate and adaptive immune escape strategies of hepatitis C virus. <i>Antiviral Research</i> , 2006, 69, 129-141.	4.1	109
27	A jumping profile Hidden Markov Model and applications to recombination sites in HIV and HCV genomes. <i>BMC Bioinformatics</i> , 2006, 7, 265.	2.6	85
28	The clinical and physiological spectrum of interferon-alpha induced thyroiditis: Toward a new classification. <i>Hepatology</i> , 2006, 43, 661-672.	7.3	172
29	Hepatitis C databases, principles and utility to researchers. <i>Hepatology</i> , 2006, 43, 1157-1165.	7.3	36
30	Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. <i>Hepatology</i> , 2006, 43, 1385-1391.	7.3	302
31	Hepatitis C virus genotype distribution among intravenous drug user and the general population in Hong Kong. <i>Journal of Medical Virology</i> , 2006, 78, 574-581.	5.0	42
32	Surveillance of the genetic variation in incident HIV, HCV, and HBV infections in blood and plasma donors: Implications for blood safety, diagnostics, treatment, and molecular epidemiology. <i>Journal of Medical Virology</i> , 2006, 78, S30-S35.	5.0	15
33	Complete genomic sequences for hepatitis C virus subtypes 6e and 6g isolated from Chinese patients with injection drug use and HIV-1 co-infection. <i>Journal of Medical Virology</i> , 2006, 78, 1061-1069.	5.0	30
34	Characterization of HCV strains in an oncohematological pediatric department reveals little horizontal transmission but multiple introductions by un-screened blood products in the past. <i>Journal of Medical Virology</i> , 2006, 78, 1411-1422.	5.0	6
35	A natural inter-genotypic (2b/1b) recombinant of hepatitis C virus in the Philippines. <i>Journal of Medical Virology</i> , 2006, 78, 1423-1428.	5.0	81
36	Genotyping Hepatitis C Viruses from Southeast Asia by a Novel Line Probe Assay That Simultaneously Detects Core and 5' Untranslated Regions. <i>Journal of Clinical Microbiology</i> , 2006, 44, 3969-3974.	3.9	47
37	Identification of a Naturally Occurring Recombinant Genotype 2/6 Hepatitis C Virus. <i>Journal of Virology</i> , 2006, 80, 7569-7577.	3.4	131
38	Replication of Hepatitis C Virus (HCV) RNA in Mouse Embryonic Fibroblasts: Protein Kinase R (PKR)-Dependent and PKR-Independent Mechanisms for Controlling HCV RNA Replication and Mediating Interferon Activities. <i>Journal of Virology</i> , 2006, 80, 7364-7374.	3.4	91
39	Phylogenetic Analysis of Previously Nontypeable Hepatitis C Virus Isolates from Argentina. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2229-2232.	3.9	8
40	Characterization of the Early Steps of Hepatitis C Virus Infection by Using Luciferase Reporter Viruses. <i>Journal of Virology</i> , 2006, 80, 5308-5320.	3.4	363

#	ARTICLE	IF	CITATIONS
41	Hepatitis C virus complete genome sequences identified from China representing subtypes 6k and 6n and a novel, as yet unassigned subtype within genotype 6. <i>Journal of General Virology</i> , 2006, 87, 629-634.	2.9	29
42	A new subtype of hepatitis C virus genotype 1: complete genome and phylogenetic relationships of an Equatorial Guinea isolate. <i>Journal of General Virology</i> , 2006, 87, 1697-1702.	2.9	15
43	Analysis of the 5' Noncoding Region versus the NS5b Region in Genotyping Hepatitis C Virus Isolates from Blood Donors in France. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2051-2056.	3.9	57
44	Evidence of Viral Adaptation to HLA Class I-Restricted Immune Pressure in Chronic Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2006, 80, 11094-11104.	3.4	103
45	Analysis of Hepatitis C Virus Hypervariable Region 1 Sequence from Cryoglobulinemic Patients and Associated Controls. <i>Journal of Virology</i> , 2007, 81, 4564-4571.	3.4	16
46	Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 16269-16274.	7.1	127
47	Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. <i>Journal of General Virology</i> , 2007, 88, 1526-1531.	2.9	121
48	The Lipid Droplet Binding Domain of Hepatitis C Virus Core Protein Is a Major Determinant for Efficient Virus Assembly. <i>Journal of Biological Chemistry</i> , 2007, 282, 37158-37169.	3.4	218
49	Impact of Hepatitis C Virus (HCV) Genotypes on Quantification of HCV RNA in Serum by COBAS AmpliPrep/COBAS TaqMan HCV Test, Abbott Antiretroviral Therapy HCV RealTime Assay, and VERSANT HCV RNA Assay. <i>Journal of Clinical Microbiology</i> , 2007, 45, 3077-3081.	3.9	35
50	Complete genomes for hepatitis C virus subtypes 6f, 6i, 6j and 6m: viral genetic diversity among Thai blood donors and infected spouses. <i>Journal of General Virology</i> , 2007, 88, 1505-1518.	2.9	37
51	Use of Sequence Analysis of the NS5B Region for Routine Genotyping of Hepatitis C Virus with Reference to C/E1 and 5' Untranslated Region Sequences. <i>Journal of Clinical Microbiology</i> , 2007, 45, 1102-1112.	3.9	246
52	Hepatitis C Virus p7 Protein Is Crucial for Assembly and Release of Infectious Virions. <i>PLoS Pathogens</i> , 2007, 3, e103.	4.7	290
53	The hepatitis C sequence database in Los Alamos. <i>Nucleic Acids Research</i> , 2007, 36, D512-D516.	14.5	68
54	Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to Therapy. <i>Journal of Virology</i> , 2007, 81, 8211-8224.	3.4	106
55	Increase in HCV Incidence among Men Who Have Sex with Men in Amsterdam Most Likely Caused by Sexual Transmission. <i>Journal of Infectious Diseases</i> , 2007, 196, 230-238.	4.0	261
56	euHCVdb: the European hepatitis C virus database. <i>Nucleic Acids Research</i> , 2007, 35, D363-D366.	14.5	128
57	Chronic Hepatitis in West and East. <i>Digestive Diseases</i> , 2007, 25, 274-276.	1.9	0
58	Shortened Therapy for Hepatitis C Virus Genotype 2 or 3 " Is Less More?. <i>New England Journal of Medicine</i> , 2007, 357, 176-178.	27.0	8

#	ARTICLE	IF	CITATIONS
59	Prediction of Efficient Virological Response to Pegylated Interferon/Ribavirin Combination Therapy by NS5A Sequences of Hepatitis C Virus and Anti-NS5A Antibodies in Pre-treatment Sera. <i>Microbiology and Immunology</i> , 2007, 51, 471-482.	1.4	38
60	Emerging drugs for hepatitis B. <i>Expert Opinion on Emerging Drugs</i> , 2007, 12, 199-217.	2.4	13
61	Complete genomes of hepatitis C virus (HCV) subtypes 6c, 6l, 6o, 6p and 6q: completion of a full panel of genomes for HCV genotype 6. <i>Journal of General Virology</i> , 2007, 88, 1519-1525.	2.9	29
62	Cell Culture Adaptation of Hepatitis C Virus and In Vivo Viability of an Adapted Variant. <i>Journal of Virology</i> , 2007, 81, 13168-13179.	3.4	147
63	Identification of Determinants Involved in Initiation of Hepatitis C Virus RNA Synthesis by Using Intergenotypic Replicase Chimeras. <i>Journal of Virology</i> , 2007, 81, 5270-5283.	3.4	92
64	Recombinant hepatitis C virus in experimentally infected chimpanzees. <i>Journal of General Virology</i> , 2007, 88, 143-147.	2.9	25
65	Small Interfering RNA Targeted to Hepatitis C Virus 5' Nontranslated Region Exerts Potent Antiviral Effect. <i>Journal of Virology</i> , 2007, 81, 669-676.	3.4	80
66	Production of Infectious Hepatitis C Virus of Various Genotypes in Cell Cultures. <i>Journal of Virology</i> , 2007, 81, 4405-4411.	3.4	95
67	Characterization of Hepatitis C Virus Deletion Mutants Circulating in Chronically Infected Patients. <i>Journal of Virology</i> , 2007, 81, 12496-12503.	3.4	44
68	Prediction of Response to Pegylated Interferon and Ribavirin in Hepatitis C by Polymorphisms in the Viral Core Protein and Very Early Dynamics of Viremia. <i>Intervirology</i> , 2007, 50, 361-368.	2.8	54
69	Full-length genome sequences of hepatitis C virus subtype 4f. <i>Journal of General Virology</i> , 2007, 88, 2985-2990.	2.9	15
70	Binding-Site Identification and Genotypic Profiling of Hepatitis C Virus Polymerase Inhibitors. <i>Journal of Virology</i> , 2007, 81, 6909-6919.	3.4	68
71	Viral Determinants of Resistance to Treatment in Patients with Hepatitis C. <i>Clinical Microbiology Reviews</i> , 2007, 20, 23-38.	13.6	142
72	Determination of the hepatitis C virus subtype: comparison of sequencing and reverse hybridization assays. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 167-70.	2.3	21
73	Evaluation of a New-Generation Line-Probe Assay That Detects 5' Untranslated and Core Regions to Genotype and Subtype Hepatitis C Virus. <i>American Journal of Clinical Pathology</i> , 2007, 128, 300-304.	0.7	17
74	Improvement of Hepatitis C Virus (HCV) Genotype Determination with the New Version of the INNO-LiPA HCV Assay. <i>Journal of Clinical Microbiology</i> , 2007, 45, 1140-1145.	3.9	108
75	The Level of CD81 Cell Surface Expression Is a Key Determinant for Productive Entry of Hepatitis C Virus into Host Cells. <i>Journal of Virology</i> , 2007, 81, 588-598.	3.4	201
76	New Natural Intergenotypic (2/5) Recombinant of Hepatitis C Virus. <i>Journal of Virology</i> , 2007, 81, 4357-4362.	3.4	103

#	ARTICLE	IF	CITATIONS
77	Characterization of Fusion Determinants Points to the Involvement of Three Discrete Regions of Both E1 and E2 Glycoproteins in the Membrane Fusion Process of Hepatitis C Virus. <i>Journal of Virology</i> , 2007, 81, 8752-8765.	3.4	157
78	Cross-genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes. <i>Journal of General Virology</i> , 2007, 88, 458-469.	2.9	25
79	Biological Feasibility of Developing Prophylactic Vaccines for Viral Pathogens: Incubation Period as a Critical Parameter. <i>Hum Vaccin</i> , 2007, 3, 1-7.	2.4	9
80	Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. <i>Vaccine</i> , 2007, 25, 7773-7784.	3.8	81
81	Variable intensity of purifying selection on cytotoxic T-lymphocyte epitopes in hepatitis C virus. <i>Virus Research</i> , 2007, 123, 147-153.	2.2	9
82	Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type 1. <i>Virus Research</i> , 2007, 123, 161-169.	2.2	27
84	Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: Long-term follow-up of 196 patients (4535 patient-years). <i>Journal of Hepatology</i> , 2007, 46, 19-25.	3.7	27
85	Hepatitis C virus infection among HIV-1 infected individuals from northern Mexico. <i>Hepatology Research</i> , 2007, 37, 311-316.	3.4	11
86	Hepatitis C virus genotype distribution in Myanmar: Predominance of genotype 6 and existence of new genotype 6 subtype. <i>Hepatology Research</i> , 2007, 37, 337-345.	3.4	59
87	Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir. <i>Gastroenterology</i> , 2007, 132, 1767-1777.	1.3	602
88	Evolution of naturally occurring 5' non-coding region variants of Hepatitis C virus in human populations of the South American region. <i>Virology Journal</i> , 2007, 4, 79.	3.4	8
89	The Neutralizing Activity of Anti-Hepatitis C Virus Antibodies Is Modulated by Specific Glycans on the E2 Envelope Protein. <i>Journal of Virology</i> , 2007, 81, 8101-8111.	3.4	187
91	Hepatitis C virus: Virology, diagnosis and management of antiviral therapy. <i>World Journal of Gastroenterology</i> , 2007, 13, 2461.	3.3	119
92	Identification of hepatitis C virus subtype 2c by sequencing analysis in patients from Córdoba, Argentina. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2007, 102, 995-998.	1.6	6
93	Ruolo del sequenziamento diretto nella tipizzazione di HCV-RNA a fini clinico-epidemiologici. <i>Microbiologia Medica</i> , 2007, 22, .	0.1	0
94	Antiviral therapy: Inhibition of Hepatitis C Virus expression by RNA interference directed against the NS5B region of the Viral Genome. <i>Annals of Hepatology</i> , 2007, 6, 174-180.	1.5	11
95	Selection and application of serotypical synthetic peptides derived from hepatitis C virus NS5A region. <i>Chinese Medical Journal</i> , 2007, 120, 1159-1165.	2.3	0
96	Transcription-mediated amplification linked to line probe assay as a routine tool for HCV typing in clinical laboratories. <i>Journal of Clinical Laboratory Analysis</i> , 2007, 21, 340-347.	2.1	2

#	ARTICLE	IF	CITATIONS
97	Genetic diversity of HCV genotype 2 strains in South Western France. <i>Journal of Medical Virology</i> , 2007, 79, 26-34.	5.0	24
98	Hepatitis C virus infection and genotypes in Antananarivo, Madagascar. <i>Journal of Medical Virology</i> , 2007, 79, 1082-1088.	5.0	10
99	Genetic characterization of hepatitis C virus strains in Estonia: Fluctuations in the predominating subtype with time. <i>Journal of Medical Virology</i> , 2007, 79, 374-382.	5.0	58
100	Determining the source of nosocomial transmission in hemodialysis units in Tunisia by sequencing NS5B and E2 sequences of HCV. <i>Journal of Medical Virology</i> , 2007, 79, 1089-1094.	5.0	16
101	Discovery of novel dialkyl substituted thiophene inhibitors of HCV by in silico screening of the NS5B RdRp. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 3905-3909.	2.2	29
102	Mannan binding lectin and viral hepatitis. <i>Immunology Letters</i> , 2007, 108, 34-44.	2.5	62
103	Replication of hepatitis C virus. <i>Nature Reviews Microbiology</i> , 2007, 5, 453-463.	28.6	1,158
104	Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 615-633.	2.8	144
105	Hepatitis C virus genotypes among patients with thalassemia and inherited bleeding disorders in Markazi province, Iran. <i>Haemophilia</i> , 2007, 13, 156-163.	2.1	50
106	Characterization of full-length hepatitis C virus genotype 4 sequences. <i>Journal of Viral Hepatitis</i> , 2007, 14, 330-337.	2.0	27
107	The epidemiology and virology of hepatitis C virus genotype 5 in central France. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 1437-1446.	3.7	15
108	Computer-aided identification of polymorphism sets diagnostic for groups of bacterial and viral genetic variants. <i>BMC Bioinformatics</i> , 2007, 8, 278.	2.6	23
109	Investigating the endemic transmission of the hepatitis C virus. <i>International Journal for Parasitology</i> , 2007, 37, 839-849.	3.1	66
110	Inhibition of hepatitis C virus p7 membrane channels in a liposome-based assay system. <i>Antiviral Research</i> , 2007, 76, 48-58.	4.1	75
111	Genotyping of hepatitis C virus isolates by a new line probe assay using sequence information from both the 5' untranslated and the core regions. <i>Journal of Virological Methods</i> , 2007, 143, 153-160.	2.1	16
113	A Shope Fibroma virus PYRIN-only protein modulates the host immune response. <i>Virus Genes</i> , 2007, 33, 271-8.	1.6	5
114	Sequence uniqueness and sequence variability as modulating factors of human anti-HCV humoral immune response. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1215-1223.	4.2	32
115	Baculovirus Mediated Production of Infectious Hepatitis C Virus in Human Hepatoma Cells Stably Expressing T7 RNA Polymerase. <i>Molecular Biotechnology</i> , 2008, 40, 186-194.	2.4	4

#	ARTICLE	IF	CITATIONS
116	Hepatitis C in India. <i>Journal of Biosciences</i> , 2008, 33, 465-473.	1.1	88
117	Treatment strategy for hepatitis C after liver transplantation. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2008, 15, 111-123.	2.0	5
118	Change in hepatitis C virus genotype in hemodialysis patients after end-of-treatment response to interferon monotherapy—relapse or re-infection?. <i>Journal of Medical Virology</i> , 2008, 80, 80-86.	5.0	9
119	Epidemiological and clinical evaluation of hepatitis B, hepatitis C, and delta hepatitis viruses in Tajikistan. <i>Journal of Medical Virology</i> , 2008, 80, 268-276.	5.0	42
120	Diversity of hepatitis C virus genotype 1b in Buenos Aires, Argentina: description of a new cluster associated with response to treatment. <i>Journal of Medical Virology</i> , 2008, 80, 619-627.	5.0	15
121	Identification of hepatitis C virus genotype 6 in Korean patients by analysis of 5' untranslated region using a matrix assisted laser desorption/ionization time of flight-based assay, restriction fragment mass polymorphism. <i>Journal of Medical Virology</i> , 2008, 80, 1712-1719.	5.0	26
122	The unique HCV genotype distribution and the discovery of a novel subtype 6u among IDUs co-infected with HIV-1 in Yunnan, China. <i>Journal of Medical Virology</i> , 2008, 80, 1142-1152.	5.0	76
123	A set of reference sequences for the hepatitis C genotypes 4d, 4f, and 4k covering the full open reading frame. <i>Journal of Medical Virology</i> , 2008, 80, 1370-1378.	5.0	10
124	High prevalence of hepatitis C virus infection and predominance of genotype 4 in rural Gabon. <i>Journal of Medical Virology</i> , 2008, 80, 1581-1587.	5.0	33
125	Molecular characterization of genotype 2 and 4 hepatitis C virus isolates in French blood donors. <i>Journal of Medical Virology</i> , 2008, 80, 1732-1739.	5.0	25
126	Complete genome sequencing and phylogenetic analysis of HCV isolates from China reveals a new subtype, designated 6u. <i>Journal of Medical Virology</i> , 2008, 80, 1740-1746.	5.0	27
127	Hepatitis C genotype 4: What we know and what we don't yet know. <i>Hepatology</i> , 2008, 47, 1371-1383.	7.3	257
128	Using evolutionary tools to refine the new hypervariable region 3 within the envelope 2 protein of hepatitis C virus. <i>Infection, Genetics and Evolution</i> , 2008, 8, 74-82.	2.3	18
129	Variable epidemic histories of hepatitis C virus genotype 2 infection in West Africa and Cameroon. <i>Infection, Genetics and Evolution</i> , 2008, 8, 676-681.	2.3	29
130	Diagnosis and management of chronic viral hepatitis: Antigens, antibodies and viral genomes. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2008, 22, 1031-1048.	2.4	63
131	Hepatitis C Virus Core Protein Induces Lipid Droplet Redistribution in a Microtubule- and Dynein-Dependent Manner. <i>Traffic</i> , 2008, 9, 1268-1282.	2.7	194
132	Methamphetamine enhances Hepatitis C virus replication in human hepatocytes. <i>Journal of Viral Hepatitis</i> , 2008, 15, 261-270.	2.0	32
133	Refined analysis of genetic variability parameters in hepatitis C virus and the ability to predict antiviral treatment response. <i>Journal of Viral Hepatitis</i> , 2008, 15, 578-590.	2.0	16

#	ARTICLE	IF	CITATIONS
134	Response to pegylated interferon plus ribavirin in HIV-1 infected patients with chronic hepatitis C due to genotype 4. <i>Journal of Viral Hepatitis</i> , 2008, 15, 710-715.	2.0	15
135	Immune responses during acute and chronic infection with hepatitis C virus. <i>Clinical Immunology</i> , 2008, 128, 133-147.	3.2	89
136	Towards a better resolution of hepatitis C virus variants: CLIP ₂ sequencing of an HCV core fragment and automated assignment of genotypes and subtypes. <i>Journal of Virological Methods</i> , 2008, 148, 25-33.	2.1	14
137	Development and evaluation of a sensitive enzyme-linked oligonucleotide-sorbent assay for detection of polymerase chain reaction-amplified hepatitis C virus of genotypes 1-6. <i>Journal of Virological Methods</i> , 2008, 151, 211-216.	2.1	8
138	Taxonomy of genus Hepacivirus. Application of palindromic nucleotide substitutions for the determination of genotypes of human hepatitis C virus species. <i>Journal of Virological Methods</i> , 2008, 153, 280-299.	2.1	4
139	Chapter 2 Cutting the Gordian Knot-Development and Biological Relevance of Hepatitis C Virus Cell Culture Systems. <i>Advances in Virus Research</i> , 2008, 71, 51-133.	2.1	88
140	Therapeutic Control of Hepatitis C Virus: The Role of Neutralizing Monoclonal Antibodies. <i>Current Topics in Microbiology and Immunology</i> , 2008, 317, 1-38.	1.1	22
141	Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a. <i>Virology Journal</i> , 2008, 5, 78.	3.4	18
142	Complete genome of a European hepatitis C virus subtype 1g isolate: phylogenetic and genetic analyses. <i>Virology Journal</i> , 2008, 5, 72.	3.4	19
143	Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus. <i>Genome Biology</i> , 2008, 9, R16.	9.6	74
144	The changing epidemiology of hepatitis C virus infection in Europe. <i>Journal of Hepatology</i> , 2008, 48, 148-162.	3.7	379
145	HCV genotype 5: Epidemiology and spread of an uncommon genotype. <i>Journal of Clinical Virology</i> , 2008, 41, 170-171.	3.1	11
146	Outcome of an exercise to notify patients treated by a general surgeon infected with the hepatitis C virus. <i>Journal of Clinical Virology</i> , 2008, 41, 314-317.	3.1	6
147	Restricted quasispecies variation following infection with the GB virus B. <i>Virus Research</i> , 2008, 135, 181-186.	2.2	6
148	Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in Western Turkey. <i>International Journal of Infectious Diseases</i> , 2008, 12, 239-244.	3.3	53
149	Detection of hepatitis C virus natural recombinant RF1_2k/1b strain among intravenous drug users in Uzbekistan. <i>Hepatology Research</i> , 2008, 38, 457-464.	3.4	47
150	Recognition of Genetic Factors Influencing the Progression of Hepatitis C. <i>Molecular Diagnosis and Therapy</i> , 2008, 12, 209-218.	3.8	18
151	Evaluation of Versant Hepatitis C Virus Genotype Assay (LiPA) 2.0. <i>Journal of Clinical Microbiology</i> , 2008, 46, 1901-1906.	3.9	107

#	ARTICLE	IF	CITATIONS
152	Investigation of Putative Multisubtype Hepatitis C Virus Infections In Vivo by Heteroduplex Mobility Analysis of Core/Envelope Subgenomes. <i>Journal of Virology</i> , 2008, 82, 7524-7532.	3.4	15
153	Role of the Hepatitis C Virus Core+1 Open Reading Frame and Core <i>cis</i> -Acting RNA Elements in Viral RNA Translation and Replication. <i>Journal of Virology</i> , 2008, 82, 11503-11515.	3.4	91
154	Evaluation of a New Assay in Comparison with Reverse Hybridization and Sequencing Methods for Hepatitis C Virus Genotyping Targeting Both 5' Noncoding and Nonstructural 5b Genomic Regions. <i>Journal of Clinical Microbiology</i> , 2008, 46, 192-197.	3.9	48
155	Hepatitis C Virus Genotype in Blood Donors and Associated Liver Disease in Indonesia. <i>Intervirology</i> , 2008, 51, 410-416.	2.8	18
156	Seven nucleotide changes characteristic of the hepatitis C virus genotype 3 5' untranslated region: correlation with reduced in vitro replication. <i>Journal of General Virology</i> , 2008, 89, 212-221.	2.9	16
157	Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 997-1002.	7.1	167
158	Structural and Functional Characterization of Nonstructural Protein 2 for Its Role in Hepatitis C Virus Assembly. <i>Journal of Biological Chemistry</i> , 2008, 283, 28546-28562.	3.4	135
159	Complete genomes of three subtype 6t isolates and analysis of many novel hepatitis C virus variants within genotype 6. <i>Journal of General Virology</i> , 2008, 89, 444-452.	2.9	26
160	Classification of hepatitis C virus and human immunodeficiency virus-1 sequences with the branching index. <i>Journal of General Virology</i> , 2008, 89, 2098-2107.	2.9	16
161	Complete genome analysis of hepatitis C virus subtypes 6t and 6u. <i>Journal of General Virology</i> , 2008, 89, 1276-1281.	2.9	19
162	Chronic Hepatitis C Virus Genotype 6 Infection: Response to Pegylated Interferon and Ribavirin. <i>Journal of Infectious Diseases</i> , 2008, 198, 808-812.	4.0	80
163	Molecular Epidemiology and Interferon Susceptibility of the Natural Recombinant Hepatitis C Virus Strain RF1_2k/1b. <i>Journal of Infectious Diseases</i> , 2008, 198, 1448-1456.	4.0	47
164	Differential reactivity of putative genotype 2 hepatitis C virus F protein between chronic and recovered infections. <i>Journal of General Virology</i> , 2008, 89, 1890-1900.	2.9	16
165	Highly Efficient JFH1-Based Cell Culture System for Hepatitis C Virus Genotype 5a: Failure of Homologous Neutralizing Antibody Treatment to Control Infection. <i>Journal of Infectious Diseases</i> , 2008, 198, 1756-1765.	4.0	101
166	Distinctive pattern of sequence polymorphism in the NS3 protein of hepatitis C virus type 1b reflects conflicting evolutionary pressures. <i>Journal of General Virology</i> , 2008, 89, 1921-1929.	2.9	12
167	Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. <i>Journal of General Virology</i> , 2008, 89, 653-659.	2.9	144
169	Evidence for a Complex Mosaic Genome Pattern in a Full-length Hepatitis C Virus Sequence. <i>Evolutionary Bioinformatics</i> , 2008, 4, EBO.S1038.	1.2	15
170	The Impact of Rapid Evolution of Hepatitis Viruses. , 2008, , 303-349.		11

#	ARTICLE	IF	CITATIONS
171	Prevalence of hepatitis C virus infection in quilombo remnant communities in Central Brazil. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2008, 50, 359-360.	1.1	6
172	Epidemiological aspects of hepatitis C virus infection among renal transplant recipients in Central Brazil. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2008, 103, 472-476.	1.6	4
173	Hepatitis C Virus Genetics and the Discovery of Mechanism-Based Inhibitors of the NS3/4A Protease and NS5B Polymerase. <i>Translational Research in Biomedicine</i> , 2008, , 63-93.	0.4	0
174	Genotyping of hepatitis C virus (HCV) in infected patients from Northeast Mexico. <i>Annals of Hepatology</i> , 2008, 7, 144-147.	1.5	21
175	47.10 Hepatitis-C-Virus. , 2009, , .		0
176	Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives. <i>Viruses</i> , 2009, 1, 144-165.	3.3	11
178	Innate immunity and hepatitis C virus: eluding the host cell defense. <i>Frontiers in Bioscience - Landmark</i> , 2009, 14, 4950.	3.0	8
179	Chronic Hepatitis C: Pathophysiology, Diagnosis and Treatment Options. <i>Frontiers of Gastrointestinal Research</i> , 2009, , 42-58.	0.1	0
180	The Evolution of the Major Hepatitis C Genotypes Correlates with Clinical Response to Interferon Therapy. <i>PLoS ONE</i> , 2009, 4, e6579.	2.5	48
181	Hepatitis C Virus (HCV) Genotype 1 Subtype Identification in New HCV Drug Development and Future Clinical Practice. <i>PLoS ONE</i> , 2009, 4, e8209.	2.5	104
183	Reduction of Hepatitis C Virus Using Lectin Affinity Plasmapheresis in Dialysis Patients. <i>Blood Purification</i> , 2009, 27, 64-69.	1.8	43
184	The Hepatitis C Virus NS4B Protein Can <i>trans</i> -Complement Viral RNA Replication and Modulates Production of Infectious Virus. <i>Journal of Virology</i> , 2009, 83, 2163-2177.	3.4	124
185	Natural Variability of NS3 Protease in Patients Infected with Genotype 4 Hepatitis C Virus (HCV): Implications for Antiviral Treatment Using Specifically Targeted Antiviral Therapy for HCV. <i>Journal of Infectious Diseases</i> , 2009, 200, 524-527.	4.0	10
186	An Amphipathic α -Helix at the C Terminus of Hepatitis C Virus Nonstructural Protein 4B Mediates Membrane Association. <i>Journal of Virology</i> , 2009, 83, 11378-11384.	3.4	60
187	Selection and Characterization of Hepatitis C Virus Replicons Dually Resistant to the Polymerase and Protease Inhibitors HCV-796 and Boceprevir (SCH 503034). <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 401-411.	3.2	47
188	Gene expression and hepatitis C virus infection. <i>Gut</i> , 2009, 58, 846-858.	12.1	90
189	CS-SELEX Generates High-Affinity ssDNA Aptamers as Molecular Probes for Hepatitis C Virus Envelope Glycoprotein E2. <i>PLoS ONE</i> , 2009, 4, e8142.	2.5	78
190	An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 211-220.	4.1	37

#	ARTICLE	IF	CITATIONS
191	Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 709-725.	4.1	76
192	The Global Spread of Hepatitis C Virus 1a and 1b: A Phylodynamic and Phylogeographic Analysis. <i>PLoS Medicine</i> , 2009, 6, e1000198.	8.4	177
193	Detection of the hepatitis C virus antigen in kidney tissue from infected patients with various glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2745-2751.	0.7	31
194	Low pH-dependent Hepatitis C Virus Membrane Fusion Depends on E2 Integrity, Target Lipid Composition, and Density of Virus Particles. <i>Journal of Biological Chemistry</i> , 2009, 284, 17657-17667.	3.4	79
195	Determination of Hepatitis C Virus-Infected, Monocyte Lineage Reservoirs in Individuals With or Without HIV Coinfection. <i>Journal of Infectious Diseases</i> , 2009, 200, 947-954.	4.0	41
196	Naturally Occurring Hepatitis C Virus Subgenomic Deletion Mutants Replicate Efficiently in Huh-7 Cells and Are <i>trans</i> -Packaged In Vitro To Generate Infectious Defective Particles. <i>Journal of Virology</i> , 2009, 83, 9079-9093.	3.4	36
197	Hepatitis C Virus NS5A Protein Is a Substrate for the Peptidyl-prolyl <i>cis/trans</i> Isomerase Activity of Cyclophilins A and B. <i>Journal of Biological Chemistry</i> , 2009, 284, 13589-13601.	3.4	149
198	Complete genomic sequences for hepatitis C virus subtypes 4b, 4c, 4d, 4g, 4k, 4l, 4m, 4n, 4o, 4p, 4q, 4r and 4t. <i>Journal of General Virology</i> , 2009, 90, 1820-1826.	2.9	28
199	Phylogeography and molecular epidemiology of hepatitis C virus genotype 2 in Africa. <i>Journal of General Virology</i> , 2009, 90, 2086-2096.	2.9	89
200	Emergence of Hepatitis C Virus Genotype 4: Phylogenetic Analysis Reveals Three Distinct Epidemiological Profiles. <i>Journal of Clinical Microbiology</i> , 2009, 47, 3832-3838.	3.9	71
201	Identification of a Novel Determinant for Membrane Association in Hepatitis C Virus Nonstructural Protein 4B. <i>Journal of Virology</i> , 2009, 83, 6257-6268.	3.4	91
202	Characterization of Determinants Important for Hepatitis C Virus p7 Function in Morphogenesis by Using <i>trans</i> -Complementation. <i>Journal of Virology</i> , 2009, 83, 11682-11693.	3.4	65
203	A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen. <i>Journal of Virological Methods</i> , 2009, 157, 8-14.	2.1	120
204	Unequal distribution of RT-PCR artifacts along the E1-E2 region of Hepatitis C virus. <i>Journal of Virological Methods</i> , 2009, 161, 136-140.	2.1	3
205	Colorimetric microwell plate reverse-hybridization assay for detection and genotyping of hepatitis C virus. <i>Journal of Virological Methods</i> , 2009, 162, 75-80.	2.1	2
206	SNAD: sequence name annotation-based designer. <i>BMC Bioinformatics</i> , 2009, 10, 251.	2.6	6
207	Novel HCV replication mouse model using human hepatocellular carcinoma xenografts. <i>Antiviral Research</i> , 2009, 84, 14-22.	4.1	12
209	Diagnosis, management, and treatment of hepatitis C: An update. <i>Hepatology</i> , 2009, 49, 1335-1374.	7.3	2,610

#	ARTICLE	IF	CITATIONS
210	PCSK9 impedes hepatitis C virus infection <i>in vitro</i> and modulates liver CD81 expression. <i>Hepatology</i> , 2009, 50, 17-24.	7.3	129
211	Degree of cross-genotype reactivity of hepatitis C virus-specific CD8+ T cells directed against NS3. <i>Hepatology</i> , 2009, 50, 707-716.	7.3	32
212	Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. <i>Hepatology</i> , 2009, 50, 1017-1029.	7.3	60
213	Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. <i>Hepatology</i> , 2009, 50, 1638-1645.	7.3	108
214	The HCV ARFP/F/core+1 protein: Production and functional analysis of an unconventional viral product. <i>IUBMB Life</i> , 2009, 61, 739-752.	3.4	44
215	Molecular epidemiology of hepatitis C infection in cyprus: Evidence of polyphyletic infection. <i>Journal of Medical Virology</i> , 2009, 81, 238-248.	5.0	28
216	Mutations in the interferon sensitivity-determining region of hepatitis C virus genotype 2a correlate with response to pegylated interferon-alpha 2a monotherapy. <i>Journal of Medical Virology</i> , 2009, 81, 459-466.	5.0	14
217	Hepatitis C virus genotypes in 1,504 patients in Slovenia, 1993-2007. <i>Journal of Medical Virology</i> , 2009, 81, 634-639.	5.0	28
218	Genetic variability of hepatitis C virus in South Egypt and its possible clinical implication. <i>Journal of Medical Virology</i> , 2009, 81, 1015-1023.	5.0	40
219	HCV genotypes in Sicily: Is there any evidence of a shift?. <i>Journal of Medical Virology</i> , 2009, 81, 1040-1046.	5.0	17
220	Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. <i>Journal of Medical Virology</i> , 2009, 81, 1576-1583.	5.0	47
221	Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. <i>Journal of Medical Virology</i> , 2009, 81, 2029-2035.	5.0	56
222	Diversity of hepatitis B and C viruses in Chile. <i>Journal of Medical Virology</i> , 2009, 81, 1887-1894.	5.0	22
223	Characterization of the cellular immune response in hepatitis C virus infection. <i>Medicinal Research Reviews</i> , 2009, 29, 843-866.	10.5	17
224	Immune complexed (IC) hepatitis C virus (HCV) in chronically and acutely HCV-infected patients. <i>Medical Microbiology and Immunology</i> , 2009, 198, 13-18.	4.8	5
225	Full genome sequence of three isolates of hepatitis C virus subtype 4b from Portugal. <i>Archives of Virology</i> , 2009, 154, 127-132.	2.1	9
226	Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2009, 44, 1009-1015.	5.1	31
228	Combined antiviral activity of interferon- λ and RNA interference directed against hepatitis C without affecting vector delivery and gene silencing. <i>Journal of Molecular Medicine</i> , 2009, 87, 713-722.	3.9	46

#	ARTICLE	IF	CITATIONS
229	<i>Retracted:</i> Genetic diversity in hepatitis C virus (HCV): A brief review. <i>Reviews in Medical Virology</i> , 2009, 19, .	8.3	6
230	Lack of <i>de novo</i> hepatitis C virus infections and absence of nosocomial transmissions of GB virus C in a large cohort of German haemodialysis patients. <i>Journal of Viral Hepatitis</i> , 2009, 16, 230-238.	2.0	19
231	Entire genome sequences of two new HCV subtypes, 6r and 6s, and characterization of unique HVR1 variation patterns within genotype 6. <i>Journal of Viral Hepatitis</i> , 2009, 16, 406-417.	2.0	12
232	Never injected, but hepatitis C virus-infected: a study among self-declared never-injecting drug users from the Amsterdam Cohort Studies. <i>Journal of Viral Hepatitis</i> , 2009, 16, 568-577.	2.0	23
233	Pre-emptive antiviral therapy in living donor liver transplantation for hepatitis C: observation based on a single-center experience. <i>Transplant International</i> , 2010, 23, 580-588.	1.6	21
234	New developments in the antiviral treatment of hepatitis C. <i>Vox Sanguinis</i> , 2009, 97, 1-12.	1.5	12
235	Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. <i>Transfusion</i> , 2009, 49, 2454-2489.	1.6	196
236	Gene expression profile of Huh-7 cells expressing hepatitis C virus genotype 1b or 3a core proteins. <i>Liver International</i> , 2009, 29, 661-669.	3.9	27
237	How to use virological tools for optimal management of chronic hepatitis C. <i>Liver International</i> , 2009, 29, 9-14.	3.9	35
238	Protease and polymerase inhibitors for the treatment of hepatitis C. <i>Liver International</i> , 2009, 29, 57-67.	3.9	72
239	Genotype diversity of hepatitis C virus (HCV) in HCV-associated liver disease patients in Indonesia. <i>Liver International</i> , 2009, 30, 1152-1160.	3.9	31
240	Quasispecies of hepatitis C virus genotype 1 and treatment outcome with Peginterferon and Ribavirin†. <i>Infection, Genetics and Evolution</i> , 2009, 9, 689-698.	2.3	21
241	Epidemiological study of hepatitis A, B and C in the largest Afro-Brazilian isolated community. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2009, 103, 899-905.	1.8	20
242	Treatment of chronic hepatitis C in Asia: When East meets West. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 336-345.	2.8	227
243	Targeting the non-structural proteins of hepatitis C virus: beyond hepatitis C virus protease and polymerase. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 293-314.	5.0	17
244	Lipid droplets and hepatitis C virus infection. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2009, 1791, 552-559.	2.4	83
245	A new HCV genotype 6 subtype designated 6v was confirmed with three complete genome sequences. <i>Journal of Clinical Virology</i> , 2009, 44, 195-199.	3.1	26
246	Changes in modes of hepatitis C infection acquisition and genotypes in southwest China. <i>Journal of Clinical Virology</i> , 2009, 46, 230-233.	3.1	26

#	ARTICLE	IF	CITATIONS
247	HCV replication suppresses cellular glucose uptake through down-regulation of cell surface expression of glucose transporters. <i>Journal of Hepatology</i> , 2009, 50, 883-894.	3.7	70
248	Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. <i>Journal of Hepatology</i> , 2009, 51, 667-674.	3.7	99
249	Prospects of RNAi and microRNA-based therapies for hepatitis C. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 713-724.	3.1	20
250	Hepatitis C Virus Genome Replication. , 2009, , 61-88.		3
251	Detection and Quantification of Serum or Plasma HCV RNA: Mini Review of Commercially Available Assays. <i>Methods in Molecular Biology</i> , 2009, 510, 3-14.	0.9	17
252	A Real-Time Taqman® Method for Hepatitis C Virus Genotyping and Methods for Further Subtyping of Isolates. <i>Methods in Molecular Biology</i> , 2009, 510, 55-71.	0.9	4
253	HCV genetic variability: from quasispecies evolution to genotype classification. <i>Future Microbiology</i> , 2009, 4, 359-373.	2.0	40
254	Hepatitis C Virus entry: the early steps in the viral replication cycle. <i>Virology Journal</i> , 2009, 6, 117.	3.4	30
256	Genetic History of Hepatitis C Virus in East Asia. <i>Journal of Virology</i> , 2009, 83, 1071-1082.	3.4	190
257	Hepatitis C virus virology and new treatment targets. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 329-350.	4.4	13
258	Nomenclature and Numbering of the Hepatitis C Virus. <i>Methods in Molecular Biology</i> , 2009, 510, 33-53.	0.9	124
259	Evidence of recombination in Hepatitis C Virus populations infecting a hemophiliac patient. <i>Virology Journal</i> , 2009, 6, 203.	3.4	33
260	Hepatitis C virus core, NS3, NS4B and NS5A are the major immunogenic proteins in humoral immunity in chronic HCV infection. <i>Virology Journal</i> , 2009, 6, 84.	3.4	36
261	Conserved peptides within the E2 region of Hepatitis C virus induce humoral and cellular responses in goats. <i>Virology Journal</i> , 2009, 6, 66.	3.4	15
262	Hepatitis C Virus Genotypes are Changing in the Southeast of Turkey. <i>Biotechnology and Biotechnological Equipment</i> , 2009, 23, 1521-1523.	1.3	8
263	Nucleoside analog inhibitors of hepatitis C viral replication: recent advances, challenges and trends. <i>Future Medicinal Chemistry</i> , 2009, 1, 1429-1452.	2.3	25
264	Molecular and Contextual Markers of Hepatitis C Virus and Drug Abuse. <i>Molecular Diagnosis and Therapy</i> , 2009, 13, 153-179.	3.8	5
266	Cyclophilin Inhibitors. <i>Clinics in Liver Disease</i> , 2009, 13, 403-417.	2.1	52

#	ARTICLE	IF	CITATIONS
267	A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences. <i>Nucleic Acids Research</i> , 2009, 37, W634-W642.	14.5	142
268	Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. <i>Aids</i> , 2009, 23, F1-F7.	2.2	244
270	Chronic Hepatitis B: Pathophysiology, Diagnosis and Treatment Options. <i>Frontiers of Gastrointestinal Research</i> , 2009, , 32-41.	0.1	1
271	Influence of human t-cell lymphotropic virus type 1 (HTLV-1) Infection on laboratory parameters of patients with chronic hepatitis C virus. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2009, 51, 325-329.	1.1	14
272	The hepatitis C virus and its hepatic environment: a toxic but finely tuned partnership. <i>Biochemical Journal</i> , 2009, 423, 303-314.	3.7	39
273	Cellular and molecular biology of HCV infection and hepatitis. <i>Clinical Science</i> , 2009, 117, 49-65.	4.3	106
274	Viral and fungal infections of the oral cavity. , 2009, , 19-50.		1
278	Steatohepatic Hepatocellular Carcinoma (SH-HCC). <i>American Journal of Surgical Pathology</i> , 2010, 34, 1630-1636.	3.7	195
279	The Involvement of Tight Junction Protein Claudin-1 in Hepatitis C Virus Entry. <i>Current Topics in Membranes</i> , 2010, 65, 273-292.	0.9	1
280	Interferon-induced gene expression in chronic hepatitis C. <i>Future Virology</i> , 2010, 5, 25-31.	1.8	0
281	Contribution of charged and polar residues for the formation of the E1â€E2 heterodimer from Hepatitis C Virus. <i>Journal of Molecular Modeling</i> , 2010, 16, 1625-1637.	1.8	10
282	HCV genotype distribution in Flanders and Brussels (Belgium): unravelling the spread of an uncommon HCV genotype 5a cluster. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2010, 29, 1427-1434.	2.9	5
283	Telaprevir: a new hope in the treatment of chronic hepatitis C?. <i>Advances in Therapy</i> , 2010, 27, 512-522.	2.9	27
284	Complete genome sequences of hepatitis C virus subtype 3i and 3a subtype isolates from India. <i>Indian Journal of Gastroenterology</i> , 2010, 29, 101-105.	1.4	3
285	Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry. <i>Protein and Cell</i> , 2010, 1, 664-674.	11.0	52
286	Hepatitis C Assays: The Pitfalls of Polymerase Chain Reaction and Genotyping. <i>Current Hepatitis Reports</i> , 2010, 9, 9-14.	0.3	2
287	Immunogenic properties of chimeric potato virus X particles displaying the hepatitis C virus hypervariable region I peptide R9. <i>Journal of Virological Methods</i> , 2010, 166, 12-20.	2.1	53
288	A multicenter evaluation of the Abbott RealTime HCV Genotype II assay. <i>Journal of Virological Methods</i> , 2010, 167, 205-207.	2.1	28

#	ARTICLE	IF	CITATIONS
289	A classification approach for genotyping viral sequences based on multidimensional scaling and linear discriminant analysis. <i>BMC Bioinformatics</i> , 2010, 11, 434.	2.6	9
290	Hijacking hepatitis C viral replication with a non-coding replicative RNA. <i>Antiviral Research</i> , 2010, 87, 9-15.	4.1	2
291	Endocytic Rab proteins are required for hepatitis C virus replication complex formation. <i>Virology</i> , 2010, 398, 21-37.	2.4	57
292	Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6. <i>Hepatology</i> , 2010, 52, 1573-1580.	7.3	36
293	Hepatitis C virus recombinants are rare even among intravenous drug users. <i>Journal of Medical Virology</i> , 2010, 82, 232-238.	5.0	25
294	Molecular epidemiology of HCV genotypes among injection drug users in Taiwan: Full-length sequences of two new subtype 6w strains and a recombinant form_2b6w. <i>Journal of Medical Virology</i> , 2010, 82, 57-68.	5.0	70
295	Geographic distribution of hepatitis C virus genotype 6 subtypes in Thailand. <i>Journal of Medical Virology</i> , 2010, 82, 257-262.	5.0	52
296	Hepatitis C infection among intravenous drug users attending therapy programs in Cyprus. <i>Journal of Medical Virology</i> , 2010, 82, 263-270.	5.0	26
297	Analysis of hepatitis C virus strains circulating in Republic of the Congo. <i>Journal of Medical Virology</i> , 2010, 82, 562-567.	5.0	17
298	Multiple routes of hepatitis C virus transmission among injection drug users in Hai Phong, Northern Vietnam. <i>Journal of Medical Virology</i> , 2010, 82, 1355-1363.	5.0	26
299	Molecular and epidemiological profiles of hepatitis C virus genotype 4 in Denmark. <i>Journal of Medical Virology</i> , 2010, 82, 1869-1877.	5.0	12
300	Performance of two Real-Time RT-PCR assays for quantitation of hepatitis C virus RNA: Evaluation on HCV genotypes 1-4. <i>Journal of Medical Virology</i> , 2010, 82, 1878-1888.	5.0	20
301	Accelerating Proof of Concept for Small Molecule Drugs Using Solid-State Chemistry. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 3665-3675.	3.3	22
302	Relating the liver damage with hepatitis C virus polymorphism in core region and human variables in HIV-1-coinfected patients. <i>Infection, Genetics and Evolution</i> , 2010, 10, 1252-1261.	2.3	3
303	Epidemic history of Hepatitis C virus in Brazil. <i>Infection, Genetics and Evolution</i> , 2010, 10, 886-895.	2.3	26
304	Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory. <i>Reviews in Medical Virology</i> , 2010, 20, 117-129.	8.3	101
305	Alcohol and Hepatitis C Virus Interactions in Immune Dysfunctions and Liver Damage. <i>Alcoholism: Clinical and Experimental Research</i> , 2010, 34, 1675-1686.	2.4	70
306	The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. <i>Liver International</i> , 2010, 30, 342-355.	3.9	145

#	ARTICLE	IF	CITATIONS
307	Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. <i>Liver International</i> , 2010, 30, 1259-1269.	3.9	139
308	Prevalence of intrinsic disorder in the hepatitis C virus ARFP/Core+1/S protein. <i>FEBS Journal</i> , 2010, 277, 774-789.	4.7	13
309	An Assessment of the Use of Chimpanzees in Hepatitis C Research Past, Present and Future: 1. Validity of the Chimpanzee Model. <i>ATLA Alternatives To Laboratory Animals</i> , 2010, 38, 387-418.	1.0	13
310	High Prevalence of Hepatitis C Virus Genotype 1b Infection in a Small Town of Argentina. Phylogenetic and Bayesian Coalescent Analysis. <i>PLoS ONE</i> , 2010, 5, e8751.	2.5	21
311	Tailoring Treatment Duration to 12 to 16 Weeks in Hepatitis C Genotype 2 or 3 With Rapid Virologic Response. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 583-587.	2.2	4
312	The Threshold Bootstrap Clustering: A New Approach to Find Families or Transmission Clusters within Molecular Quasispecies. <i>PLoS ONE</i> , 2010, 5, e13619.	2.5	15
313	Baseline Prediction of Combination Therapy Outcome in Hepatitis C Virus 1b Infected Patients by Discriminant Analysis Using Viral and Host Factors. <i>PLoS ONE</i> , 2010, 5, e14132.	2.5	25
314	Simultaneous Quantification and Genotyping of Hepatitis C Virus RNA by a Two-Step Real-Time PCR Assay on the Lightcycler Instrument. <i>Folia Medica</i> , 2010, 52, 21-30.	0.5	0
315	Weight loss, leukopenia and thrombocytopenia associated with sustained virologic response to Hepatitis C treatment. <i>International Journal of Medical Sciences</i> , 2010, 7, 36-42.	2.5	22
316	Hepatitis C virus genotypes in hemodialysis patients in the Federal District, Brazil. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2010, 52, 57-60.	1.1	2
317	1a/1b Subtype Profiling of Nonnucleoside Polymerase Inhibitors of Hepatitis C Virus. <i>Journal of Virology</i> , 2010, 84, 2923-2934.	3.4	39
318	NMR Structure and Ion Channel Activity of the p7 Protein from Hepatitis C Virus. <i>Journal of Biological Chemistry</i> , 2010, 285, 31446-31461.	3.4	119
319	Challenge Pools of Hepatitis C Virus Genotypes 1 and 6 Prototype Strains: Replication Fitness and Pathogenicity in Chimpanzees and Human Liver Chimeric Mouse Models. <i>Journal of Infectious Diseases</i> , 2010, 201, 1381-1389.	4.0	67
320	Genotyping of Hepatitis C Virus by Sequence Analysis of the Amplicon from the Roche Cobas AmpliPrep/Cobas TaqMan Viral Load Assay. <i>Journal of Clinical Microbiology</i> , 2010, 48, 671-672.	3.9	1
321	Novel Infectious cDNA Clones of Hepatitis C Virus Genotype 3a (Strain S52) and 4a (Strain ED43): Genetic Analyses and <i>In Vivo</i> Pathogenesis Studies. <i>Journal of Virology</i> , 2010, 84, 5277-5293.	3.4	122
322	Preclinical Characterization of BI 201335, a C-Terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A Protease. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4611-4618.	3.2	107
323	Development of an Intergenotypic Hepatitis C Virus (HCV) Cell Culture Method To Assess Antiviral Susceptibilities and Resistance Development of HCV NS3 Protease Genes from HCV Genotypes 1 to 6. <i>Journal of Virology</i> , 2010, 84, 4597-4610.	3.4	34
324	Morphological Characterization and Fusion Properties of Triglyceride-rich Lipoproteins Obtained from Cells Transduced with Hepatitis C Virus Glycoproteins. <i>Journal of Biological Chemistry</i> , 2010, 285, 25802-25811.	3.4	13

#	ARTICLE	IF	CITATIONS
325	Performance evaluation of the Abbott RealTime HCV Genotype II for hepatitis C virus genotyping. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 469-474.	2.3	17
326	Development and evaluation of an automated hepatitis C virus NS5B sequence-based subtyping assay. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 1095-1102.	2.3	20
327	Hepatitis C Virus Hypervariable Region 1 Modulates Receptor Interactions, Conceals the CD81 Binding Site, and Protects Conserved Neutralizing Epitopes. <i>Journal of Virology</i> , 2010, 84, 5751-5763.	3.4	201
328	Clinical relevance of genetic heterogeneity in HCV. <i>Future Virology</i> , 2010, 5, 33-49.	1.8	6
329	A Novel Class of <i>meso</i> -Tetrakis-Porphyrin Derivatives Exhibits Potent Activities against Hepatitis C Virus Genotype 1b Replicons <i>In Vitro</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 197-206.	3.2	23
330	Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. <i>Viruses</i> , 2010, 2, 2696-2739.	3.3	35
331	Persistent Growth of a Human Plasma-Derived Hepatitis C Virus Genotype 1b Isolate in Cell Culture. <i>PLoS Pathogens</i> , 2010, 6, e1000910.	4.7	13
332	A New Insight into Hepatitis C Vaccine Development. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-12.	3.0	37
333	Lipid Metabolism and HCV Infection. <i>Viruses</i> , 2010, 2, 1195-1217.	3.3	43
334	Adaptation of Hepatitis C Virus to Mouse CD81 Permits Infection of Mouse Cells in the Absence of Human Entry Factors. <i>PLoS Pathogens</i> , 2010, 6, e1000978.	4.7	109
335	Clustering of rare peptide segments in the HCV immunome. <i>Self/nonself</i> , 2010, 1, 154-162.	2.0	17
337	Adaptive Immunity to the Hepatitis C Virus. <i>Advances in Virus Research</i> , 2010, 78, 43-86.	2.1	65
338	MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 305-311.	3.2	141
339	Hepatitis C Virus P7A Viroprotein Crucial for Virus Assembly and an Emerging Target for Antiviral Therapy. <i>Viruses</i> , 2010, 2, 2078-2095.	3.3	44
340	The Detection of Hepatitis Viruses. <i>Methods in Molecular Biology</i> , 2010, 665, 79-100.	0.9	1
341	Anti-HCV reactive volunteer blood donors distribution character and genotypes switch in Xi'an, China. <i>Virology Journal</i> , 2010, 7, 186.	3.4	13
342	Hepatitis C virus infection in Brazilian long-distance truck drivers. <i>Virology Journal</i> , 2010, 7, 205.	3.4	8
343	Epidemiological manifestations of hepatitis C virus genotypes and its association with potential risk factors among Libyan patients. <i>Virology Journal</i> , 2010, 7, 317.	3.4	33

#	ARTICLE	IF	CITATIONS
344	Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection. <i>Gastroenterology</i> , 2010, 138, 447-462.	1.3	489
345	Glucocorticosteroids Increase Cell Entry by Hepatitis C Virus. <i>Gastroenterology</i> , 2010, 138, 1875-1884.	1.3	68
346	Meta-Analysis of Hepatitis C Virus Vaccine Efficacy in Chimpanzees Indicates an Importance for Structural Proteins. <i>Gastroenterology</i> , 2010, 139, 965-974.	1.3	85
347	New NS5B polymerase inhibitors for hepatitis C. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 963-975.	4.1	77
348	Leukocytoclastic vasculitis and necrolytic acral erythema in patients with hepatitis C infection: Do viral load and viral genotype play a role?. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 259-265.	1.2	14
349	Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development. <i>Journal of Hepatology</i> , 2010, 52, 72-78.	3.7	53
350	Natural history of chronic hepatitis C: Genotype 1 versus genotype 6. <i>Journal of Hepatology</i> , 2010, 53, 444-448.	3.7	35
351	Natural intragenotypic and intergenotypic HCV recombinants are rare in southwest China even among patients with multiple exposures. <i>Journal of Clinical Virology</i> , 2010, 49, 272-276.	3.1	9
352	Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3â€“NS4A proteins. <i>Biochemical and Biophysical Research Communications</i> , 2010, 391, 692-697.	2.1	15
353	Circulating markers of liver fibrosis progression. <i>Clinica Chimica Acta</i> , 2010, 411, 1009-1017.	1.1	79
355	Serial Measurements of Hepatitis C Viral Load by Real-Time Polymerase Chain Reaction Among Recipients of Living-Donor Renal Transplants: A Short-Term Follow-Up Study From a Single Center. <i>Transplantation Proceedings</i> , 2010, 42, 3568-3573.	0.6	2
356	Murine neutralizing antibody response and toxicity to synthetic peptides derived from E1 and E2 proteins of hepatitis C virus. <i>Vaccine</i> , 2010, 28, 8338-8344.	3.8	10
357	Candidate hepatitis C vaccine trials and people who inject drugs: Challenges and opportunities. <i>Vaccine</i> , 2010, 28, 7273-7278.	3.8	21
358	Conflicting selection pressures target the NS3 protein in hepatitis C virus genotypes 1a and 1b. <i>Virus Research</i> , 2010, 147, 202-207.	2.2	5
359	Molecular epidemiology of hepatitis C virus genotypes in West Mexico. <i>Virus Research</i> , 2010, 151, 19-25.	2.2	20
360	Similar Treatment Response to Peginterferon and Ribavirin in Asian and Caucasian Patients With Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2010, 105, 1110-1115.	0.4	21
361	Hepatitis C Virus Genotyping Using an Oligonucleotide Microarray Based on the NS5B Sequence. <i>Journal of Clinical Microbiology</i> , 2010, 48, 3910-3917.	3.9	20
362	Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B. <i>Viruses</i> , 2010, 2, 2169-2195.	3.3	82

#	ARTICLE	IF	CITATIONS
364	Modern Infectious Disease Epidemiology. Statistics in the Health Sciences, 2010, , .	0.2	47
365	PCR for Clinical Microbiology. , 2010, , .		12
366	The metabolism and disposition of a potent inhibitor of hepatitis C virus NS3/4A protease. Xenobiotica, 2010, 40, 826-839.	1.1	16
367	Interferon in the treatment of chronic hepatitis C: a drug caught between past and future. Expert Opinion on Biological Therapy, 2011, 11, 301-313.	3.1	15
368	Hepatitis C Virus Infection Promotes Hepatic Gluconeogenesis through an NS5A-Mediated, FoxO1-Dependent Pathway. Journal of Virology, 2011, 85, 8556-8568.	3.4	84
369	Mapping a Region of Hepatitis C Virus E2 That Is Responsible for Escape from Neutralizing Antibodies and a Core CD81-Binding Region That Does Not Tolerate Neutralization Escape Mutations. Journal of Virology, 2011, 85, 10451-10463.	3.4	99
370	The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors. Clinics in Liver Disease, 2011, 15, 611-626.	2.1	50
371	Antiviral therapy: why does it fail in HCV-related chronic hepatitis?. Expert Review of Anti-Infective Therapy, 2011, 9, 535-543.	4.4	17
372	Recombinant HCV Variants With NS5A From Genotypes 1â€“7 Have Different Sensitivities to an NS5A Inhibitor but Not Interferon-Î±. Gastroenterology, 2011, 140, 1032-1042.e6.	1.3	132
373	Host genetics in immune-mediated hepatitis C virus clearance. Biomarkers in Medicine, 2011, 5, 155-169.	1.4	17
374	Hepatitis C virus infection in patients with tuberculosis in Central Brazil. International Journal of Tuberculosis and Lung Disease, 2011, 15, 1397-1402.	1.2	20
375	Vaccination for hepatitis C virus: closing in on an evasive target. Expert Review of Vaccines, 2011, 10, 659-672.	4.4	103
376	Differential Efficacy of Protease Inhibitors Against HCV Genotypes 2a, 3a, 5a, and 6a NS3/4A Protease Recombinant Viruses. Gastroenterology, 2011, 141, 1067-1079.	1.3	134
377	Identification of hnRNPH1, NF45, and C14orf166 as Novel Host Interacting Partners of the Mature Hepatitis C Virus Core Protein. Journal of Proteome Research, 2011, 10, 4522-4534.	3.7	38
378	Diagnostic Virology Protocols. Methods in Molecular Biology, 2011, , .	0.9	8
379	HCV genotype 4 circulating in the city of Franca, SÃ£o Paulo State, Brazil. Brazilian Journal of Infectious Diseases, 2011, 15, 300.	0.6	1
380	Divergent quasispecies evolution in de novo hepatitis C virus infection associated with bone marrow transplantation. Biochemical and Biophysical Research Communications, 2011, 414, 148-152.	2.1	2
381	Transmission of hepatitis C virus to recipients of parenteral vitamin therapy in a primary care facility. Journal of Clinical Virology, 2011, 51, 105-109.	3.1	2

#	ARTICLE	IF	CITATIONS
382	Hepatitis C virus resistance to protease inhibitors. <i>Journal of Hepatology</i> , 2011, 55, 192-206.	3.7	280
383	EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. <i>Journal of Hepatology</i> , 2011, 55, 245-264.	3.7	1,083
384	Hepatitis C in the general population of various ethnic origins living in the Netherlands: Should non-Western migrants be screened?. <i>Journal of Hepatology</i> , 2011, 55, 1207-1214.	3.7	32
385	New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles. <i>Vaccine</i> , 2011, 30, 69-77.	3.8	29
386	The molecular epidemiology of hepatitis E virus infection. <i>Virus Research</i> , 2011, 161, 31-39.	2.2	84
387	Sustained virological response of patients with hepatitis C virus genotype 2 depends on pegylated interferon compliance. <i>Hepatology Research</i> , 2011, 41, 722-730.	3.4	2
388	Host-specific HCV evolution and response to the combined interferon and ribavirin therapy. , 2011, , .		0
390	Geographical and chronological origin and evolution of Hepatitis C Virus.. <i>Nature Precedings</i> , 2011, , .	0.1	0
391	Infection of hepatitis C virus genotypes in hepatocellular carcinoma patients from rural areas of Faisalabad region, Pakistan. <i>African Journal of Biotechnology</i> , 2011, 10, 8471-8475.	0.6	0
393	Distribution of hepatitis C virus genotypes among different exposure categories in the State of Pará, Brazilian Amazon. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2011, 44, 8-12.	0.9	18
394	Association of hepatitis C virus NS5B variants with resistance to new antiviral drugs among untreated patients. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2011, 106, 968-975.	1.6	16
395	The Genetic and Molecular Studies of Hepatitis C Virus: A Review. <i>Bayero Journal of Pure and Applied Sciences</i> , 2011, 4, .	0.2	3
396	A Novel Genotype of GB Virus C: Its Identification and Predominance among Injecting Drug Users in Yunnan, China. <i>PLoS ONE</i> , 2011, 6, e21151.	2.5	55
397	Cell Culture Replication of a Genotype 1b Hepatitis C Virus Isolate Cloned from a Patient Who Underwent Liver Transplantation. <i>PLoS ONE</i> , 2011, 6, e23587.	2.5	14
398	Structural Basis for Broad Neutralization of Hepatitis C Virus Quasispecies. <i>PLoS ONE</i> , 2011, 6, e26981.	2.5	10
399	NS4B Self-Interaction through Conserved C-Terminal Elements Is Required for the Establishment of Functional Hepatitis C Virus Replication Complexes. <i>Journal of Virology</i> , 2011, 85, 6963-6976.	3.4	107
403	Ns3 Protease of Genotype 3 Subtype H HCV Identified in Southeastern France. <i>Antiviral Therapy</i> , 2011, 16, 615-619.	1.0	5
404	Hepatitis C virus: How genetic variability affects pathobiology of disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 83-95.	2.8	58

#	ARTICLE	IF	CITATIONS
405	Systematic review: epidemiology of hepatitis C genotype 6 and its management. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 286-296.	3.7	62
406	New trends of HCV infection in China revealed by genetic analysis of viral sequences determined from first-time volunteer blood donors. <i>Journal of Viral Hepatitis</i> , 2011, 18, 42-52.	2.0	68
407	Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated interferon alpha 2b and ribavirin combination therapy. <i>Journal of Viral Hepatitis</i> , 2011, 18, 280-286.	2.0	27
408	Genetic recombination of the hepatitis C virus: clinical implications. <i>Journal of Viral Hepatitis</i> , 2011, 18, 77-83.	2.0	61
409	How to use virological tools for the optimal management of chronic hepatitis C. <i>Liver International</i> , 2011, 31, 3-12.	3.9	19
410	Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg interferon and ribavirin therapy. <i>Liver International</i> , 2011, 31, 1359-1365.	3.9	29
411	Occupational transmission of hepatitis C virus resulting from use of the same supermarket meat slicer. <i>Clinical Microbiology and Infection</i> , 2011, 17, 238-241.	6.0	2
412	High genetic diversity including potential new subtypes of hepatitis C virus genotype 6 in Lao People's Democratic Republic. <i>Clinical Microbiology and Infection</i> , 2011, 17, E30-E34.	6.0	32
414	Non-genotype-specific role of the hepatitis C virus 5' untranslated region in virus production and in inhibition by interferon. <i>Virology</i> , 2011, 421, 222-234.	2.4	21
415	NS4A protein as a marker of HCV history suggests that different HCV genotypes originally evolved from genotype 1b. <i>Virology Journal</i> , 2011, 8, 317.	3.4	9
416	Hepatitis C virus genotypes in Pakistan: a systemic review. <i>Virology Journal</i> , 2011, 8, 433.	3.4	84
417	Naturally occurring genotype 2b/1a hepatitis C virus in the United States. <i>Virology Journal</i> , 2011, 8, 458.	3.4	29
418	Molecular epidemiology of hepatitis C infection in Cyprus within the general population and high-risk cohorts. <i>BMC Research Notes</i> , 2011, 4, 468.	1.4	4
419	Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity. <i>Antiviral Research</i> , 2011, 89, 136-148.	4.1	41
420	Current Perspective of HCV NS5B Inhibitors: A Review. <i>Current Medicinal Chemistry</i> , 2011, 18, 5564-5597.	2.4	32
421	Advances in hepatitis C virus vaccines, part one: advances in basic knowledge for hepatitis C virus vaccine design. <i>Expert Opinion on Therapeutic Patents</i> , 2011, 21, 1811-1830.	5.0	28
422	Hepatitis C virus and non-Hodgkin's lymphoma: biology, epidemiology and therapy. <i>Oncology Reviews</i> , 2011, 5, 249-260.	1.8	2
423	Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients. <i>Journal of Gastroenterology</i> , 2011, 46, 929-937.	5.1	28

#	ARTICLE	IF	CITATIONS
424	Identification and characterization of a natural inter-genotypic (2b/1b) recombinant hepatitis C virus in Japan. <i>Archives of Virology</i> , 2011, 156, 1591-1601.	2.1	23
425	Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California. <i>BMC Infectious Diseases</i> , 2011, 11, 208.	2.9	19
426	Distribution of hepatitis c virus (hcv) genotypes in patients with chronic infection from Rondônia, Brazil. <i>Virology Journal</i> , 2011, 8, 165.	3.4	9
427	Comparative performance evaluation of hepatitis C virus genotyping based on the 5' untranslated region versus partial sequencing of the NS5B region of brazilian patients with chronic hepatitis C. <i>Virology Journal</i> , 2011, 8, 459.	3.4	20
428	Long-term outcome of hepatitis C virus infections acquired after pediatric liver transplantation. <i>Liver Transplantation</i> , 2011, 17, 1474-1480.	2.4	6
429	Genotypes and viral load of hepatitis C virus among persons attending a voluntary counseling and testing center in Ethiopia. <i>Journal of Medical Virology</i> , 2011, 83, 776-782.	5.0	14
430	Mutations in two PKR-binding domains in chronic hepatitis C of genotype 3a and correlation with viral loads and interferon responsiveness. <i>Journal of Medical Virology</i> , 2011, 83, 1727-1732.	5.0	9
431	Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy. <i>Journal of Medical Virology</i> , 2011, 83, 437-444.	5.0	15
432	Hepatitis C virus sequences from different patients confirm the existence and transmissibility of subtype 2q, a rare subtype circulating in the metropolitan area of Barcelona, Spain. <i>Journal of Medical Virology</i> , 2011, 83, 820-826.	5.0	10
433	Molecular characterization of hepatitis C virus genotype 4 sequences in HIV-coinfected patients from Argentina. <i>Journal of Medical Virology</i> , 2011, 83, 935-940.	5.0	8
434	The effects of widespread methadone treatment on the molecular epidemiology of hepatitis C virus infection among injection drug users in Hong Kong. <i>Journal of Medical Virology</i> , 2011, 83, 1187-1194.	5.0	12
435	Near-full genome characterization of unclassified hepatitis c virus strains relating to genotypes 1 and 4. <i>Journal of Medical Virology</i> , 2011, 83, 2119-2127.	5.0	8
436	MicroRNAs and the resolution phase of inflammation in macrophages. <i>European Journal of Immunology</i> , 2011, 41, 2482-2485.	2.9	100
437	Hepatitis C virus targets the T cell secretory machinery as a mechanism of immune evasion. <i>Hepatology</i> , 2011, 53, 1846-1853.	7.3	14
438	Reconstruction of the evolutionary dynamics of the hepatitis C virus 1b epidemic in Turkey. <i>Infection, Genetics and Evolution</i> , 2011, 11, 863-868.	2.3	17
439	RNA-dependent RNA polymerases from different hepatitis C virus genotypes reveal distinct biochemical properties and drug susceptibilities. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2011, 1814, 1325-1332.	2.3	6
440	Evolutionary history of hepatitis C virus genotype 5a in France, a multicenter ANRS study. <i>Infection, Genetics and Evolution</i> , 2011, 11, 496-503.	2.3	14
441	Immunotherapeutic potential of neutralizing antibodies targeting conserved regions of the HCV envelope glycoprotein E2. <i>Future Microbiology</i> , 2011, 6, 279-294.	2.0	16

#	ARTICLE	IF	CITATIONS
442	MicroRNA-122 antagonism against hepatitis C virus genotypes 1â€“6 and reduced efficacy by host RNA insertion or mutations in the HCV 5â€“2 UTR. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4991-4996.	7.1	182
443	Hepatitis C Patient-Derived Glycoproteins Exhibit Marked Differences in Susceptibility to Serum Neutralizing Antibodies: Genetic Subtype Defines Antigenic but Not Neutralization Serotype. Journal of Virology, 2011, 85, 4246-4257.	3.4	51
444	The Five Hepatitis Viruses. Journal of Tropical Pediatrics, 2011, 57, 401-404.	1.5	2
445	High levels of HCV core+1 antibodies in HCV patients with hepatocellular carcinoma. Journal of General Virology, 2011, 92, 1343-1351.	2.9	29
446	Efficient Culture Adaptation of Hepatitis C Virus Recombinants with Genotype-Specific Core-NS2 by Using Previously Identified Mutations. Journal of Virology, 2011, 85, 2891-2906.	3.4	67
447	Hepatitis C Virus Infection Causes Cell Cycle Arrest at the Level of Initiation of Mitosis. Journal of Virology, 2011, 85, 7989-8001.	3.4	84
448	Coevolution of the Hepatitis C Virus Polyprotein Sites in Patients on Combined Pegylated Interferon and Ribavirin Therapy. Journal of Virology, 2011, 85, 3649-3663.	3.4	20
449	Near-Full Genome Characterisation of Two Natural Intergenotypic 2k/1b Recombinant Hepatitis C Virus Isolates. Advances in Virology, 2011, 2011, 1-7.	1.1	17
450	Seroprevalence and Genotype of Hepatitis C Virus among Immigrant Workers from Cambodia and Myanmar in Thailand. Intervirology, 2011, 54, 10-16.	2.8	30
451	Phylogenomics of Hepatitis C Virus Subtype 2c in the Province of CÃ³rdoba, Argentina. PLoS ONE, 2011, 6, e19471.	2.5	14
452	Absolute Quantitation of Different Genotypes of Hepatitis C Virus RNA in Clinical Samples by a Modified Real-Time PCR Method. Laboratory Medicine, 2011, 42, 333-337.	1.2	0
453	Development and Application of Hepatitis C Reporter Viruses with Genotype 1 to 7 Core-Nonstructural Protein 2 (NS2) Expressing Fluorescent Proteins or Luciferase in Modified JFH1 NS5A. Journal of Virology, 2011, 85, 8913-8928.	3.4	77
454	Conserved GXXXG- and S/T-Like Motifs in the Transmembrane Domains of NS4B Protein Are Required for Hepatitis C Virus Replication. Journal of Virology, 2011, 85, 6464-6479.	3.4	24
455	Recombination in hepatitis C virus genotype 1 evaluated by phylogenetic and population-genetic methods. Journal of General Virology, 2011, 92, 279-286.	2.9	5
456	Identification of New Functional Regions in Hepatitis C Virus Envelope Glycoprotein E2. Journal of Virology, 2011, 85, 1777-1792.	3.4	64
457	Hepatitis C Virus Genotypes in Clinical Specimens Tested at a National Reference Testing Laboratory in the United States. Journal of Clinical Microbiology, 2011, 49, 3040-3043.	3.9	29
458	Affinity Maturation to Improve Human Monoclonal Antibody Neutralization Potency and Breadth against Hepatitis C Virus. Journal of Biological Chemistry, 2011, 286, 44218-44233.	3.4	28
459	Completion of Hepatitis C Virus Replication Cycle in Heterokaryons Excludes Dominant Restrictions in Human Non-liver and Mouse Liver Cell Lines. PLoS Pathogens, 2011, 7, e1002029.	4.7	23

#	ARTICLE	IF	CITATIONS
460	Inactivation and Survival of Hepatitis C Virus on Inanimate Surfaces. <i>Journal of Infectious Diseases</i> , 2011, 204, 1830-1838.	4.0	90
461	A Concerted Action of Hepatitis C Virus P7 and Nonstructural Protein 2 Regulates Core Localization at the Endoplasmic Reticulum and Virus Assembly. <i>PLoS Pathogens</i> , 2011, 7, e1002144.	4.7	130
462	Hepatitis C Virus Evasion Mechanisms from Neutralizing Antibodies. <i>Viruses</i> , 2011, 3, 2280-2300.	3.3	53
463	Recombination in Hepatitis C Virus. <i>Viruses</i> , 2011, 3, 2006-2024.	3.3	78
464	Evaluation of Multiplex Nested Polymerase Chain Reaction for Routine Hepatitis C Virus Genotyping in Egyptian Patients. <i>Hepatitis Monthly</i> , 2012, 12, 265-670.	0.2	8
465	Cyclosporine as Monotherapy for Psoriasis in the Setting of Chronic HCV Infection: A Forgotten Therapeutical Option. <i>Hepatitis Monthly</i> , 2012, 12, 349-352.	0.2	4
466	Hepatitis C Viral Heterogeneity Based on Core Gene and an Attempt to Design Small Interfering RNA Against Strains Resistant to Interferon in Rawalpindi, Pakistan. <i>Hepatitis Monthly</i> , 2012, 12, 398-407.	0.2	3
467	Animal Models of Human Pathology 2012. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-2.	3.0	2
468	HCV Proteins and Immunoglobulin Variable Gene (IgV) Subfamilies in HCV-Induced Type II Mixed Cryoglobulinemia: A Concurrent Pathogenetic Role. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-11.	3.3	15
469	Analysis of Functional Differences between Hepatitis C Virus NS5A of Genotypes 1-7 in Infectious Cell Culture Systems. <i>PLoS Pathogens</i> , 2012, 8, e1002696.	4.7	34
470	Chronic Hepatitis C in Saudi Arabia: Three Years Local Experience in a University Hospital. <i>Hepatitis Monthly</i> , 2012, 12, e6178.	0.2	10
471	The p7 Protein of Hepatitis C Virus Forms Structurally Plastic, Minimalist Ion Channels. <i>PLoS Computational Biology</i> , 2012, 8, e1002702.	3.2	60
472	Human Monoclonal Antibodies to a Novel Cluster of Conformational Epitopes on HCV E2 with Resistance to Neutralization Escape in a Genotype 2a Isolate. <i>PLoS Pathogens</i> , 2012, 8, e1002653.	4.7	201
473	Advancement in the Development of Models for Hepatitis C Research. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-7.	3.0	8
474	Base Pairing between Hepatitis C Virus RNA and MicroRNA 122 3' of Its Seed Sequence Is Essential for Genome Stabilization and Production of Infectious Virus. <i>Journal of Virology</i> , 2012, 86, 7372-7383.	3.4	74
475	Hepatic steatosis in HCV infection genotype 4 in Egypt. <i>Egyptian Liver Journal</i> , 2012, 2, 16-21.	0.6	3
476	Immunogenicity and Cross-Reactivity of a Representative Ancestral Sequence in Hepatitis C Virus Infection. <i>Journal of Immunology</i> , 2012, 188, 5177-5188.	0.8	28
477	HAVCR1 Gene Haplotypes and Infection by Different Viral Hepatitis C Virus Genotypes. <i>Vaccine Journal</i> , 2012, 19, 223-227.	3.1	8

#	ARTICLE	IF	CITATIONS
478	Colonial History and Contemporary Transmission Shape the Genetic Diversity of Hepatitis C Virus Genotype 2 in Amsterdam. <i>Journal of Virology</i> , 2012, 86, 7677-7687.	3.4	48
479	Three Different Functional Microdomains in the Hepatitis C Virus Hypervariable Region 1 (HVR1) Mediate Entry and Immune Evasion. <i>Journal of Biological Chemistry</i> , 2012, 287, 35631-35645.	3.4	45
480	Computational Reconstruction of Bole1a, a Representative Synthetic Hepatitis C Virus Subtype 1a Genome. <i>Journal of Virology</i> , 2012, 86, 5915-5921.	3.4	21
481	Multiple Mutations in Hepatitis C Virus NS5A Domain II Are Required To Confer a Significant Level of Resistance to Alisporivir. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5113-5121.	3.2	39
482	Amino Acid Residue-Specific Neutralization and Nonneutralization of Hepatitis C Virus by Monoclonal Antibodies to the E2 Protein. <i>Journal of Virology</i> , 2012, 86, 12686-12694.	3.4	29
483	Ketoamide Resistance and Hepatitis C Virus Fitness in Val55 Variants of the NS3 Serine Protease. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1907-1915.	3.2	32
484	Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 19757-19762.	7.1	109
485	Conserved Glycine 33 Residue in Flexible Domain I of Hepatitis C Virus Core Protein Is Critical for Virus Infectivity. <i>Journal of Virology</i> , 2012, 86, 679-690.	3.4	17
486	The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors. <i>PLoS Pathogens</i> , 2012, 8, e1002832.	4.7	179
487	Structural Analysis of Hepatitis C Virus Core-E1 Signal Peptide and Requirements for Cleavage of the Genotype 3a Signal Sequence by Signal Peptide Peptidase. <i>Journal of Virology</i> , 2012, 86, 7818-7828.	3.4	21
488	Eleven-Year Distribution Pattern of Hepatitis C Virus in Southern Italy. <i>Journal of Pathogens</i> , 2012, 2012, 1-7.	1.4	19
489	Evolving Trends in the Hepatitis C Virus Molecular Epidemiology Studies: From the Viral Sequences to the Human Genome. <i>Epidemiology Research International</i> , 2012, 2012, 1-10.	0.2	4
490	Naturally Occurring Antibodies That Recognize Linear Epitopes in the Amino Terminus of the Hepatitis C Virus E2 Protein Confer Noninterfering, Additive Neutralization. <i>Journal of Virology</i> , 2012, 86, 2739-2749.	3.4	54
491	Genetic Diversity of Recently Acquired and Prevalent HIV, Hepatitis B Virus, and Hepatitis C Virus Infections in US Blood Donors. <i>Journal of Infectious Diseases</i> , 2012, 205, 875-885.	4.0	54
492	Hepatitis C and Hepatocellular Carcinoma: Implications for Pathogenesis and Treatment. , 2012, , 143-203.		0
493	Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms?. <i>Antiviral Therapy</i> , 2012, 17, 1163-1170.	1.0	7
494	Hepatitis C virus genotype 5: an orphan virus. <i>Antiviral Therapy</i> , 2012, 18, 263-269.	1.0	4
495	4 Biological validation of blood components. , 0, , .		0

#	ARTICLE	IF	CITATIONS
497	Evaluation of the immunogenicity of liposome encapsulated HVR1 and NS3 regions of genotype 3 HCV, either singly or in combination. <i>Virology Journal</i> , 2012, 9, 74.	3.4	10
498	In Vitro and Ex Vivo Delivery of Short Hairpin RNAs for Control of Hepatitis C Viral Transcript Expression. <i>Archives of Surgery</i> , 2012, 147, 384.	2.2	4
499	Limited effect on NS3â€“NS4A protein cleavage after alanine substitutions within the immunodominant HLA-A2-restricted epitope of the hepatitis C virus genotype 3a non-structural 3/4A protease. <i>Journal of General Virology</i> , 2012, 93, 1680-1686.	2.9	0
500	Insertion and recombination events at hypervariable region 1 over 9.6 years of hepatitis C virus chronic infection. <i>Journal of General Virology</i> , 2012, 93, 2614-2624.	2.9	20
501	Evaluation of Two Hepatitis C Virus Genotyping Assays Based on the 5â€² Untranslated Region (UTR): the Limitations of 5â€² UTR-Based Assays and the Need for a Supplementary Sequencing-Based Approach. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3741-3743.	3.9	13
502	Reproductive clonality of pathogens: A perspective on pathogenic viruses, bacteria, fungi, and parasitic protozoa. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E3305-13.	7.1	177
504	Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 2481-2531.	6.4	253
505	New insights into hepatitis C virus infection in the tribal-dominant part of Northeast India. <i>Archives of Virology</i> , 2012, 157, 2083-2093.	2.1	30
506	Does interferon and ribavirin combination therapy ameliorate growth hormone deficiency in HCV genotype-4 infected patients?. <i>Clinical Biochemistry</i> , 2012, 45, 3-6.	1.9	9
507	Treating hepatitis C infection by targeting the host. <i>Translational Research</i> , 2012, 159, 421-429.	5.0	11
508	Distribution and molecular characterization of hepatitis C virus (HCV) genotypes in patients with chronic infection from Pernambuco State, Brazil. <i>Virus Research</i> , 2012, 169, 8-12.	2.2	6
509	Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein. <i>Virus Research</i> , 2012, 170, 1-14.	2.2	76
510	Molecular analysis of hepatitis E virus from farm rabbits in Inner Mongolia, China and its successful propagation in A549 and PLC/PRF/5 cells. <i>Virus Research</i> , 2012, 170, 126-137.	2.2	43
511	Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis. <i>Molecular BioSystems</i> , 2012, 8, 2753.	2.9	26
512	Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E1101-10.	7.1	78
513	Proteomic Analysis of Hepatitis C Virus (HCV) Core Protein Transfection and Host Regulator PA28 ³ Knockout in HCV Pathogenesis: A Network-Based Study. <i>Journal of Proteome Research</i> , 2012, 11, 3664-3679.	3.7	13
514	Functional reconstitution of defective myeloid dendritic cells in chronic hepatitis C infection on successful antiviral treatment. <i>Liver International</i> , 2012, 32, 1128-1137.	3.9	11
515	A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C. <i>Journal of Hepatology</i> , 2012, 56, 1012-1018.	3.7	34

#	ARTICLE	IF	CITATIONS
516	Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2â€™6: TMC435-C202, a phase IIa, open-label study. <i>Journal of Hepatology</i> , 2012, 56, 1247-1253.	3.7	98
517	Hepatitis C virus genotype distribution varies by underlying disease status among patients in the same geographic region: A retrospective multicenter study. <i>Journal of Clinical Virology</i> , 2012, 54, 218-222.	3.1	11
518	Complex patterns of HCV epidemic in Suzhou: Evidence for dual infection and HCV recombination in East China. <i>Journal of Clinical Virology</i> , 2012, 54, 207-212.	3.1	25
519	Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2012, 48, 1977-1987.	2.8	94
520	Hepatitis C virus genotype 4d in Southern Italy: Reconstruction of its origin and spread by a phylodynamic analysis. <i>Journal of Medical Virology</i> , 2012, 84, 1613-1619.	5.0	29
521	Distribution of hepatitis C virus genotypes in a diverse US integrated health care population. <i>Journal of Medical Virology</i> , 2012, 84, 1744-1750.	5.0	78
522	Modulation of replication efficacy of the hepatitis C virus replicon Con1 by siteâ€™directed mutagenesis of an NS4B aminoterminal basic leucine zipper. <i>Journal of Viral Hepatitis</i> , 2012, 19, 775-783.	2.0	3
523	NS5A Sequence Heterogeneity of Hepatitis C Virus Genotype 4a Predicts Clinical Outcome of Pegylated-Interferonâ€™Ribavirin Therapy in Egyptian Patients. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3886-3892.	3.9	17
524	Distribution of hepatitis <sc>C</sc> virus genotypes in <sc>C</sc>hinese patients with chronic hepatitis <sc>C</sc>: Correlation with patientsâ€™ characteristics and clinical parameters. <i>Journal of Digestive Diseases</i> , 2012, 13, 564-570.	1.5	17
525	Laboratory Diagnostics for Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2012, 55, S43-S48.	5.8	135
526	Systems Biology Analyses to Define Host Responses to HCV Infection and Therapy. <i>Current Topics in Microbiology and Immunology</i> , 2012, 363, 143-167.	1.1	3
527	A Plant-Derived Flavonoid Inhibits Entry of All HCV Genotypes Into Human Hepatocytes. <i>Gastroenterology</i> , 2012, 143, 213-222.e5.	1.3	111
528	Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference. <i>Antiviral Research</i> , 2012, 96, 82-89.	4.1	27
529	New targets for treatment against HCV infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 505-515.	2.4	1
530	Genetic characterization and codon usage bias of full-length Hepatitis E virus sequences shed new lights on genotypic distribution, host restriction and genome evolution. <i>Infection, Genetics and Evolution</i> , 2012, 12, 1842-1853.	2.3	38
531	Hepatitis C Therapy: Lessons of the Last Two Decades. <i>Current Hepatitis Reports</i> , 2012, 11, 119-127.	0.3	1
532	Chronic Hepatitis C Virus. , 2012, , .		3
533	Flaviviridae. , 2012, , 1003-1020.		22

#	ARTICLE	IF	CITATIONS
534	Phylogeny and phylodynamic of Hepatitis C in Italy. BMC Infectious Diseases, 2012, 12, S5.	2.9	17
535	Future research and collaboration: the "SINERGIE" project on HCV (South Italian Network for) Tj ETQq1 1 0.784314 rgBT /Overlo	2.9	12
536	Viral Sequence Variation in Chronic Carriers of Hepatitis C Virus Has a Low Impact on Liver Steatosis. PLoS ONE, 2012, 7, e33749.	2.5	6
537	Phylogeography, Risk Factors and Genetic History of Hepatitis C Virus in Gabon, Central Africa. PLoS ONE, 2012, 7, e42002.	2.5	51
538	Molecular Survey of Hepatitis C Virus in the Touristic City of Mar Del Plata, Argentina. PLoS ONE, 2012, 7, e44757.	2.5	7
539	Interplay between Basic Residues of Hepatitis C Virus Glycoprotein E2 with Viral Receptors, Neutralizing Antibodies and Lipoproteins. PLoS ONE, 2012, 7, e52651.	2.5	18
540	A Gaussia Luciferase Cell-Based System to Assess the Infection of Cell Culture- and Serum-Derived Hepatitis C Virus. PLoS ONE, 2012, 7, e53254.	2.5	7
542	Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C Group Study. Annals of Hepatology, 2012, 11, 338-342.	1.5	9
543	Genomic determinants of hepatitis C virus antiviral therapy outcomes: toward individualized treatment. Annals of Hepatology, 2012, 11, 827-837.	1.5	6
544	Nonprimate Hepaciviruses in Domestic Horses, United Kingdom. Emerging Infectious Diseases, 2012, 18, 1976-1982.	4.3	98
545	Prevalence of Hepatitis C Virus Infections and Distribution of Hepatitis C Virus Genotypes among Korean Blood Donors. Annals of Laboratory Medicine, 2012, 32, 210-215.	2.5	29
546	Epidemic history of hepatitis C virus infection in two remote communities in Nigeria, West Africa. Journal of General Virology, 2012, 93, 1410-1421.	2.9	41
547	Full-length sequences of 11 hepatitis C virus genotype 2 isolates representing five subtypes and six unclassified lineages with unique geographical distributions and genetic variation patterns. Journal of General Virology, 2012, 93, 1173-1184.	2.9	26
548	Prospects for Prophylactic and Therapeutic Vaccines Against Hepatitis C Virus. Clinical Infectious Diseases, 2012, 55, S25-S32.	5.8	49
549	Assays for RNA synthesis and replication by the hepatitis C virus. Frontiers in Biology, 2012, 7, 233-245.	0.7	1
550	Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agents. Immunologic Research, 2012, 52, 200-210.	2.9	41
551	Human poly- and cross-reactive anti-viral antibodies and their impact on protection and pathology. Immunologic Research, 2012, 53, 148-161.	2.9	20
552	APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatology International, 2012, 6, 409-435.	4.2	152

#	ARTICLE	IF	CITATIONS
553	Hepatitis C virus amino acid sequence diversity correlates with the outcome of combined interferon/ribavirin therapy in Chinese patients with chronic hepatitis C. <i>Archives of Virology</i> , 2012, 157, 1113-1121.	2.1	4
554	Reducing agents affect inhibitory activities of compounds: Results from multiple drug targets. <i>Analytical Biochemistry</i> , 2012, 423, 46-53.	2.4	31
555	An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. <i>Liver International</i> , 2012, 32, 339-345.	3.9	104
556	2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. <i>Liver International</i> , 2012, 32, 2-8.	3.9	101
557	Oxidative stress, endogenous antioxidants, alcohol, and hepatitis C: pathogenic interactions and therapeutic considerations. <i>Free Radical Biology and Medicine</i> , 2012, 52, 1135-1150.	2.9	65
558	Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435. <i>Antiviral Research</i> , 2012, 93, 126-137.	4.1	79
559	New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials. <i>International Journal of Clinical Practice</i> , 2012, 66, 342-355.	1.7	55
560	A novel assay for detection of hepatitis C virus-specific effector CD4+ T cells via co-expression of CD25 and CD134. <i>Journal of Immunological Methods</i> , 2012, 375, 148-158.	1.4	29
561	Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a. <i>Virology</i> , 2012, 429, 57-62.	2.4	21
562	Hepatitis C virus "T" cell responses and viral escape mutations. <i>European Journal of Immunology</i> , 2012, 42, 17-26.	2.9	33
563	Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated interferon-alpha 2b and ribavirin. <i>Journal of Medical Virology</i> , 2012, 84, 438-444.	5.0	20
564	Introduction of new subtypes and variants of hepatitis C virus genotype 4 in South Africa. <i>Journal of Medical Virology</i> , 2012, 84, 601-607.	5.0	22
565	A clustering phenomenon among HCV 1a strains among patients coinfecting with HIV from Buenos Aires, Argentina. <i>Journal of Medical Virology</i> , 2012, 84, 570-581.	5.0	6
566	Hepatitis C virus infection in the Middle East and North Africa "MENA" region: injecting drug users (IDUs) is an under-investigated population. <i>Infection</i> , 2012, 40, 1-10.	4.7	12
567	Differential Reactivity to IMPDH2 by Anti-rod/rings Autoantibodies and Unresponsiveness to Pegylated Interferon-alpha/Ribavirin Therapy in US and Italian HCV Patients. <i>Journal of Clinical Immunology</i> , 2013, 33, 420-426.	3.8	46
568	The modulation of apoptosis by oncogenic viruses. <i>Virology Journal</i> , 2013, 10, 182.	3.4	43
569	Novel therapies for hepatitis C "one pill fits all?". <i>Nature Reviews Drug Discovery</i> , 2013, 12, 595-610.	46.4	174
570	The presence of resistance mutations to protease and polymerase inhibitors in hepatitis C virus sequences from the <i>Los Alamos</i> databank. <i>Journal of Viral Hepatitis</i> , 2013, 20, 414-421.	2.0	42

#	ARTICLE	IF	CITATIONS
571	Hepatitis C virus infection in the Maghreb region. <i>Journal of Medical Virology</i> , 2013, 85, 1542-1549.	5.0	22
572	Entry and replication of recombinant hepatitis C viruses in cell culture. <i>Methods</i> , 2013, 59, 233-248.	3.8	46
573	Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. <i>BMC Infectious Diseases</i> , 2013, 13, 190.	2.9	48
574	Analysis of HCV quasispecies dynamic under selective pressure of combined therapy. <i>BMC Infectious Diseases</i> , 2013, 13, 61.	2.9	16
575	Hepatitis C virus genotype 4 in Southern and Central Spain does not originate from recent foreign migration waves. <i>Journal of Medical Virology</i> , 2013, 85, 1734-1740.	5.0	8
576	Response to peginterferon-alpha 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 1. <i>Hepatology International</i> , 2013, 7, 144-152.	4.2	8
577	Treating Chronic Hepatitis C Viral Infection: Rethinking Dose Reduction Strategies for PEG-IFN and Ribavirin in the Setting of New Direct Acting Agents. <i>Current Hepatitis Reports</i> , 2013, 12, 13-19.	0.3	0
578	Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance. <i>Infection, Genetics and Evolution</i> , 2013, 19, 113-119.	2.3	19
579	A panel of 16 full-length HCV genomes was characterized in China belonging to genotypes 1-6 including subtype 2f and two novel genotype 6 variants. <i>Infection, Genetics and Evolution</i> , 2013, 20, 225-229.	2.3	14
580	Generalized Linear Model (GLM) framework for the association of host variables and viral strains with liver fibrosis in HCV/HIV coinfecting patients. <i>Infection, Genetics and Evolution</i> , 2013, 13, 284-291.	2.3	7
581	An increased diversity of HCV isolates were characterized among 393 patients with liver disease in China representing six genotypes, 12 subtypes, and two novel genotype 6 variants. <i>Journal of Clinical Virology</i> , 2013, 57, 311-317.	3.1	18
582	Accuracy of a commercially available assay for HCV genotyping and subtyping in the clinical practice. <i>Journal of Clinical Virology</i> , 2013, 58, 593-597.	3.1	5
583	Nucleotide polymorphisms in the 5'-UTR region of HCV can affect the ability of two widely used assays to assign an HCV genotype. <i>Journal of Virological Methods</i> , 2013, 193, 205-208.	2.1	13
584	Detailed Computational Study of the Active Site of the Hepatitis C Viral RNA Polymerase to Aid Novel Drug Design. <i>Journal of Chemical Information and Modeling</i> , 2013, 53, 3031-3043.	5.4	27
585	Identification of Alpha Interferon-Induced Envelope Mutations of Hepatitis C Virus <i>In Vitro</i> Associated with Increased Viral Fitness and Interferon Resistance. <i>Journal of Virology</i> , 2013, 87, 12776-12793.	3.4	25
586	Identification of a series of 1,3,4-trisubstituted pyrazoles as novel hepatitis C virus entry inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 6467-6473.	2.2	14
587	Reconstruction of the evolutionary dynamics of hepatitis C virus subtypes in Montenegro and the Balkan region. <i>Infection, Genetics and Evolution</i> , 2013, 17, 223-230.	2.3	22
588	Predictors of treatment response in patients with hepatitis C 1b genotype. <i>Open Medicine (Poland)</i> , 2013, 8, 822-829.	1.3	0

#	ARTICLE	IF	CITATIONS
589	Progress towards a hepatitis C virus vaccine. <i>Emerging Microbes and Infections</i> , 2013, 2, 1-7.	6.5	41
590	Amplification and Sequencing of the Hepatitis C Virus NS3/4A Protease and the NS5B Polymerase Regions for Genotypic Resistance Detection of Clinical Isolates of Subtypes 1a and 1b. <i>Methods in Molecular Biology</i> , 2013, 1030, 137-149.	0.9	17
591	Development of a multiplex phenotypic cell-based high throughput screening assay to identify novel hepatitis C virus antivirals. <i>Antiviral Research</i> , 2013, 99, 6-11.	4.1	15
592	Virologic response and characterisation of HCV genotype 2 in patients receiving TMC435 monotherapy (study TMC435-C202). <i>Journal of Hepatology</i> , 2013, 58, 445-451.	3.7	82
593	Whole Genome Pyrosequencing of Rare Hepatitis C Virus Genotypes Enhances Subtype Classification and Identification of Naturally Occurring Drug Resistance Variants. <i>Journal of Infectious Diseases</i> , 2013, 208, 17-31.	4.0	37
594	Thermostability of seven hepatitis C virus genotypes <i>in vitro</i> and <i>in vivo</i> . <i>Journal of Viral Hepatitis</i> , 2013, 20, 478-485.	2.0	17
595	Telaprevir Activity in Treatment-Naive Patients Infected Hepatitis C Virus Genotype 4: A Randomized Trial. <i>Journal of Infectious Diseases</i> , 2013, 208, 1000-1007.	4.0	27
596	Molecular Epidemiology and Genetic History of Hepatitis C Virus Subtype 3a Infection in Thailand. <i>Intervirology</i> , 2013, 56, 284-294.	2.8	26
597	Development of Innovative and Versatile Polythiol Probes for Use on ELOSA or Electrochemical Biosensors: Application in Hepatitis C Virus Genotyping. <i>Analytical Chemistry</i> , 2013, 85, 9204-9212.	6.5	19
598	Analysis of hepatitis C virus core/NS5A protein co-localization using novel cell culture systems expressing core, NS2 and NS5A of genotypes 1-7. <i>Journal of General Virology</i> , 2013, 94, 2221-2235.	2.9	21
599	Nucleotide Prodrugs for the Treatment of HCV Infection. <i>Advances in Pharmacology</i> , 2013, 67, 39-73.	2.0	45
600	Hepatitis B and C virus infection among hemodialysis patients in Yogyakarta, Indonesia: Prevalence and molecular evidence for nosocomial transmission. <i>Journal of Medical Virology</i> , 2013, 85, 1348-1361.	5.0	29
601	Hepatitis C vaccines. , 2013, , 1074-1084.		0
602	Lipids and HCV. <i>Seminars in Immunopathology</i> , 2013, 35, 87-100.	6.1	89
603	Hepatitis C virus genotype diversity in Shanghai, China. <i>Archives of Virology</i> , 2013, 158, 187-191.	2.1	3
604	Prevalence and risk factors of hepatitis C and B virus infections in hemodialysis patients and their spouses: A multicenter study in Beijing, China. <i>Journal of Medical Virology</i> , 2013, 85, 425-432.	5.0	29
605	Evolutionary dynamics of the E1-E2 viral populations during combination therapy in non-responder patients chronically infected with hepatitis C virus subtype 1b. <i>Infection, Genetics and Evolution</i> , 2013, 13, 1-10.	2.3	4
606	Performance evaluation and comparison of the newly developed Elecsys anti-HCV II assay with other widely used assays. <i>Clinica Chimica Acta</i> , 2013, 426, 95-101.	1.1	19

#	ARTICLE	IF	CITATIONS
607	Validation of a solid-phase electrochemical array for genotyping hepatitis C virus. <i>Experimental and Molecular Pathology</i> , 2013, 95, 18-22.	2.1	19
608	Rapid and sustained autologous neutralizing response leading to early spontaneous recovery after HCV infection. <i>Virology</i> , 2013, 444, 90-99.	2.4	16
609	Construction and characterization of infectious hepatitis C virus chimera containing structural proteins directly from genotype 1b clinical isolates. <i>Virology</i> , 2013, 443, 80-88.	2.4	18
610	Infectivity of hepatitis C virus correlates with the amount of envelope protein E2: Development of a new aptamer-based assay system suitable for measuring the infectious titer of HCV. <i>Virology</i> , 2013, 439, 13-22.	2.4	42
611	Relapse of hepatitis C virus after 14 months of sustained virological response following pegylated-interferon alpha plus ribavirin therapy in a human immunodeficiency virus type 1 infected patient. <i>Journal of Clinical Virology</i> , 2013, 58, 309-314.	3.1	13
612	Accuracy of a commercially available assay for HCV genotyping and subtyping in the clinical practice. <i>Journal of Clinical Virology</i> , 2013, 58, 249-253.	3.1	40
613	Early Increased Ficolin-2 Concentrations are Associated with Severity of Liver Inflammation and Efficacy of anti-viral Therapy in Chronic Hepatitis C Patients. <i>Scandinavian Journal of Immunology</i> , 2013, 77, 144-150.	2.7	20
614	Molecular epidemiology of hepatitis C virus among different groups of people in the province of Fujian, China. <i>Archives of Virology</i> , 2013, 158, 611-618.	2.1	7
615	The Origin of Hepatitis C Virus. <i>Current Topics in Microbiology and Immunology</i> , 2013, 369, 1-15.	1.1	149
616	Full-length genome sequences of five hepatitis C virus isolates representing subtypes 3g, 3h, 3i and 3k, and a unique genotype 3 variant. <i>Journal of General Virology</i> , 2013, 94, 543-548.	2.9	23
617	Signal Peptide Peptidase. , 2013, , 281-284.		0
618	An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission. <i>Hepatology</i> , 2013, 58, 932-939.	7.3	69
619	Hepatitis C virus subtyping based on sequencing of the C/E1 and NS5B genomic regions in comparison to a commercially available line probe assay. <i>Journal of Medical Virology</i> , 2013, 85, 815-822.	5.0	40
620	A Hepatitis C Virus (HCV) Vaccine Comprising Envelope Glycoproteins gpE1/gpE2 Derived from a Single Isolate Elicits Broad Cross-Genotype Neutralizing Antibodies in Humans. <i>PLoS ONE</i> , 2013, 8, e59776.	2.5	151
621	Characterization of full-length hepatitis C virus sequences for subtypes 1e, 1h and 1l, and a novel variant revealed Cameroon as an area in origin for genotype 1. <i>Journal of General Virology</i> , 2013, 94, 1780-1790.	2.9	19
622	The C terminus of NS5A domain II is a key determinant of hepatitis C virus genome replication, but is not required for virion assembly and release. <i>Journal of General Virology</i> , 2013, 94, 1009-1018.	2.9	39
623	Cost-Effectiveness Analysis of Boceprevir for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Portugal. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 65-78.	2.1	34
624	Current progress in development of hepatitis C virus vaccines. <i>Nature Medicine</i> , 2013, 19, 869-878.	30.7	144

#	ARTICLE	IF	CITATIONS
625	Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine. <i>Hepatology</i> , 2013, 57, 1303-1313.	7.3	54
626	Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1107-1121.	4.1	67
627	Hepatitis C Virus-Associated Glomerulonephritis. <i>Contributions To Nephrology</i> , 2013, 181, 194-206.	1.1	11
628	T-cell responses in hepatitis B and C virus infection: similarities and differences. <i>Emerging Microbes and Infections</i> , 2013, 2, 1-8.	6.5	70
629	The Current Hepatitis C Virus Prevalence in China May Have Resulted Mainly from an Officially Encouraged Plasma Campaign in the 1990s: a Coalescence Inference with Genetic Sequences. <i>Journal of Virology</i> , 2013, 87, 12041-12050.	3.4	19
630	Endogenous IFN λ 3 in chronic HCV genotype 4 patients treated with PEG-IFN λ 2 and ribavirin. <i>Journal of Infection in Developing Countries</i> , 2013, 7, 859-867.	1.2	3
631	Hepatitis C Virus NS5B Sequence-Based Genotyping Analysis of Patients From the Sharkia Governorate, Egypt. <i>Hepatitis Monthly</i> , 2013, 13, e12706.	0.2	15
632	Combination Treatment with Hepatitis C Virus Protease and NS5A Inhibitors Is Effective against Recombinant Genotype 1a, 2a, and 3a Viruses. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1291-1303.	3.2	35
633	Hospital-Based Surveillance for Viral Hemorrhagic Fevers and Hepatitides in Ghana. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2435.	3.0	24
634	Distribution of Hepatitis C Virus Genotypes Among Patients With Hepatitis C Virus Infection in Hormozgan, Iran. <i>Hepatitis Monthly</i> , 2013, 13, e14324.	0.2	13
635	Productive Homologous and Non-homologous Recombination of Hepatitis C Virus in Cell Culture. <i>PLoS Pathogens</i> , 2013, 9, e1003228.	4.7	43
636	Evidence for Novel Hepaciviruses in Rodents. <i>PLoS Pathogens</i> , 2013, 9, e1003438.	4.7	187
637	Hepatitis C viral infection among prisoners. <i>Vojnosanitetski Pregled</i> , 2013, 70, 1006-1009.	0.2	1
638	Sensitive Detection of Viral Transcripts in Human Tumor Transcriptomes. <i>PLoS Computational Biology</i> , 2013, 9, e1003228.	3.2	29
639	A New Subtype of Hepatitis C Virus Genotype 3: Analysis of Available Evidence. <i>Hepatitis Monthly</i> , 2013, 13, e13380.	0.2	4
640	Structural Basis of HCV Neutralization by Human Monoclonal Antibodies Resistant to Viral Neutralization Escape. <i>PLoS Pathogens</i> , 2013, 9, e1003364.	4.7	86
641	Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2 λ 1 + Ribavirine Treated Chronic Hepatitis C Patients. <i>Hepatitis Monthly</i> , 2013, 13, e6750.	0.2	11
642	The comparison of the efficacy of pegylated interferon λ 2a and λ 2b in chronic hepatitis C patients with genotype 1. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 1082-1085.	1.6	9

#	ARTICLE	IF	CITATIONS
643	Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons $\hat{1}\pm$ -2a and $\hat{1}\pm$ -2b, plus ribavirin. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 1317-1320.	1.6	8
644	Positive ratio of specific antibodies to F protein in serum samples from chronic HCV-infected patients using an enzyme-linked immunosorbent assay. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 1.	1.6	2
645	The anti-genomic (negative) strand of Hepatitis C Virus is not targetable by shRNA. <i>Nucleic Acids Research</i> , 2013, 41, 3688-3698.	14.5	12
646	Characterization of Hepatitis C Virus Recombinants with Chimeric E1/E2 Envelope Proteins and Identification of Single Amino Acids in the E2 Stem Region Important for Entry. <i>Journal of Virology</i> , 2013, 87, 1385-1399.	3.4	23
647	Sequencing Assays for Failed Genotyping with the Versant Hepatitis C Virus Genotype Assay (LiPA), Version 2.0. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2815-2821.	3.9	35
648	Comparison of three different HCV genotyping methods: Core, NS5B sequence analysis and line probe assay. <i>International Journal of Molecular Medicine</i> , 2013, 31, 347-352.	4.0	71
649	Laboratory Methods for Diagnosis and Management of Hepatitis C Virus Infection. <i>Laboratory Medicine</i> , 2013, 44, 292-299.	1.2	9
650	Genetic Variability and the Classification of Hepatitis E Virus. <i>Journal of Virology</i> , 2013, 87, 4161-4169.	3.4	122
651	Morphological and Biochemical Characterization of the Membranous Hepatitis C Virus Replication Compartment. <i>Journal of Virology</i> , 2013, 87, 10612-10627.	3.4	220
652	Hepatitis C genotype 4: Genotypic diversity, epidemiological profile, and clinical relevance of subtypes in Saudi Arabia. <i>Saudi Journal of Gastroenterology</i> , 2013, 19, 28.	1.1	30
653	Cyclophilin A as a New Therapeutic Target for Hepatitis C Virus-induced Hepatocellular Carcinoma. <i>Korean Journal of Physiology and Pharmacology</i> , 2013, 17, 375.	1.2	15
654	Distribution of Hepatitis C Virus Genotypes Among Chronic Infected Injecting Drug Users in Tehran, Iran. <i>Jundishapur Journal of Microbiology</i> , 2013, , .	0.5	4
655	Pegylated interferon monotherapy in patients with chronic hepatitis C with low viremia and its relationship to mutations in the NS5A region and the single nucleotide polymorphism of interleukin-28B. <i>Hepatology Research</i> , 2013, 43, 580-588.	3.4	2
656	Viral Hepatitis C Gets Personal - The Value of Human Genomics to Public Health. <i>Public Health Genomics</i> , 2013, 16, 192-197.	1.0	8
657	Adapted J6/JFH1-Based Hepatitis C Virus Recombinants with Genotype-Specific NS4A Show Similar Efficacies against Lead Protease Inhibitors, Alpha Interferon, and a Putative NS4A Inhibitor. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6034-6049.	3.2	17
658	Emerging Viral Infections. , 2013, , 1142-1154.		2
659	Current approaches to the management of hepatitis C. <i>The Prescriber</i> , 2013, 24, 30-34.	0.3	0
660	Multicenter evaluation of the Elecsys [®] anti-HCV II assay for the diagnosis of hepatitis C virus infection. <i>Journal of Medical Virology</i> , 2013, 85, 1362-1368.	5.0	18

#	ARTICLE	IF	CITATIONS
661	Prevalence and associated clinical characteristics of hepatitis B, C, and HIV infections among injecting drug users in Korea. <i>Journal of Medical Virology</i> , 2013, 85, 575-582.	5.0	20
662	Evidence for two phylogenetic clusters within hepatitis C virus (HCV) genotype 2 inferred from analysis of complete coding sequences of 15 HCV strains. <i>Journal of Medical Virology</i> , 2013, 85, 1754-1764.	5.0	9
663	Screening for hepatitis B and C in first-generation Egyptian migrants living in the Netherlands. <i>Liver International</i> , 2013, 33, 727-738.	3.9	32
664	Pegylated versus standard interferon plus ribavirin in chronic hepatitis C genotype 4: A systematic review and meta-analysis. <i>Hepatology Research</i> , 2013, 43, 1255-1263.	3.4	3
665	Development of Norwalk Virus-Specific Monoclonal Antibodies with Therapeutic Potential for the Treatment of Norwalk Virus Gastroenteritis. <i>Journal of Virology</i> , 2013, 87, 9547-9557.	3.4	47
666	Eight novel hepatitis C virus genomes reveal the changing taxonomic structure of genotype 6. <i>Journal of General Virology</i> , 2013, 94, 76-80.	2.9	21
667	Prospects for prophylactic hepatitis C vaccines based on virus-like particles. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1112-1118.	3.3	12
668	Therapeutic DNA Vaccination Using In Vivo Electroporation Followed by Standard of Care Therapy in Patients With Genotype 1 Chronic Hepatitis C. <i>Molecular Therapy</i> , 2013, 21, 1796-1805.	8.2	62
669	Genetic Diversity of HCV in Brazil. <i>Antiviral Therapy</i> , 2013, 18, 435-444.	1.0	24
670	Bioinformatics methods for the analysis of hepatitis viruses. <i>Antiviral Therapy</i> , 2013, 18, 531-539.	1.0	3
671	A Chronic Subdural Hematoma in a Patient Receiving Combination Therapy with Pegylated Interferon Alfa-2b and Ribavirin for Chronic Hepatitis C. <i>Internal Medicine</i> , 2013, 52, 2057-2060.	0.7	3
672	Hepatitis C virus: virology and life cycle. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 17.	8.9	134
673	Selection of Conserved Epitopes from Hepatitis C Virus for Pan-Population Stimulation of T-Cell Responses. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-10.	3.3	48
674	Prevalence of hepatitis C virus infection among recyclable waste collectors in Central-West Brazil. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2013, 108, 519-522.	1.6	9
675	Profile of alisporivir and its potential in the treatment of hepatitis C. <i>Drug Design, Development and Therapy</i> , 2013, 7, 105.	4.3	87
676	Peginterferon Alfa-2a plus Ribavirin in Japanese Patients Infected with Hepatitis C Virus Genotype 2 Who Failed Previous Interferon Therapy. <i>International Journal of Medical Sciences</i> , 2013, 10, 43-49.	2.5	4
678	Base-Calling Algorithm with Vocabulary (BCV) Method for Analyzing Population Sequencing Chromatograms. <i>PLoS ONE</i> , 2013, 8, e54835.	2.5	11
679	The Evolutionary Rates of HCV Estimated with Subtype 1a and 1b Sequences over the ORF Length and in Different Genomic Regions. <i>PLoS ONE</i> , 2013, 8, e64698.	2.5	27

#	ARTICLE	IF	CITATIONS
680	Sequencing of the Hepatitis C Virus: A Systematic Review. PLoS ONE, 2013, 8, e67073.	2.5	25
681	T Lymphocytes from Chronic HCV-Infected Patients Are Primed for Activation-Induced Apoptosis and Express Unique Pro-Apoptotic Gene Signature. PLoS ONE, 2013, 8, e77008.	2.5	18
682	Chimeric Mouse Model for the Infection of Hepatitis B and C Viruses. PLoS ONE, 2013, 8, e77298.	2.5	54
683	No Correlation between PNPLA3 rs738409 Genotype and Fatty Liver and Hepatic Cirrhosis in Japanese Patients with HCV. PLoS ONE, 2013, 8, e81312.	2.5	30
684	Molecular Epidemiologic Characterization of a Clustering HCV Infection Caused by Inappropriate Medical Care in Heyuan City of Guangdong, China. PLoS ONE, 2013, 8, e82304.	2.5	3
685	Isolation and Characterization of Highly Replicable Hepatitis C Virus Genotype 1a Strain HCV-RMT. PLoS ONE, 2013, 8, e82527.	2.5	5
686	A Screen for Genetic Suppressor Elements of Hepatitis C Virus Identifies a Supercharged Protein Inhibitor of Viral Replication. PLoS ONE, 2013, 8, e84022.	2.5	2
687	Epidemiology and Treatment of Hepatitis C Genotypes 5 and 6. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, e8-e12.	1.7	21
688	Distribution of HCV genotypes in the metropolitan area of Naples. Microbiologia Medica, 2013, 28, .	0.1	1
689	A Neutralization Epitope in the Hepatitis C Virus E2 Glycoprotein Interacts with Host Entry Factor CD81. PLoS ONE, 2014, 9, e84346.	2.5	9
690	Alternate Reading Frame Protein (F Protein) of Hepatitis C Virus: Paradoxical Effects of Activation and Apoptosis on Human Dendritic Cells Lead to Stimulation of T Cells. PLoS ONE, 2014, 9, e86567.	2.5	15
691	Characterization of Hepatitis C Virus Genotypes by Direct Sequencing of HCV 5'UTR Region of Isolates from Saudi Arabia. PLoS ONE, 2014, 9, e103160.	2.5	13
692	Distinct Patterns of the Lipid Alterations between Genotype 1 and 2 Chronic Hepatitis C Patients after Viral Clearance. PLoS ONE, 2014, 9, e104783.	2.5	24
693	Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World Journal of Gastroenterology, 2014, 20, 9633.	3.3	135
694	A complete molecular biology assay for hepatitis C virus detection, quantification and genotyping. Revista Da Sociedade Brasileira De Medicina Tropical, 2014, 47, 287-294.	0.9	10
695	Establishment of chronic hepatitis C virus infection: Translational evasion of oxidative defence. World Journal of Gastroenterology, 2014, 20, 2785.	3.3	8
696	Do differences exist between chronic hepatitis C genotypes 2 and 3?. Revista Da Sociedade Brasileira De Medicina Tropical, 2014, 47, 143-148.	0.9	3
697	Factors associated with treatment interruption for hepatitis C. Revista Da Associação Médica Brasileira, 2014, 60, 29-34.	0.7	1

#	ARTICLE	IF	CITATIONS
698	Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-Related Chronic Disease. <i>Journal of Liver</i> , 2014, 03, .	0.3	4
699	Peginterferon alpha-2b plus ribavirin for chronic hepatitis C virus mixed genotype infection. <i>Annals of Hepatology</i> , 2014, 13, 350-355.	1.5	5
701	Accounting for strain variations and resistance mutations in the characterization of hepatitis C NS3 protease inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2014, 29, 868-876.	5.2	8
702	Hepatitis C: Diagnosis, Management and Treatment. , 2014, , 58-77.		0
703	Update on different aspects of HCV variability: focus on NS5B polymerase. <i>BMC Infectious Diseases</i> , 2014, 14, S1.	2.9	25
704	Increased prevalence of hepatitis C virus subtype 6a in China: a comparison between 2004–2007 and 2008–2011. <i>Archives of Virology</i> , 2014, 159, 3231-3237.	2.1	29
705	Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2366-2377.	3.3	7
706	Viral load is associated with abnormal serum levels of micronutrients and glutathione and glutathione-dependent enzymes in genotype 3 HCV patients. <i>BBA Clinical</i> , 2014, 2, 72-78.	4.1	6
707	Natural reservoirs for homologs of hepatitis C virus. <i>Emerging Microbes and Infections</i> , 2014, 3, 1-9.	6.5	88
708	Migration Patterns of Hepatitis C Virus in China Characterized for Five Major Subtypes Based on Samples from 411 Volunteer Blood Donors from 17 Provinces and Municipalities. <i>Journal of Virology</i> , 2014, 88, 7120-7129.	3.4	32
709	Optimal Management of HCV Genotype 3. <i>Current Hepatology Reports</i> , 2014, 13, 279-285.	0.9	0
710	Resistance to Cyclophilin Inhibitors. , 2014, , 1-24.		0
711	Substrate-Envelope-Guided Design of Drugs with a High Barrier to the Evolution of Resistance. , 2014, , 1-23.		2
712	Aminoterminal Amphipathic α -Helix AH1 of Hepatitis C Virus Nonstructural Protein 4B Possesses a Dual Role in RNA Replication and Virus Production. <i>PLoS Pathogens</i> , 2014, 10, e1004501.	4.7	46
713	The success of treatment of chronic hepatitis C in opiate addicts in Clinical center of Vojvodina. <i>Medicinski Pregled</i> , 2014, 67, 123-130.	0.1	0
714	Human Viruses and Cancer. <i>Viruses</i> , 2014, 6, 4047-4079.	3.3	169
715	Unfolded protein response in hepatitis C virus infection. <i>Frontiers in Microbiology</i> , 2014, 5, 233.	3.5	57
716	High rate of seronegative HCV infection in HIV-positive patients. <i>Biomedical Reports</i> , 2014, 2, 79-84.	2.0	16

#	ARTICLE	IF	CITATIONS
717	The Association of Toll-Like Receptor 4 Polymorphism with Hepatitis C Virus Infection in Saudi Arabian Patients. <i>BioMed Research International</i> , 2014, 2014, 1-9.	1.9	21
718	Hepatitis C virus genotypes in Adana and Antakya regions of Turkey*. <i>Turkish Journal of Medical Sciences</i> , 2014, 44, 661-665.	0.9	3
719	Efficiency of Incorporation and Chain Termination Determines the Inhibition Potency of 2'-Modified Nucleotide Analogs against Hepatitis C Virus Polymerase. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3636-3645.	3.2	68
720	Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2014, 135, 1119-1126.	5.1	57
721	Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy. <i>Journal of Medical Virology</i> , 2014, 86, 1360-1365.	5.0	7
722	Consensus proposals for classification of the family Hepeviridae. <i>Journal of General Virology</i> , 2014, 95, 2223-2232.	2.9	570
723	Hepatitis C genotype 1. <i>Current Opinion in Infectious Diseases</i> , 2014, 27, 535-539.	3.1	0
724	Comparison of dengue virus and HCV: from impact on global health to their RNA-dependent RNA polymerases. <i>Future Virology</i> , 2014, 9, 53-67.	1.8	9
725	A Novel Strategy To Develop a Robust Infectious Hepatitis C Virus Cell Culture System Directly from a Clinical Isolate. <i>Journal of Virology</i> , 2014, 88, 1484-1491.	3.4	25
726	Molecular Cell Biology and Immunobiology of Mammalian Rod/Ring Structures. <i>International Review of Cell and Molecular Biology</i> , 2014, 308, 35-74.	3.2	54
727	Necessity for Reassessment of Patients with Serogroup 2 Hepatitis C Virus (HCV) and Undetectable Serum HCV RNA. <i>Journal of Clinical Microbiology</i> , 2014, 52, 544-548.	3.9	1
728	HCV NS5A co-operates with PKR in modulating HCV IRES-dependent translation. <i>Infection, Genetics and Evolution</i> , 2014, 26, 113-122.	2.3	9
729	Subtyping genotype 2 hepatitis C viruses from Tunisia: identification of two putative new subtypes. <i>Virus Genes</i> , 2014, 48, 209-217.	1.6	7
730	Importance of HCV genotype 1 subtypes for drug resistance and response to therapy. <i>Journal of Viral Hepatitis</i> , 2014, 21, 229-240.	2.0	65
731	The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors. <i>Protein Science</i> , 2014, 23, 723-734.	7.6	96
732	Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 14-24.	1.5	22
733	Genetic diversity of hepatitis C virus quasispecies in chronic renal failure patients in Midwest Brazil. <i>Archives of Virology</i> , 2014, 159, 1917-1925.	2.1	0
734	Emergence of genetically variant Hepatitis C virus population in response to increased antiviral drug pressure, Pakistan. <i>Virus Genes</i> , 2014, 48, 543-549.	1.6	8

#	ARTICLE	IF	CITATIONS
735	Comparative analysis of the molecular mechanisms of recombination in hepatitis C virus. Trends in Microbiology, 2014, 22, 354-364.	7.7	63
736	Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Alimentary Pharmacology and Therapeutics, 2014, 39, 137-147.	3.7	74
737	The need for a sequencing-based assay to supplement the Abbott m2000 RealTime HCV Genotype II assay: A 1 year analysis. Journal of Clinical Virology, 2014, 60, 301-304.	3.1	29
738	Evaluation of the Abbott RealTime HCV genotype II RUO (GT II) assay with reference to 5'UTR, core and NS5B sequencing. Journal of Clinical Virology, 2014, 60, 22-26.	3.1	28
739	Hepatitis C Virus. , 2014, , 859-877.		0
740	Phylogenetic analysis of hepatitis C virus strains and risk factors associated with infection and viral subtypes among Iranian patients. Journal of Medical Virology, 2014, 86, 1342-1349.	5.0	15
741	Near full-length genome analysis of HCV genotype 5 strains from South Africa. Infection, Genetics and Evolution, 2014, 21, 118-123.	2.3	15
742	Interferon-Free Strategies without a Nucleoside/Nucleotide Analogue. Seminars in Liver Disease, 2014, 34, 047-057.	3.6	14
743	Optimization of peptide arrays for studying antibodies to hepatitis C virus continuous epitopes. Journal of Immunological Methods, 2014, 402, 35-42.	1.4	11
744	Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource. Hepatology, 2014, 59, 318-327.	7.3	1,141
745	Interleukin-28B Polymorphisms and Response of Chronic Hepatitis C Patients from Indonesia to Pegylated Interferon/Ribavirin Treatment. Journal of Clinical Microbiology, 2014, 52, 2193-2195.	3.9	1
746	Origin of hepatitis C virus genotype 3 in Africa as estimated through an evolutionary analysis of the full-length genomes of nine subtypes, including the newly sequenced 3d and 3e. Journal of General Virology, 2014, 95, 1677-1688.	2.9	34
747	Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut, 2014, 63, 1137-1149.	12.1	148
748	Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents. Journal of Infection, 2014, 68, 1-20.	3.3	69
749	Viruses and Human Cancer. Recent Results in Cancer Research, 2014, , .	1.8	1
750	Hepatitis B and hepatitis C viruses: a review of viral genomes, viral induced host immune responses, genotypic distributions and worldwide epidemiology. Asian Pacific Journal of Tropical Disease, 2014, 4, 88-96.	0.5	25
751	Therapeutic vaccines against hepatitis C virus. Infection, Genetics and Evolution, 2014, 22, 120-129.	2.3	19
752	Structure-Activity Relationship (SAR) Optimization of 6-(Indol-2-yl)pyridine-3-sulfonamides: Identification of Potent, Selective, and Orally Bioavailable Small Molecules Targeting Hepatitis C (HCV) NS4B. Journal of Medicinal Chemistry, 2014, 57, 2121-2135.	6.4	36

#	ARTICLE	IF	CITATIONS
753	Hepatitis C Virus RNA Replication and Virus Particle Assembly Require Specific Dimerization of the NS4A Protein Transmembrane Domain. <i>Journal of Virology</i> , 2014, 88, 628-642.	3.4	23
754	Marked genomic heterogeneity of rat hepatitis E virus strains in Indonesia demonstrated on a full-length genome analysis. <i>Virus Research</i> , 2014, 179, 102-112.	2.2	43
755	Discovery of functionalized bisimidazoles bearing cyclic aliphatic-phenyl motifs as HCV NS5A inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 5731-5737.	2.2	26
756	The Linker Region of NS3 Plays a Critical Role in the Replication and Infectivity of Hepatitis C Virus. <i>Journal of Virology</i> , 2014, 88, 10970-10974.	3.4	19
757	Intra-host diversity and evolution of hepatitis C virus endemic to Côte d'Ivoire. <i>Journal of Medical Virology</i> , 2014, 86, 765-771.	5.0	13
758	Outcomes of a Hepatitis C Screening Protocol in At-Risk Adults With Prior Cardiac Surgery. <i>World Journal for Pediatric & Congenital Heart Surgery</i> , 2014, 5, 503-506.	0.8	14
759	Evidence that hepatitis C virus genome partly controls infection outcome. <i>Evolutionary Applications</i> , 2014, 7, 533-547.	3.1	4
761	Identification of Conserved Residues in Hepatitis C Virus Envelope Glycoprotein E2 That Modulate Virus Dependence on CD81 and SRB1 Entry Factors. <i>Journal of Virology</i> , 2014, 88, 10584-10597.	3.4	41
762	HCV transmission in industrialized countries and resource-constrained areas. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 28-35.	17.8	93
763	Role of Hypervariable Region 1 for the Interplay of Hepatitis C Virus with Entry Factors and Lipoproteins. <i>Journal of Virology</i> , 2014, 88, 12644-12655.	3.4	42
764	Hepatitis C Virus: Epidemiology and Clinical Features of Related Cancer. , 2014, , 87-112.		0
765	Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: Novel insights about targeted genotyping approaches. <i>Journal of Medical Virology</i> , 2014, 86, 1714-1721.	5.0	16
766	Full-length genomes of 16 hepatitis C virus genotype 1 isolates representing subtypes 1c, 1d, 1e, 1g, 1h, 1i, 1j and 1k, and two new subtypes 1m and 1n, and four unclassified variants reveal ancestral relationships among subtypes. <i>Journal of General Virology</i> , 2014, 95, 1479-1487.	2.9	26
767	Cross-Genotypic Examination of Hepatitis C Virus Polymerase Inhibitors Reveals a Novel Mechanism of Action for Thumb Binders. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7215-7224.	3.2	12
768	The potential impact of P53 and APO-1 genetic polymorphisms on hepatitis C genotype 4a susceptibility. <i>Gene</i> , 2014, 550, 40-45.	2.2	3
769	Conservation in China of a novel group of HCV variants dating to six centuries ago. <i>Virology</i> , 2014, 464-465, 21-25.	2.4	18
770	Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, 117-140.	0.9	22
771	The genetic diversity and evolutionary history of hepatitis C virus in Vietnam. <i>Virology</i> , 2014, 468-470, 197-206.	2.4	25

#	ARTICLE	IF	CITATIONS
772	Computational models of liver fibrosis progression for hepatitis C virus chronic infection. <i>BMC Bioinformatics</i> , 2014, 15, S5.	2.6	19
773	Nine additional complete genome sequences of HCV genotype 6 from Vietnam including new subtypes 6xb and 6xc. <i>Virology</i> , 2014, 468-470, 172-177.	2.4	9
774	Genetic variability of the core protein in hepatitis C virus genotype 4 in Saudi Arabian patients and its implication on pegylated interferon and ribavirin therapy. <i>Journal of Translational Medicine</i> , 2014, 12, 91.	4.4	8
775	Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir. <i>Virology Journal</i> , 2014, 11, 93.	3.4	4
777	Is genotype 3 of the hepatitis C virus the new villain?. <i>Hepatology</i> , 2014, 59, 2403-2412.	7.3	116
778	A near-full length genotypic assay for HCV1b. <i>Journal of Virological Methods</i> , 2014, 209, 126-135.	2.1	11
779	Modulation of Hepatitis C Virus Genome Replication by Glycosphingolipids and Four-Phosphate Adaptor Protein 2. <i>Journal of Virology</i> , 2014, 88, 12276-12295.	3.4	77
780	Resistance to cyclosporin A derives from mutations in hepatitis C virus nonstructural proteins. <i>Biochemical and Biophysical Research Communications</i> , 2014, 448, 56-62.	2.1	11
781	Serum proteomics of hepatitis C virus infection reveals retinol-binding protein 4 as a novel regulator. <i>Journal of General Virology</i> , 2014, 95, 1654-1667.	2.9	13
782	Review article: <scp>HCV</scp> genotype 3 “ the new treatment challenge. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 686-698.	3.7	103
783	Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1“6. <i>Virology</i> , 2014, 458-459, 190-208.	2.4	20
784	Suppression of hepatitis C virus replication by cyclin-dependent kinase inhibitors. <i>Antiviral Research</i> , 2014, 108, 79-87.	4.1	8
785	Low Prevalence of Hepatitis C Virus Infection Among HIV-Positive Patients: Data From a Large-Scale Cohort Study in Istanbul, Turkey. <i>Hepatitis Monthly</i> , 2014, 14, e18128.	0.2	8
786	Hepatitis C virus genotype 6: Virology, epidemiology, genetic variation and clinical implication. <i>World Journal of Gastroenterology</i> , 2014, 20, 2927.	3.3	48
787	Investigation of biomarkers in peripheral blood cells of Pakistani chronic HCV patients with genotype 3a: an assessment of HCV-induced pathogenesis. <i>Future Virology</i> , 2014, 9, 275-282.	1.8	1
788	Aminoadamantanes for chronic hepatitis C. <i>The Cochrane Library</i> , 2014, , CD010125.	2.8	2
789	IL28B genotyping and treatment of HCV infected subjects. <i>Asian Biomedicine</i> , 2014, 8, 445-452.	0.3	0
790	Trends in hepatitis C virus infections among MSM attending a sexually transmitted infection clinic; 1995“2010. <i>Aids</i> , 2014, 28, 781-790.	2.2	56

#	ARTICLE	IF	CITATIONS
791	Hepatitis C virus alternate reading frame protein decreases interferon- λ secretion in peripheral blood mononuclear cells. <i>Molecular Medicine Reports</i> , 2014, 9, 730-736.	2.4	8
792	Aminoadamantanes versus other antiviral drugs for chronic hepatitis C. , 2014, , CD011132.		4
793	Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin. <i>Medicine (United States)</i> , 2015, 94, e1876.	1.0	8
794	Phylogenetic analysis of HCV subgenotypes in patients from Sichuan province in China based on the NS5B region. <i>International Journal of Molecular Medicine</i> , 2015, 36, 1028-1034.	4.0	6
795	Molecular Assay and Genotyping of Hepatitis C Virus among Infected Egyptian and Saudi Arabian Patients. <i>Virology: Research and Treatment</i> , 2015, 6, VRT.S32016.	3.5	8
796	Economic, organizational and budget impact of a new diagnostic plan for HCV detection: what's new?. <i>Rivista Italiana Della Medicina Di Laboratorio</i> , 2015, 11, 236-242.	0.4	2
797	Associations between responses to interferon therapy and genetic variation in interleukin-28B and the core region of hepatitis C virus genotype 3a. <i>Journal of Medical Virology</i> , 2015, 87, 1361-1367.	5.0	0
798	Sensitivity of hepatitis C virus core antigen and antibody combination assays in a global panel of window period samples. <i>Transfusion</i> , 2015, 55, 2489-2498.	1.6	18
799	Hepatitis C virus genotype 4 in England: Diversity and demographic associations. <i>Journal of Medical Virology</i> , 2015, 87, 417-423.	5.0	3
800	Diversity of 1,213 hepatitis C virus NS3 protease sequences from a clinical virology laboratory database in Marseille university hospitals, southeastern France. <i>Journal of Medical Virology</i> , 2015, 87, 1921-1933.	5.0	2
801	Genotyping of hepatitis B and C virus Russian isolates for reference serum panel construction. <i>Journal of Medical Virology</i> , 2015, 87, 1192-1198.	5.0	2
802	Hepatitis C Virus Genotype Distribution in Kermanshah Province, Western Iran. <i>Modern Applied Science</i> , 2015, 10, 138.	0.6	0
803	The evolutionary epidemiology of the hepatitis C virus. , 0, , 450-472.		0
804	Analysis of different HCV NS4B domains for the development of global consensus sequence. <i>Acta Virologica</i> , 2015, 59, 276-283.	0.8	1
806	Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. <i>Viruses</i> , 2015, 7, 3995-4046.	3.3	42
807	Production of Hybrid Chimeric PVX Particles Using a Combination of TMV and PVX-Based Expression Vectors. <i>Frontiers in Bioengineering and Biotechnology</i> , 2015, 3, 189.	4.1	10
808	Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance. <i>Viruses</i> , 2015, 7, 5206-5224.	3.3	102
809	Computational Docking Study of p7 Ion Channel from HCV Genotype 3 and Genotype 4 and Its Interaction with Natural Compounds. <i>PLoS ONE</i> , 2015, 10, e0126510.	2.5	18

#	ARTICLE	IF	CITATIONS
810	The Replacement of 10 Non-Conserved Residues in the Core Protein of JFH-1 Hepatitis C Virus Improves Its Assembly and Secretion. <i>PLoS ONE</i> , 2015, 10, e0137182.	2.5	6
811	IFN-λ3: A New Class of Interferon with Distinct Functions-Implications for Hepatitis C Virus Research. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-9.	1.5	8
812	Inter and inpatient evolution of hepatitis C virus. <i>Annals of Hepatology</i> , 2015, 14, 442-449.	1.5	10
813	Biomarkers in HCV Infection. <i>Advances in Clinical Chemistry</i> , 2015, 70, 131-196.	3.7	4
814	The full-length genome sequences of nine HCV genotype 4 variants representing a new subtype 4s and eight unclassified lineages. <i>Virology</i> , 2015, 482, 111-116.	2.4	10
815	Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease. <i>Gene</i> , 2015, 570, 115-121.	2.2	14
816	Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon α Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection. <i>Gut and Liver</i> , 2015, 9, 516.	2.9	2
817	Hepatitis C virus genetic variability and evolution. <i>World Journal of Hepatology</i> , 2015, 7, 831.	2.0	85
818	Geographic distribution of HCV genotypes in Libya and analysis of risk factors involved in their transmission. <i>BMC Research Notes</i> , 2015, 8, 367.	1.4	21
819	Prevalence of hepatitis C virus in patients with tuberculosis and its impact in the incidence of anti-tuberculosis drugs induced hepatotoxicity. <i>The Egyptian Journal of Chest Diseases and Tuberculosis</i> , 2015, 64, 91-96.	0.2	8
820	Cross-reactivity of hepatitis C virus specific vaccine-induced T cells at immunodominant epitopes. <i>European Journal of Immunology</i> , 2015, 45, 309-316.	2.9	34
821	An expanded taxonomy of hepatitis C virus genotype 6: Characterization of 22 new full-length viral genomes. <i>Virology</i> , 2015, 476, 355-363.	2.4	27
822	Gene Therapies for Hepatitis C Virus. <i>Advances in Experimental Medicine and Biology</i> , 2015, 848, 1-29.	1.6	8
823	Hepatitis E Virus Genotype 3 Diversity: Phylogenetic Analysis and Presence of Subtype 3b in Wild Boar in Europe. <i>Viruses</i> , 2015, 7, 2704-2726.	3.3	59
824	A Novel Approach to Identify Candidate Prognostic Factors for Hepatitis C Treatment Response Integrating Clinical and Viral Genetic Data. <i>Evolutionary Bioinformatics</i> , 2015, 11, EBO.S20853.	1.2	0
825	Identification, Molecular Cloning, and Analysis of Full-Length Hepatitis C Virus Transmitted/Founder Genotypes 1, 3, and 4. <i>MBio</i> , 2015, 6, e02518.	4.1	15
826	Identification of a duplicated V3 domain in NS5A associated with cirrhosis and hepatocellular carcinoma in HCV-1b patients. <i>Journal of Clinical Virology</i> , 2015, 69, 203-209.	3.1	6
827	Genotype 3 is the predominant hepatitis C genotype in a multi-ethnic Asian population in Malaysia. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2015, 14, 281-286.	1.3	13

#	ARTICLE	IF	CITATIONS
828	Characterization of HCV genotype 4d infections in Kayseri, Turkey*. Turkish Journal of Medical Sciences, 2015, 45, 547-552.	0.9	3
829	Evaluation of sequencing of HCV core/E1, NS5A and NS5B as a genotype predictive tool in comparison with commercial assays targeting 5'UTR. Journal of Clinical Virology, 2015, 66, 56-59.	3.1	17
830	P53 rs1042522 and CD95 rs1800682 genetic variations in HCV-4a response to antiviral therapy. Genes and Diseases, 2015, 2, 197-210.	3.4	2
831	Risk factors of hepatitis C virus transmission and genotype distribution in former blood donors from Chinese rural area. BMC Public Health, 2015, 15, 184.	2.9	13
832	Safely treating hepatitis C in patients with HIV or hepatitis B virus coinfection. Expert Opinion on Drug Safety, 2015, 14, 713-731.	2.4	1
833	Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden. Infectious Diseases, 2015, 47, 555-562.	2.8	34
835	Overtreating versus undertreating: what is the optimized treatment duration in HCV?. Future Virology, 2015, 10, 1049-1056.	1.8	0
836	Recent advances on the synthesis of hepatitis C virus NS5B RNA-dependent RNA-polymerase inhibitors. European Journal of Medicinal Chemistry, 2015, 102, 188-214.	5.5	13
837	Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection. Pharmacogenomics, 2015, 16, 1179-1188.	1.3	24
838	Transmission of Hepatitis C Virus among Prisoners, Australia, 2005-2012. Emerging Infectious Diseases, 2015, 21, 765-774.	4.3	37
839	A reliable multiplex genotyping assay for HCV using a suspension bead array. Microbial Biotechnology, 2015, 8, 93-102.	4.2	4
840	Association of interleukin 28B polymorphism and mutations in the NS5A region of hepatitis C virus genotype 2 with interferon responsiveness. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 178-183.	2.8	6
841	Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era. Clinics in Liver Disease, 2015, 19, 591-604.	2.1	0
842	Hepatitis C Virus Envelope Glycoprotein E1 Forms Trimers at the Surface of the Virion. Journal of Virology, 2015, 89, 10333-10346.	3.4	59
843	The evolutionary patterns of hepatitis C virus subtype 2a and 6a isolates linked to an outbreak in China in 2012. Virology, 2015, 485, 431-438.	2.4	5
844	Variation analysis of E1 and E2 in HCV subtypes. Archives of Virology, 2015, 160, 2479-2482.	2.1	7
845	NCBI Viral Genomes Resource. Nucleic Acids Research, 2015, 43, D571-D577.	14.5	541
846	Phylogenetic analysis of the emergence of main hepatitis C virus subtypes in São Paulo, Brazil. Brazilian Journal of Infectious Diseases, 2015, 19, 473-478.	0.6	7

#	ARTICLE	IF	CITATIONS
847	Hepatitis C Virus Genotype 7, a New Genotype Originating from Central Africa. <i>Journal of Clinical Microbiology</i> , 2015, 53, 967-972.	3.9	138
848	Hepatic expression of <i>miR-122</i> , <i>miR-126</i> , <i>miR-136</i> and <i>miR-181a</i> and their correlation to histopathological and clinical characteristics of patients with hepatitis C. <i>Journal of Viral Hepatitis</i> , 2015, 22, 146-157.	2.0	22
849	Influence of amino acid variations in the NS3, NS4A and NS4B of HCV genotypes 1a, 1b, 3a, 3b and 6f on the response to pegylated interferon and ribavirin combination therapy. <i>Virus Research</i> , 2015, 196, 37-43.	2.2	3
850	Efficient Infectious Cell Culture Systems of the Hepatitis C Virus (HCV) Prototype Strains HCV-1 and H77. <i>Journal of Virology</i> , 2015, 89, 811-823.	3.4	47
851	Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin. <i>Hepatology</i> , 2015, 61, 471-480.	7.3	80
852	NS5B induces up-regulation of the BH3-only protein, BIK, essential for the hepatitis C virus RNA replication and viral release. <i>Virology</i> , 2015, 474, 41-51.	2.4	8
853	HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome. <i>Hepatology International</i> , 2015, 9, 52-57.	4.2	9
854	Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies. <i>Critical Reviews in Microbiology</i> , 2016, 42, 535-547.	6.1	33
855	Hepatitis C Virus. , 0, , 351-361.		0
856	Hepatitis C Virus. , 2016, , 1313-1345.		61
858	The Distribution of Hepatitis C Virus Genotypes in Middle Eastern Countries: A Systematic Review and Meta-Analysis. <i>Hepatitis Monthly</i> , 2016, 16, e40357.	0.2	48
859	Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents. <i>Brazilian Journal of Medical and Biological Research</i> , 2016, 49, e5504.	1.5	9
860	A Novel Structurally Stable Multi-epitope Protein for Detection of HCV. <i>Hepatitis Research and Treatment</i> , 2016, 2016, 1-9.	2.0	9
861	Response to Pegylated Interferon Plus Ribavirin in Patients with Hepatitis C Virus Genotype 6a Infection from Guangdong and Guangxi Province of China. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-6.	1.5	0
862	An outbreak of HCV genotype 6a and 2a infection in South China: Confirmation of iatrogenic transmission by phylogenetic analysis of the NS5B region. <i>Molecular Medicine Reports</i> , 2016, 14, 4285-4292.	2.4	2
863	Hepatitis C virus: Promising discoveries and new treatments. <i>World Journal of Gastroenterology</i> , 2016, 22, 6393.	3.3	19
864	Evolving Diversity of Hepatitis C Viruses in Yunnan Honghe, China. <i>International Journal of Molecular Sciences</i> , 2016, 17, 403.	4.1	5
865	Ultra-Deep Sequencing Characterization of HCV Samples with Equivocal Typing Results Determined with a Commercial Assay. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1679.	4.1	9

#	ARTICLE	IF	CITATIONS
866	Geno2pheno[HCV] – A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents. <i>PLoS ONE</i> , 2016, 11, e0155869.	2.5	101
867	Elevated serum α -fetoprotein levels in patients with chronic hepatitis C virus genotype 4. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 313-322.	1.6	3
868	Peginterferon Therapy in Children With Chronic Hepatitis C. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2016, 63, 88-93.	1.8	13
869	Development and Validation of a Template-Independent Next-Generation Sequencing Assay for Detecting Low-Level Resistance-Associated Variants of Hepatitis C Virus. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 643-656.	2.8	11
870	Heterogeneous genomic locations within NS3, NS4A and NS4B identified for genotyping and subtyping of Hepatitis C virus: A simple genome analysis approach. <i>Infection, Genetics and Evolution</i> , 2016, 44, 61-68.	2.3	3
871	Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype 4 chronic hepatitis C patients. <i>Journal of Medical Virology</i> , 2016, 88, 2170-2178.	5.0	33
872	Characterization of partial NS5B region among hepatitis C virus genotype 6 subtypes isolated from Thai blood donors. <i>Journal of Medical Virology</i> , 2016, 88, 1785-1790.	5.0	2
873	Incident Hepatitis C Virus Genotype Distribution and Multiple Infection in Australian Prisons. <i>Journal of Clinical Microbiology</i> , 2016, 54, 1855-1861.	3.9	12
874	A Unique Pattern of HCV Genotype Distribution on Hainan Island in China Revealed by Evolutionary Analysis. <i>Cellular Physiology and Biochemistry</i> , 2016, 39, 316-330.	1.6	11
875	Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. <i>Scientific Reports</i> , 2016, 6, 22995.	3.3	7
876	Hepatitis por el virus C. <i>Medicine</i> , 2016, 12, 484-493.	0.0	0
878	Sequencing Analysis of NS3/4A, NS5A, and NS5B Genes from Patients Infected with Hepatitis C Virus Genotypes 5 and 6. <i>Journal of Clinical Microbiology</i> , 2016, 54, 1835-1841.	3.9	8
879	Distribution of hepatitis C virus genotypes in volunteer blood donors from Chengdu, China. <i>Archives of Virology</i> , 2016, 161, 1873-1882.	2.1	3
880	A method for near full-length amplification and sequencing for six hepatitis C virus genotypes. <i>BMC Genomics</i> , 2016, 17, 247.	2.8	52
881	Effects of Heart Bypass Surgery on Plasma $\text{A}\hat{1}^{240}$ and $\text{A}\hat{1}^{242}$ Levels in Infants and Young Children. <i>Medicine (United States)</i> , 2016, 95, e2684.	1.0	7
882	HCV dispersal patterns among intravenous drug users (IDUs) in Athens metropolitan area. <i>Infection, Genetics and Evolution</i> , 2016, 45, 415-419.	2.3	3
883	microRNA-155 and microRNA-196b in Hepatitis C Virus Infection. <i>Exposure and Health</i> , 2016, , 1-28.	4.9	0
884	Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6207-6215.	3.2	3

#	ARTICLE	IF	CITATIONS
885	Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease. <i>Journal of the American Chemical Society</i> , 2016, 138, 11850-11859.	13.7	55
886	A novel real-time reverse transcription-polymerase chain reaction assay with partially double-stranded linear DNA probe for sensitive detection of hepatitis C viral RNA. <i>Journal of Virological Methods</i> , 2016, 236, 132-138.	2.1	1
887	First next-generation sequencing full-genome characterization of a hepatitis C virus genotype 7 divergent subtype. <i>Clinical Microbiology and Infection</i> , 2016, 22, 947.e1-947.e8.	6.0	21
888	The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control. <i>Journal of Hepatology</i> , 2016, 65, S2-S21.	3.7	195
889	Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature. <i>Journal of Viral Hepatitis</i> , 2016, 23, 545-559.	2.0	43
890	Coevolution analysis of Hepatitis C virus genome to identify the structural and functional dependency network of viral proteins. <i>Scientific Reports</i> , 2016, 6, 26401.	3.3	26
891	Subtype distribution of Hepatitis C virus in Jiangsu, China. <i>Journal of Medical Virology</i> , 2016, 88, 498-505.	5.0	14
892	A robust model of natural hepatitis C infection using hepatocyte-like cells derived from human induced pluripotent stem cells as a long-term host. <i>Virology Journal</i> , 2016, 13, 59.	3.4	27
893	Computational study on the binding and unbinding mechanism of HCV NS5B with the inhibitor GS-461203 and substrate using conventional and steered molecular dynamics simulations. <i>Chemometrics and Intelligent Laboratory Systems</i> , 2016, 156, 72-80.	3.5	9
894	Molecular characterization of Hepatitis C virus 3a in Peshawar. <i>BMC Infectious Diseases</i> , 2016, 16, 163.	2.9	5
895	Serum-derived hepatitis C virus 1a infection of human astrocyte cell line SVG. <i>Journal of Viral Hepatitis</i> , 2016, 23, 211-216.	2.0	3
896	Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection. <i>Cellular and Molecular Immunology</i> , 2016, 13, 11-35.	10.5	91
897	Immunization with a Recombinant Expression Vector Encoding NS3/NS4A of Hepatitis C Virus Genotype 3a Elicits Cell-Mediated Immune Responses in C57BL/6 Mice. <i>Viral Immunology</i> , 2016, 29, 138-147.	1.3	3
898	Hepatitis C Virus Genotype and Subtype Distribution in Patient Specimens Tested at the University of Texas Medical Branch, Galveston, Between January 2011 and November 2014. <i>Laboratory Medicine</i> , 2016, 47, 112-118.	1.2	4
899	Hepatitis C Virus Subtype and Evolution Characteristic Among Drug Users, Men Who Have Sex With Men, and the General Population in Beijing, China. <i>Medicine (United States)</i> , 2016, 95, e2688.	1.0	8
900	Analysis of HCV-6 isolates among Asian-born immigrants in North America reveals their high genetic diversity and a new subtype. <i>Virology</i> , 2016, 492, 25-31.	2.4	9
901	Generation and Characterization of Monoclonal Antibodies against a Cyclic Variant of Hepatitis C Virus E2 Epitope 412-422. <i>Journal of Virology</i> , 2016, 90, 3745-3759.	3.4	39
902	Ion Channel Function and Cross-Species Determinants in Viral Assembly of Nonprimate Hepacivirus p7. <i>Journal of Virology</i> , 2016, 90, 5075-5089.	3.4	4

#	ARTICLE	IF	CITATIONS
903	Structural and Thermodynamic Effects of Macrocyclization in HCV NS3/4A Inhibitor MK-5172. <i>ACS Chemical Biology</i> , 2016, 11, 900-909.	3.4	39
904	Six-year distribution pattern of hepatitis C virus in Turkey: a multicentre study. <i>Biotechnology and Biotechnological Equipment</i> , 2016, 30, 335-340.	1.3	6
905	Single-Genome Sequencing of Hepatitis C Virus in Donor-Recipient Pairs Distinguishes Modes and Models of Virus Transmission and Early Diversification. <i>Journal of Virology</i> , 2016, 90, 152-166.	3.4	17
906	Novel indole-flutimide heterocycles with activity against influenza PA endonuclease and hepatitis C virus. <i>MedChemComm</i> , 2016, 7, 447-456.	3.4	24
907	Characterization of Samples Identified as Hepatitis C Virus Genotype 1 without Subtype by Abbott RealTime HCV Genotype II Assay Using the New Abbott HCV Genotype Plus RUO Test. <i>Journal of Clinical Microbiology</i> , 2016, 54, 296-299.	3.9	16
908	Cutaneous Adverse Events in Chronic Hepatitis C Patients Treated With New Direct-Acting Antivirals. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016, 20, 58-66.	1.2	14
909	On-chip purification and detection of hepatitis C virus RNA from human plasma. <i>Biophysical Chemistry</i> , 2016, 208, 54-61.	2.8	12
910	Molecular characterization of hepatitis C virus genotype 6 subtypes in Thai blood donors. <i>Journal of Microbiology, Immunology and Infection</i> , 2017, 50, 26-31.	3.1	6
911	High-resolution melting combines with Bayes discriminant analysis: a novel hepatitis C virus genotyping method. <i>Clinical and Experimental Medicine</i> , 2017, 17, 325-332.	3.6	6
912	A Point Mutation in the N-Terminal Amphipathic Helix α_1 in NS3 Promotes Hepatitis C Virus Assembly by Altering Core Localization to the Endoplasmic Reticulum and Facilitating Virus Budding. <i>Journal of Virology</i> , 2017, 91, .	3.4	16
913	Hepatitis C virus genotype 3A in a population of injecting drug users in Montenegro: Bayesian and evolutionary analysis. <i>Archives of Virology</i> , 2017, 162, 1549-1561.	2.1	3
914	Novel nucleoside analogues targeting HCV replication through an NS5A-dependent inhibition mechanism. <i>Chemical Biology and Drug Design</i> , 2017, 90, 352-367.	3.2	5
915	Applications of computer-aided approaches in the development of hepatitis C antiviral agents. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 407-425.	5.0	45
916	Hepatitis C Virus in mainland China with an emphasis on genotype and subtype distribution. <i>Virology Journal</i> , 2017, 14, 41.	3.4	68
917	Mice Antibody Response to Conserved Nonadjuvanted Multiple Antigenic Peptides Derived from E1/E2 Regions of Hepatitis C Virus. <i>Viral Immunology</i> , 2017, 30, 359-365.	1.3	8
918	Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. <i>Drugs</i> , 2017, 77, 1043-1055.	10.9	40
920	Prevalence of Equine Hepacivirus Infections in France and Evidence for Two Viral Subtypes Circulating Worldwide. <i>Transboundary and Emerging Diseases</i> , 2017, 64, 1884-1897.	3.0	16
921	Prevalence of naturally occurring protease inhibitor resistance-associated variants in hemodialysis and renal transplant patients with hepatitis C virus infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 754-758.	1.6	0

#	ARTICLE	IF	CITATIONS
922	Hepatitis C Virus-associated Non-Hodgkin Lymphomas. <i>Clinics in Liver Disease</i> , 2017, 21, 499-515.	2.1	22
923	Evaluation of the Abbott RealTime HCV genotype II plus RUO (PLUS) assay with reference to core and NS5B sequencing. <i>Journal of Clinical Virology</i> , 2017, 90, 26-31.	3.1	12
924	An Optimized Hepatitis C Virus E2 Glycoprotein Core Adopts a Functional Homodimer That Efficiently Blocks Virus Entry. <i>Journal of Virology</i> , 2017, 91, .	3.4	17
925	Identification and evolutionary dynamics of two novel human coronavirus OC43 genotypes associated with acute respiratory infections: phylogenetic, spatiotemporal and transmission network analyses. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-13.	6.5	23
926	Assessment of a Novel Automatic Real-Time PCR Assay on the Cobas 4800 Analyzer as a Screening Platform for Hepatitis C Virus Genotyping in Clinical Practice: Comparison with Massive Sequencing. <i>Journal of Clinical Microbiology</i> , 2017, 55, 504-509.	3.9	15
927	Recombination in hepatitis C virus is not uncommon among people who inject drugs in Kolkata, India. <i>Infection, Genetics and Evolution</i> , 2017, 48, 156-163.	2.3	7
928	<i>In vitro</i> Selection of Resistance to Sofosbuvir in HCV Replicons of Genotype-1 to -6. <i>Antiviral Therapy</i> , 2017, 22, 587-597.	1.0	31
929	Subtyping of hepatitis C virus with high resolution mass spectrometry. <i>Clinical Mass Spectrometry</i> , 2017, 4-5, 19-24.	1.9	8
930	Younger trend of cirrhosis incidence in genotype 3 HCV infected patients in Eastern China. <i>Journal of Medical Virology</i> , 2017, 89, 1973-1980.	5.0	10
931	Development of Hepatocyte-like Cell Derived from Human Induced Pluripotent Stem cell as a Host for Clinically Isolated Hepatitis C Virus. <i>Current Protocols in Stem Cell Biology</i> , 2017, 42, 4A.13.1-4A.13.34.	3.0	4
932	Flavonoids from <i>Pterogyne nitens</i> Inhibit Hepatitis C Virus Entry. <i>Scientific Reports</i> , 2017, 7, 16127.	3.3	38
933	Toll-like receptor 4 polymorphism as pretreatment predictor of response to HCV genotype 3a interferon-based treatment. <i>Future Virology</i> , 2017, 12, 739-746.	1.8	7
934	Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients. <i>Scientific Reports</i> , 2017, 7, 4688.	3.3	17
935	Plaques Formed by Mutagenized Viral Populations Have Elevated Coinfection Frequencies. <i>MBio</i> , 2017, 8, .	4.1	46
936	Molecular Testing in Emerging Infectious Diseases. , 2017, , 179-200.		1
937	Phylogeographical Analysis Reveals Distinct Sources of HIV-1 and HCV Transmitted to Former Blood Donors in China. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 284-289.	1.1	3
938	Comparison of Three Different Hepatitis C Virus Genotyping Methods: NCR PCR, RFLP, Core Type-specific PCR, and NS5b Sequencing in a Tertiary Care Hospital in South India. <i>Journal of Clinical Laboratory Analysis</i> , 2017, 31, .	2.1	2
940	Distance-based pattern matching of DNA sequences for evaluating primary mutation. , 2017, , .		2

#	ARTICLE	IF	CITATIONS
941	Prototype Infrastructure Cloud Expert System DNA Analysis (CESDA) as the Basis of Sustainability DNA Software Improvement in Indonesia. , 2017, , .		3
942	Is Predominant Clonal Evolution a Common Evolutionary Adaptation to Parasitism in Pathogenic Parasitic Protozoa, Fungi, Bacteria, and Viruses?. <i>Advances in Parasitology</i> , 2017, 97, 243-325.	3.2	29
943	EpidemiologÃa molecular del virus de la hepatitis C.. <i>Infectio</i> , 2017, 21, .	0.4	0
944	Identification of Genotype 2 HCV in Serotype-1 Hepatitis C Patients Unresponsive to Daclatasvir plus Asunaprevir Treatment. <i>Tohoku Journal of Experimental Medicine</i> , 2017, 241, 21-28.	1.2	3
945	Interrelationship of hepatitis C virus genotypes with patient characteristics in Bahrain. <i>Hepatic Medicine: Evidence and Research</i> , 2017, Volume 9, 7-11.	2.5	3
946	Research progress on the direct antiviral drugs for hepatitis C virus. <i>BioScience Trends</i> , 2017, 11, 41-45.	3.4	5
947	Molecular evolution of hepatitis C virus in China: A nationwide study. <i>Virology</i> , 2018, 516, 210-218.	2.4	13
948	Indeterminate genotypes of hepatitis C virus by the Abbott RealTime HCV Genotype II assay in Morocco. About eight cases resolved by a sequencing method. <i>Journal of Medical Virology</i> , 2018, 90, 1352-1357.	5.0	3
949	5â€² UTR and NS5B-based genotyping of hepatitis C virus in patients from Damietta governorate, Egypt. <i>Journal of Advanced Research</i> , 2018, 10, 39-47.	9.5	10
950	Differential virusâ€specific <scp>CD</scp>8⁺ Tâ€cell epitope repertoire in hepatitis C virus genotype 1 versus 4. <i>Journal of Viral Hepatitis</i> , 2018, 25, 779-790.	2.0	7
951	Hepatitis C virus deep sequencing for sub-genotype identification in mixed infections: A real-life experience. <i>International Journal of Infectious Diseases</i> , 2018, 67, 114-117.	3.3	23
952	Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1â€7 and Escape Variants. <i>Gastroenterology</i> , 2018, 154, 1435-1448.	1.3	89
953	Biophysical Studies on HCV 1a NS3/4A Protease and Its Catalytic Triad in Wild Type and Mutants by the In Silico Approach. <i>Interdisciplinary Sciences, Computational Life Sciences</i> , 2018, 10, 143-156.	3.6	3
954	Comparison of direct sequencing and Invader assay for Y93H mutation and response to interferonâ€free therapy in hepatitis C virus genotype 1b. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 249-255.	2.8	6
955	Epidemiologic features of 348 children with hepatitis C virus infection over a 30-year period: a nationwide survey in Japan. <i>Journal of Gastroenterology</i> , 2018, 53, 419-426.	5.1	23
956	Identification of potential inhibitors for HCV NS3 genotype 4a by combining proteinâ€ligand interaction fingerprint, 3D pharmacophore, docking, and dynamic simulation. <i>Journal of Biomolecular Structure and Dynamics</i> , 2018, 36, 1713-1727.	3.5	22
957	Establishment of a platform for molecular and immunological characterization of the RNAâ€dependentâ€RNAâ€polymerase NS5B of an Egyptian HCV isolate. <i>Journal of Medical Virology</i> , 2018, 90, 545-558.	5.0	0
958	Molecular characterization of hepatitis C virus in endâ€stage renal disease patients under hemodialysis. <i>Journal of Medical Virology</i> , 2018, 90, 537-544.	5.0	4

#	ARTICLE	IF	CITATIONS
959	Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct-acting antivirals. <i>Hepatology Research</i> , 2018, 48, E372-E378.	3.4	9
960	In vivo analysis at the cellular level reveals similar steatosis induction in both hepatitis C virus genotype 1 and 3 infections. <i>Journal of Viral Hepatitis</i> , 2018, 25, 262-271.	2.0	3
961	Immunogenetic studies of the hepatitis C virus infection in an era of pan-genotype antiviral therapies - Effective treatment is coming. <i>Infection, Genetics and Evolution</i> , 2018, 66, 376-391.	2.3	11
962	A first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending oral dose study to assess the safety, tolerability, and pharmacokinetics of BZF961 with and without ritonavir in healthy adult volunteers. <i>Journal of Drug Assessment</i> , 2018, 7, 66-74.	2.2	0
963	Virology and Pathogenesis of Hepatitis C. , 2018, , 412-427.e8.		0
964	Hepatitis C Virus in Thalassemia. , 0, , .		0
965	An open-source k-mer based machine learning tool for fast and accurate subtyping of HIV-1 genomes. <i>PLoS ONE</i> , 2018, 13, e0206409.	2.5	70
966	Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 1993-2000.	2.7	12
967	Analysis of HCV Isolates Among the Li Ethnic in Hainan Island of South China Reveals Their HCV-6 Unique Evolution and a New Subtype. <i>Cellular Physiology and Biochemistry</i> , 2018, 50, 1832-1839.	1.6	8
968	The Multifaceted Roles of Autophagy in Flavivirus-Host Interactions. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3940.	4.1	46
969	Hepatitis C virus: Morphogenesis, infection and therapy. <i>World Journal of Hepatology</i> , 2018, 10, 186-212.	2.0	98
970	Profile of the VERSANT HCV genotype 2.0 assay. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 995-1004.	3.1	6
971	Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies. <i>Antiviral Research</i> , 2018, 160, 25-37.	4.1	8
972	Substitutions in interferon sensitivity-determining region and hepatocarcinogenesis after hepatitis C virus eradication. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1904-1911.	2.8	3
973	Expanding the chemical space of anti-HCV NS5A inhibitors by stereochemical exchange and peptidomimetic approaches. <i>Archiv Der Pharmazie</i> , 2018, 351, e1800017.	4.1	4
974	Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes. <i>Journal of Infectious Diseases</i> , 2018, 218, 1722-1729.	4.0	202
975	Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: Essential tools in testing of antivirals and emerging vaccine strategies. <i>Antiviral Research</i> , 2018, 158, 264-287.	4.1	40
976	Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies. <i>Frontiers in Immunology</i> , 2018, 9, 910.	4.8	86

#	ARTICLE	IF	CITATIONS
977	Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus. <i>Frontiers in Microbiology</i> , 2017, 8, 2692.	3.5	43
978	Analysis of Naturally Occurring Resistance-Associated Variants to NS3/4A Protein Inhibitors, NS5A Protein Inhibitors, and NS5B Polymerase Inhibitors in Patients With Chronic Hepatitis C. <i>Gene Expression</i> , 2018, 18, 63-69.	1.2	14
979	Evolutionary dynamics of Hepatitis C virus in a chronic HIV co-infected patient and its correlation with the immune status. <i>Infection, Genetics and Evolution</i> , 2018, 63, 30-38.	2.3	1
980	Epidemic history of hepatitis C virus genotypes and subtypes in Portugal. <i>Scientific Reports</i> , 2018, 8, 12266.	3.3	16
981	Hepatitis C Virus. , 2018, , 3-11.		0
982	The Prevalence of Mixed Hepatitis C Virus Genotype Infection and Its Effect on the Response to Direct-Acting Antivirals Therapy. <i>Intervirology</i> , 2019, 62, 23-29.	2.8	2
983	Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-naïve subjects. <i>Antiviral Research</i> , 2019, 170, 104574.	4.1	17
984	Tracing the epidemic history of hepatitis C virus genotype 1b in Tunisia and in the world, using a Bayesian coalescent approach. <i>Infection, Genetics and Evolution</i> , 2019, 75, 103944.	2.3	3
985	Core encoding sequences of Hepatitis C virus in Ghanaian blood donors are predominantly mosaics of different genotype 2 strains and cannot distinguish subtypes. <i>BMC Infectious Diseases</i> , 2019, 19, 533.	2.9	2
986	A novel molecular mechanism to explain mutations of the HCV protease associated with resistance against covalently bound inhibitors. <i>Virus Research</i> , 2019, 274, 197778.	2.2	9
987	Alphavirus-based hepatitis C virus therapeutic vaccines: can universal helper epitopes enhance HCV-specific cytotoxic T lymphocyte responses?. , 2019, 7, 251513551987467.	2.3	2
988	The First Complete Genome Sequences of Hepatitis C Virus Subtype 2b from Latin America: Molecular Characterization and Phylogeographic Analysis. <i>Viruses</i> , 2019, 11, 1000.	3.3	2
989	DAA failures in African patients with "unusual" HCV subtypes: Hey! Didn't you know there was another world?. <i>Journal of Hepatology</i> , 2019, 71, 1070-1072.	3.7	17
990	Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 492-505.	3.7	14
991	A method for detecting hepatitis C envelope specific memory B cells from multiple genotypes using cocktail E2 tetramers. <i>Journal of Immunological Methods</i> , 2019, 472, 65-74.	1.4	15
992	Complete genome sequencing and evolutionary analysis of HCV subtype 6xg from IDUs in Yunnan, China. <i>PLoS ONE</i> , 2019, 14, e0217010.	2.5	8
993	Hepatitis C virus sequence divergence preserves p7 viroporin structural and dynamic features. <i>Scientific Reports</i> , 2019, 9, 8383.	3.3	13
995	Toward an Alignment-Free Method for Feature Extraction and Accurate Classification of Viral Sequences. <i>Journal of Computational Biology</i> , 2019, 26, 519-535.	1.6	20

#	ARTICLE	IF	CITATIONS
996	Reliable resolution of ambiguous hepatitis C virus genotype 1 results with the Abbott HCV Genotype Plus RUO assay. <i>Scientific Reports</i> , 2019, 9, 3678.	3.3	8
997	Human Pathobiochemistry. , 2019, , .		0
998	Detection Of Hepatitis C Virus (Hcv) Infection And Its Genotype In Patients At Hepatology Outpatient Clinic, Dr Soetomo General Hospital, Surabaya.. IOP Conference Series: Earth and Environmental Science, 2019, 217, 012051.	0.3	1
999	A case of genotype 3 hepatitis C virus in which the whole genome was successfully analyzed using third-generation nanopore sequencing. <i>Hepatology Research</i> , 2019, 49, 1083-1087.	3.4	7
1000	Subtype-Specific Prevalence of Hepatitis C Virus NS5A Resistance Associated Substitutions in Mainland China. <i>Frontiers in Microbiology</i> , 2019, 10, 535.	3.5	17
1001	Small, Smaller, Nano: New Applications for Potato Virus X in Nanotechnology. <i>Frontiers in Plant Science</i> , 2019, 10, 158.	3.6	39
1002	Phylogenetic analysis of hepatitis C virus among HIV/ HCV co-infected patients in Nigeria. <i>PLoS ONE</i> , 2019, 14, e0210724.	2.5	9
1003	A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 382-388.	1.6	3
1004	Statistical Linear Models in Virus Genomic Alignment-free Classification: Application to Hepatitis C Viruses. , 2019, , .		4
1005	Sequence variability of HCV 3a isolates based on core gene in patients from Lahore, Pakistan. <i>Future Virology</i> , 2019, 14, 641-653.	1.8	3
1006	A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1. <i>Journal of Virology</i> , 2019, 93, .	3.4	13
1007	A 2-year retrospective study of viral and host-associated risk factors in Pakistani hepatocellular carcinoma patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1103-1109.	1.6	2
1008	The nationwide distribution and trends of hepatitis C virus genotypes in mainland China. <i>Journal of Medical Virology</i> , 2019, 91, 401-410.	5.0	14
1009	Conserved and variable natural killer cell receptors: diverse approaches to viral infections. <i>Immunology</i> , 2019, 156, 319-328.	4.4	28
1010	Using high-throughput sequencing for investigating intra-host hepatitis C evolution over long retrospective periods. <i>Infection, Genetics and Evolution</i> , 2019, 67, 136-144.	2.3	3
1011	A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches. <i>Life Sciences</i> , 2019, 217, 176-184.	4.3	7
1012	Recombinant identification, molecular classification and proposed reference genomes for hepatitis delta virus. <i>Journal of Viral Hepatitis</i> , 2019, 26, 183-190.	2.0	13
1013	High prevalence of genotype 6 hepatitis C virus infection in Southern Taiwan using Abbott genotype assays. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 413-419.	1.7	25

#	ARTICLE	IF	CITATIONS
1014	Comparative genomics of hepatitis A virus, hepatitis C virus, and hepatitis E virus provides insights into the evolutionary history of <i>Hepatovirus</i> species. <i>MicrobiologyOpen</i> , 2020, 9, e973.	3.0	5
1015	Generation of Combinatorial Lentiviral Vectors Expressing Multiple Anti-Hepatitis C Virus shRNAs and Their Validation on a Novel HCV Replicon Double Reporter Cell Line. <i>Viruses</i> , 2020, 12, 1044.	3.3	5
1016	Hepatitis C virus genotypes and associated risk factors in the state of Pará, Northern Brazil. <i>Brazilian Journal of Infectious Diseases</i> , 2020, 24, 304-309.	0.6	6
1017	Hepatitis C virus genotype/subtype distribution and evolution among Chinese blood donors: Revealing recent viral expansion. <i>PLoS ONE</i> , 2020, 15, e0235612.	2.5	4
1018	Label-free RNA-based electrochemical nanobiosensor for detection of Hepatitis C. <i>Current Research in Biotechnology</i> , 2020, 2, 187-192.	3.7	8
1019	Molecular Characterization of Hepatitis C Virus for Developed Antiviral Agents Resistance Mutations and New Insights into in-silico Prediction Studies. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 4235-4248.	2.7	1
1020	Synthesis, Characterization and Docking Studies of Anti-HCV Molecules. <i>Asian Journal of Chemistry</i> , 2020, 32, 1221-1229.	0.3	0
1021	A safety and efficacy analysis of direct-antiviral therapy in patients with chronic hepatitis C after renal transplantation. <i>Translational Andrology and Urology</i> , 2020, 9, 583-590.	1.4	0
1022	CRISPR/CAS9-Mediated Antiviral Activity: A Tool to Combat Viral Infection. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2020, 30, 45-56.	0.9	2
1023	Dissection of two drug-targeted regions of Hepatitis C virus subtype 4a infecting Egyptian patients. <i>Virus Genes</i> , 2020, 56, 564-581.	1.6	4
1024	Domain I of hepatitis C virus NS5A associates with ACBD3 in a genotype-dependent manner. <i>Microbiology and Immunology</i> , 2020, 64, 574-577.	1.4	0
1025	CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN β -THALASSEMIA: PAST, PRESENT AND FUTURE PERSPECTIVES. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020006.	1.3	18
1026	An update on hepatitis C virus genotype distribution in Jordan: a 12-year retrospective study from a tertiary care teaching hospital in Amman. <i>BMC Infectious Diseases</i> , 2020, 20, 3.	2.9	6
1028	Hepatitis C Virus Origin. , 2021, , 45-53.		0
1029	Thiophen urea derivatives as a new class of hepatitis C virus entry inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021, 36, 462-468.	5.2	4
1030	Current HCC Clinical and Research in Egypt. , 2021, , 313-321.		1
1031	Classification, Genetic Diversity and Global Distribution of Hepatitis C Virus (HCV) Genotypes and Subtypes. , 2021, , 55-69.		1
1033	Validated High-performance Liquid Chromatography Method for the Determination of JW5624, A New Class Of Hepatitis C Virus Inhibitor, in Rat Plasma and its Application in the Pharmacokinetic Study of JW5624. <i>Drug Research</i> , 2021, 71, 312-316.	1.7	0

#	ARTICLE	IF	CITATIONS
1034	Genetic diversity of hepatitis C virus in Nanaian region, Khabarovsk territory. Russian Journal of Infection and Immunity, 2021, 11, 148-156.	0.7	1
1035	Evaluation of the Inflammatory Cytokines and IL-10 Network in Individuals Co-infected With Human T-Cell Lymphotropic Virus and Hepatitis C Virus (HTLV/HCV). Frontiers in Microbiology, 2021, 12, 632695.	3.5	1
1036	Identification of two novel hepatitis C virus subtype 2 from Tunisia (2v and 2w). PLoS ONE, 2021, 16, e0248249.	2.5	4
1037	Genotype distribution and risk factors in patients with chronic hepatitis C infection. Journal of Biotechnology and Strategic Health Research, 0, , .	1.8	0
1038	Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies. Vaccines, 2021, 9, 291.	4.4	11
1039	Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C. PLoS ONE, 2021, 16, e0249770.	2.5	5
1040	HCV genotype 1a. Acta Hepatologica Japonica, 2021, 62, 194-196.	1.6	0
1041	Prevalence of HCV genotypes and subtypes in Southeast Asia: A systematic review and meta-analysis. PLoS ONE, 2021, 16, e0251673.	2.5	11
1042	The genotype analysis of the hepatitis C virus in Heilongjiang Province, China. Medicine (United States), 2021, 100, e25203.	1.0	0
1043	A Review of Hepatitis C Virus: Prevalence, Genotype, Risk Factors in Pakistan Last Quarter of Century. Journal of Life and Bio Sciences Research, 2021, 2, 26-30.	0.2	0
1044	Hepatitis C Virus Subtypes Novel 6g-Related Subtype and 6w Could Be Indigenous in Southern Taiwan with Characteristic Geographic Distribution. Viruses, 2021, 13, 1316.	3.3	3
1045	Host-Targeting Antivirals for Treatment of Hepatitis C. , 0, , .		0
1046	Hepatitis C virus genotype 4: A poorly characterized endemic genotype. Journal of Medical Virology, 2021, 93, 6079-6088.	5.0	6
1047	Using host genetics to infer the global spread and evolutionary history of HCV subtype 3a. Virus Evolution, 2021, 7, veab065.	4.9	0
1048	Haplotype Network Analysis and Phylogenetic Tree Construction of Hepatitis C Virus (HCV) Isolated from Tuban, Indonesia. Research Journal of Pharmacy and Technology, 2021, , 4231-4235.	0.8	3
1049	Genetic Variability of NS5B Region of Hepatitis C Virus in Togo. Medical Journal of Viral Hepatitis, 2021, 5.3, 8-13.	0.1	1
1050	Evolution of the <scp>SARS-CoV-2</scp> proteome in three dimensions (3D) during the first 6 months of the <scp>COVID-19</scp> pandemic. Proteins: Structure, Function and Bioinformatics, 2022, 90, 1054-1080.	2.6	31
1051	Assessing hepatitis C virus distribution among vulnerable populations in London using whole genome sequencing: results from the TB-REACH study. Wellcome Open Research, 0, 6, 229.	1.8	0

#	ARTICLE	IF	CITATIONS
1052	Japanese Man with HCV Genotype 4 Infection and Cirrhosis Who was Successfully Treated by the Combination of Glecaprevir and Pibrentasvir. <i>Internal Medicine</i> , 2021, 60, 2061-2066.	0.7	1
1053	Focus on hepatitis C virus genotype distribution in Tunisia prior to elimination: a 16-year retrospective study. <i>Archives of Virology</i> , 2021, 166, 501-510.	2.1	3
1054	Hepatitis C Virus: Propagation, Quantification, and Storage. <i>Current Protocols in Microbiology</i> , 2010, 19, Unit 15D.1.	6.5	15
1055	Hepatitis Virus Resistance. , 2008, , 291-323.		2
1056	Substrate-Envelope-Guided Design of Drugs with a High Barrier to the Evolution of Resistance. , 2017, , 149-173.		1
1058	Prevention of Hepatitis C Virus Infection and Liver Cancer. <i>Recent Results in Cancer Research</i> , 2014, 193, 113-133.	1.8	16
1059	Natural History, Pathogenesis, and Prevention of HCV Infection. , 2012, , 11-19.		1
1060	microRNA-155 and microRNA-196b in Hepatitis C Virus Infection. <i>Biomarkers in Disease</i> , 2017, , 809-836.	0.1	1
1061	Single-nucleotide variants in human CD81 influence hepatitis C virus infection of hepatoma cells. <i>Medical Microbiology and Immunology</i> , 2020, 209, 499-514.	4.8	6
1063	Replication of Hepatitis C Virus. , 2012, , 97-110.		1
1064	Hepatitis C virus in vitro replication is efficiently inhibited by acridone Fac4. <i>Journal of General Virology</i> , 2017, 98, 1693-1701.	2.9	12
1065	Hepatitis C virus subtype 3a was introduced in the USSR in the early 1980s. <i>Journal of General Virology</i> , 2017, 98, 2079-2087.	2.9	3
1066	Assessment of cross-species transmission of hepatitis C virus-related non-primate hepacivirus in a population of humans at high risk of exposure. <i>Journal of General Virology</i> , 2015, 96, 2636-2642.	2.9	19
1069	Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro. <i>Journal of Clinical Investigation</i> , 2011, 121, 37-56.	8.2	290
1070	Occult HCV in Egyptian Volunteer Blood Donors. <i>The Egyptian Journal of Hospital Medicine</i> , 2013, 50, 103-107.	0.1	1
1071	Anti-hepatic fibrosis effects of traditional Chinese medicine: A review. <i>OA Inflammation</i> , 2013, 1, .	0.3	3
1072	A Novel Diagnostic Target in the Hepatitis C Virus Genome. <i>PLoS Medicine</i> , 2009, 6, e1000031.	8.4	48
1073	Hepatitis C Virus Diversity and Evolution in the Full Open-Reading Frame during Antiviral Therapy. <i>PLoS ONE</i> , 2008, 3, e2123.	2.5	45

#	ARTICLE	IF	CITATIONS
1074	Evidence of Recombination in Inpatient Populations of Hepatitis C Virus. PLoS ONE, 2008, 3, e3239.	2.5	54
1075	Genetic History of Hepatitis C Virus in Venezuela: High Diversity and Long Time of Evolution of HCV Genotype 2. PLoS ONE, 2010, 5, e14315.	2.5	21
1076	De Novo Polymerase Activity and Oligomerization of Hepatitis C Virus RNA-Dependent RNA-Polymerases from Genotypes 1 to 5. PLoS ONE, 2011, 6, e18515.	2.5	23
1077	A Possible Geographic Origin of Endemic Hepatitis C Virus 6a in Hong Kong: Evidences for the Association with Vietnamese Immigration. PLoS ONE, 2011, 6, e24889.	2.5	13
1078	Novel Nucleotide and Amino Acid Covariation between the 5'UTR and the NS2/NS3 Proteins of Hepatitis C Virus: Bioinformatic and Functional Analyses. PLoS ONE, 2011, 6, e25530.	2.5	2
1079	Bile Acids Specifically Increase Hepatitis C Virus RNA-Replication. PLoS ONE, 2012, 7, e36029.	2.5	23
1080	A Meta-Analysis of the Existing Knowledge of Immunoreactivity against Hepatitis C Virus (HCV). PLoS ONE, 2012, 7, e38028.	2.5	24
1081	Hepatitis C Virus in Vietnam: High Prevalence of Infection in Dialysis and Multi-Transfused Patients Involving Diverse and Novel Virus Variants. PLoS ONE, 2012, 7, e41266.	2.5	50
1082	Different HCV Genotype Distributions of HIV-Infected Individuals in Henan and Guangxi, China. PLoS ONE, 2012, 7, e50343.	2.5	24
1083	Correlation of Viral Loads with HCV Genotypes: Higher Levels of Virus Were Revealed among Blood Donors Infected with 6a Strains. PLoS ONE, 2012, 7, e52467.	2.5	20
1084	Prevalence of Hepatitis C Virus Subgenotypes 1a and 1b in Japanese Patients: Ultra-Deep Sequencing Analysis of HCV NS5B Genotype-Specific Region. PLoS ONE, 2013, 8, e73615.	2.5	29
1085	Hepatitis C Virus Diversification in Argentina: Comparative Analysis between the Large City of Buenos Aires and the Small Rural Town of O'Brien. PLoS ONE, 2013, 8, e84007.	2.5	6
1086	Characteristics of HCV Co-Infection among HIV Infected Individuals from an Area with High Risk of Blood-Borne Infections in Central China. PLoS ONE, 2014, 9, e94219.	2.5	6
1087	MicroRNAs as Predictor Markers for Response to Interferon Treatment of Chronic Hepatitis C Genotype-4 in Egyptian Patients. PLoS ONE, 2015, 10, e0121524.	2.5	13
1088	Genotypic Distribution of Hepatitis C Virus in Thailand and Southeast Asia. PLoS ONE, 2015, 10, e0126764.	2.5	65
1089	The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis. PLoS ONE, 2015, 10, e0131437.	2.5	48
1090	In Silico Design and Experimental Validation of siRNAs Targeting Conserved Regions of Multiple Hepatitis C Virus Genotypes. PLoS ONE, 2016, 11, e0159211.	2.5	27
1091	The Phylogeographic and Spatiotemporal Spread of HCV in Pakistani Population. PLoS ONE, 2016, 11, e0164265.	2.5	4

#	ARTICLE	IF	CITATIONS
1092	Partial sequencing analysis of the NS5B region confirmed the predominance of hepatitis C virus genotype 1 infection in Jeddah, Saudi Arabia. PLoS ONE, 2017, 12, e0178225.	2.5	9
1093	Genetic diversity of hepatitis C virus in Ethiopia. PLoS ONE, 2017, 12, e0179064.	2.5	14
1094	Molecular characterization and epidemic history of hepatitis C virus using core sequences of isolates from Central Province, Saudi Arabia. PLoS ONE, 2017, 12, e0184163.	2.5	8
1095	Prevalence of HCV Infection in Adults with Congenital Heart Disease and Treatment with Direct Antiviral Agents. Southern Medical Journal, 2018, 111, 137-141.	0.7	2
1096	MOLECULAR EPIDEMIOLOGY FEATURES OF HEPATITIS C VIRUS ISOLATES FROM DIFFERENT REGIONS OF THE REPUBLIC SAKHA (YAKUTIA). Russian Journal of Infection and Immunity, 2016, 5, 359-372.	0.7	3
1097	Interferon-induced parkinsonism in a patient with chronic hepatitis C. Arquivos De Neuro-Psiquiatria, 2009, 67, 715-716.	0.8	6
1098	Prevalência, fatores de risco e genótipos da hepatite C entre usuários de drogas. Revista De Saude Publica, 2009, 43, 43-50.	1.7	38
1100	Pathogenesis of hepatitis C: HCV consensus 2007. Brazilian Journal of Infectious Diseases, 0, 11, 14-19.	0.6	1
1101	Hepatitis C: genotyping. Brazilian Journal of Infectious Diseases, 0, 11, .	0.6	4
1102	Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy. Oncotarget, 2016, 7, 61325-61335.	1.8	7
1103	Efficacy of Peginterferon alfa-2a and Ribavirin Combination Therapy in Treatment-naive Estonian Patients with Chronic Hepatitis C. Central European Journal of Public Health, 2012, 20, 150-155.	1.1	5
1104	Underlying Pathways for Interferon Risk to Type II Diabetes Mellitus. Current Diabetes Reviews, 2013, 9, 472-477.	1.3	6
1105	Development of a Flow Cytometry Live Cell Assay for the Screening of Inhibitors of Hepatitis C Virus (HCV) Replication. The Open Virology Journal, 2012, 6, 97-102.	1.8	7
1106	Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells. The Open Virology Journal, 2014, 8, 1-8.	1.8	6
1107	Hepatitis C crónica: aspectos clínicos, serológicos y de tratamiento en dos centros de atención en Bogotá, Colombia. Revista Colombiana De Gastroenterologia, 2014, 29, 424-432.	0.2	2
1109	Diagnosis and monitoring of chronic viral hepatitis serologic and molecular markers. Frontiers in Bioscience - Scholar, 2011, S3, 156-167.	2.1	3
1110	Molecular epidemiology of hepatitis C virus genotypes and subtypes among injecting drug users in Hungary. Eurosurveillance, 2013, 18, .	7.0	10
1111	Development of Preventive Vaccines for Hepatitis C Virus E1/E2 Protein. , 2018, 13, 113-124.		2

#	ARTICLE	IF	CITATIONS
1112	Evolution and Diversity of Hepatitis C Virus and Peculiarity of Modern Laboratory Diagnostic of Hepatitis C Markers. <i>Epidemiologiya I Vaktsinoprofilaktika</i> , 2015, 14, 23-30.	0.8	2
1113	Coordinated evolution among hepatitis C virus genomic sites is coupled to host factors and resistance to interferon. <i>In Silico Biology</i> , 2011, 11, 213-24.	0.9	10
1114	Current Standards in the Treatment of Chronic Hepatitis C. <i>Deutsches A&#x0308;rzteblatt International</i> , 2012, 109, 352-8.	0.9	20
1115	Hepatitis C virus and dental health workers: an update. <i>Oral Health & Preventive Dentistry</i> , 2014, 12, 313-21.	0.5	5
1116	KASL clinical practice guidelines: Management of Hepatitis C. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 89.	8.9	35
1117	KASL clinical practice guidelines: management of hepatitis C. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 76-139.	8.9	68
1119	New Antiviral Agents for Hepatitis C. <i>F1000 Biology Reports</i> , 2012, 4, 5.	4.0	30
1120	Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006. <i>World Journal of Gastroenterology</i> , 2008, 14, 1237.	3.3	48
1121	Genetic diversity of the hepatitis C virus: Impact and issues in the antiviral therapy. <i>World Journal of Gastroenterology</i> , 2007, 13, 2416.	3.3	79
1122	Sequence diversity of hepatitis C virus: Implications for immune control and therapy. <i>World Journal of Gastroenterology</i> , 2007, 13, 4808.	3.3	82
1123	Steatosis as a co-factor in chronic liver diseases. <i>World Journal of Gastroenterology</i> , 2010, 16, 1171.	3.3	42
1124	Distribution of different hepatitis C virus genotypes in patients with hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2010, 16, 2005.	3.3	24
1125	Prevalence of hepatitis C infection among intravenous drug users in Shanghai. <i>World Journal of Gastroenterology</i> , 2013, 19, 5320.	3.3	10
1126	Molecular epidemiology and putative origin of hepatitis C virus in random volunteers from Argentina. <i>World Journal of Gastroenterology</i> , 2013, 19, 5813.	3.3	15
1127	Challenges in managing hepatitis C virus infection in cancer patients. <i>World Journal of Gastroenterology</i> , 2014, 20, 2771.	3.3	31
1128	Understanding the interaction of hepatitis C virus with host DEAD-box RNA helicases. <i>World Journal of Gastroenterology</i> , 2014, 20, 2913.	3.3	28
1129	Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging. <i>World Journal of Gastroenterology</i> , 2014, 20, 3431.	3.3	35
1130	Autophagy in hepatitis C virus-host interactions: Potential roles and therapeutic targets for liver-associated diseases. <i>World Journal of Gastroenterology</i> , 2014, 20, 5773.	3.3	36

#	ARTICLE	IF	CITATIONS
1131	Virus-related liver cirrhosis: Molecular basis and therapeutic options. <i>World Journal of Gastroenterology</i> , 2014, 20, 6457.	3.3	43
1132	Impact of hepatitis C virus heterogeneity on interferon sensitivity: An overview. <i>World Journal of Gastroenterology</i> , 2014, 20, 7555.	3.3	40
1133	Progress in the development of vaccines for hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2015, 21, 11984.	3.3	33
1134	HCV-Core Region: Its Significance in HCV-Genotyping and Type Dependent Genomic Expression. <i>Macedonian Journal of Medical Sciences</i> , 2012, 5, 30-39.	0.0	3
1135	Computational Approaches for the Discovery of Novel Hepatitis C Virus NS3/4A and NS5B Inhibitors. , 2017, , 482-518.		1
1136	Understanding the mechanism of hepatic fibrosis and potential therapeutic approaches. <i>Saudi Journal of Gastroenterology</i> , 2012, 18, 155.	1.1	86
1137	Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infectionâ€”A brief review of literature. <i>Journal of Family Medicine and Primary Care</i> , 2020, 9, 531.	0.9	9
1138	Molecular Docking and Molecular Dynamic Simulation: Insight into the Difference in Binding of HCV NS3/4A Macrocyclic Inhibitors to Genotypes 1b and 4a. <i>Drug Designing: Open Access</i> , 2015, 04, .	0.2	2
1139	Fuzzy Logic Strategy for Solving an Optimal Control Problem of Therapeutic Hepatitis C Virus Dynamics. <i>Open Journal of Applied Sciences</i> , 2015, 05, 527-541.	0.4	3
1140	Hepatitis C genotype 6: A concise review and response-guided therapy proposal. <i>World Journal of Hepatology</i> , 2013, 5, 496.	2.0	26
1141	Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees. <i>World Journal of Hepatology</i> , 2015, 7, 53.	2.0	14
1142	Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease. <i>World Journal of Hepatology</i> , 2015, 7, 616.	2.0	28
1143	Impact of all oral anti-hepatitis C virus therapy: A meta-analysis. <i>World Journal of Hepatology</i> , 2015, 7, 806.	2.0	50
1144	Hepatitis C virus and non-Hodgkinâ€™s lymphomas: Meta-analysis of epidemiology data and therapy options. <i>World Journal of Hepatology</i> , 2016, 8, 107.	2.0	52
1146	Interferons and hepatitis C virus. <i>Swiss Medical Weekly</i> , 2012, 142, w13586.	1.6	23
1147	Gut immune response in the presence of hepatitis C virus infection. <i>World Journal of Immunology</i> , 2014, 4, 52.	0.5	22
1148	The Prevalence and Subtype Distribution of Hepatitis C Virus Infection among Hemodialysis Patients in a Private Hospital in Surabaya, Indonesia. <i>Microbiology Indonesia</i> , 2012, 6, 173-179.	0.3	4
1149	The follow-up results with sustained virologic response in chronic hepatitis C patients in Åžanlıurfa/Turkey. <i>Journal of Microbiology and Infectious Diseases</i> , 2012, 2, 141-20.	0.1	2

#	ARTICLE	IF	CITATIONS
1150	Hepatitis C Virus Genotypes and Association With Viral Load in Yazd, Central Province of Iran. <i>Hepatitis Monthly</i> , 2014, 14, e11705.	0.2	19
1151	Molecular Epidemiology of Different Hepatitis C Genotypes in Serum and Peripheral Blood Mononuclear Cells in Jahrom City of Iran. <i>Hepatitis Monthly</i> , 2014, 14, e16391.	0.2	14
1152	Evaluation of Multiplex Nested Polymerase Chain Reaction for Routine Hepatitis C Virus Genotyping in Egyptian Patients. <i>Hepatitis Monthly</i> , 2012, 12, 265-270.	0.2	3
1153	Comparative Phylogenetic and Residue Analysis of Hepatitis C Virus E1 Protein from the Middle East and North Africa Region. <i>Hepatitis Monthly</i> , 2019, 19, .	0.2	1
1154	Distribution of Hepatitis C Virus Genotypes and Related Risk Factors Among Iranian Blood Donors: A Penalized Logistic Regression. <i>Jundishapur Journal of Microbiology</i> , 2018, 11, .	0.5	2
1155	Automated, phylogeny-based genotype delimitation of the Hepatitis Viruses HBV and HCV. <i>PeerJ</i> , 2019, 7, e7754.	2.0	3
1156	Inhibition of viral RNA-dependent RNA polymerases with clinically relevant nucleotide analogs. <i>The Enzymes</i> , 2021, 49, 315-354.	1.7	9
1157	Hepatitis D _{ij} in Russia and the Northwest federal region of Russia: results of the first stage the global programme of infection elimination. <i>HIV Infection and Immunosuppressive Disorders</i> , 2021, 13, 40-51.	0.3	2
1158	The bioinformatics analysis of hepatitis C virus E2 protein. , 2007, , .		0
1159	Controversies in and challenges to our understanding of hepatitis C. <i>World Journal of Gastroenterology</i> , 2007, 13, 4168.	3.3	1
1160	Recent advances in hepatitis C virus research and understanding the biology of the virus. <i>World Journal of Gastroenterology</i> , 2007, 13, 2404.	3.3	2
1161	Blood Borne and Sexual Transmission: Hepatitis B and C. <i>Statistics in the Health Sciences</i> , 2009, , 333-356.	0.2	0
1163	Hepatitis C Virus. , 2009, , 47-69.		1
1164	Hepatitis C Virus. , 2010, , 253-256.		0
1165	Function of nonstructural 5A protein of genotype 2a in replication and infection of HCV with gene substitution. <i>World Journal of Gastroenterology</i> , 2011, 17, 3398.	3.3	1
1167	Viral Hepatitis C. , 2011, , 427-432.		2
1169	Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C. <i>Journal of the Nepal Medical Association</i> , 2013, 51, .	0.4	1
1170	Mutations and the Development of Anti-viral Resistance. , 2012, , 227-249.		0

#	ARTICLE	IF	CITATIONS
1171	Correlation between a single nucleotide polymorphism (G/T at nt 88) in the Mx1 gene promoter and the response to interferon therapy for hepatitis C virus in Egyptian patients. African Journal of Biotechnology, 2011, 10, .	0.6	0
1173	Occult Hepatitis C Virus Infection: Where are We Now?. , 0, , .		0
1174	Immune Modulators and Other Agents. , 2012, , 131-148.		0
1175	Hepatitis C Virus (HCV) Genotype Assay (LiPA). , 2012, , 141-151.		0
1176	Hepatitis C Virus. , 2012, , 1105-1112.e4.		1
1178	The markers predicting response to Hepatitis C virus treatment and evaluation of treatment responses. Journal of Microbiology and Infectious Diseases, 2012, 2, 100-108.	0.1	0
1179	ANALYSIS OF THE INFLUENCE OF GENETIC FACTORS OF HEPATITIS C VIRUS AND GENE POLYMORPHISM IN INFECTED PATIENTS ON THE DEVELOPMENT OF LIVER FIBROSIS. Epidemiology and Infectious Diseases (Russian Journal), 2012, 17, 7-13.	0.1	3
1180	Expression and Functions of Hepatitis C Virus F Protein. , 2012, , 271-291.		0
1181	Advances in the Diagnosis and Monitoring of Hepatitis C Virus Infection. Gastroenterology Research, 2013, 6, 161-170.	1.3	10
1182	Viral Arthritis. , 2013, , 1865-1874.e3.		0
1183	Evaluation of IL-8 Level in Hepatitis C Infected Patients : Relation to Combined Peg-Interferon / Ribavirin Treatment Response. Egyptian Journal of Medical Microbiology, 2013, 22, 139-148.	0.2	0
1185	Hepatitis C Virus Testing. , 2014, , 57-80.		0
1186	Infections of the Liver. , 2014, , 285-312.		1
1187	Effect of Differentially Expressed MicroRNAs 602 and 323-5p on Hepatitis C Virus Genotype 1b Viral Load in Infected Liver Cells. Journal of Infectious Disease and Therapy, 2014, 02, .	0.1	1
1188	Viral Factors Associated with Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection. Journal of Antivirals & Antiretrovirals, 2014, S3, .	0.1	0
1189	Molecular detection of the Hepatitis C virus genotypes circulating among both sexes of Khyber Pakhtunkhwa, Pakistan. Asian Journal of Medical Sciences, 2014, 5, 72-76.	0.1	0
1190	Plasticity of the Hepatitis C Virus Genome. , 0, , 178-190.		0
1191	Clinical Aspects of Hepatitis C Virus Infection. , 0, , 241-264.		0

#	ARTICLE	IF	CITATIONS
1192	The Impact of Pegylated-Interferon- α plus Ribavirin on Prolactinemia and Testosteronemia among Hepatitis C-Genotype-4a Patients. <i>Open Journal of Biochemistry</i> , 2014, 1, 25-36.	0.2	0
1193	Spectrum of Incidentally Detected Hepatitis C Virus Infection in Southern India- A Prospective Study. <i>Global Journal of Gastroenterology & Hepatology</i> , 2014, 2, 69-73.	0.1	0
1194	GENOME ORGANIZATION AND GEOGRAPHICAL DISTRIBUTION OF THE NATURAL INTERGENOTYPIC RECOMBINANT OF HEPATITIS C VIRUS RF1_2k/1b. <i>Russian Journal of Infection and Immunity</i> , 2014, 2, 677.	0.7	3
1195	Retrospective Study of Hepatitis C Virus Genotypes and its Association with Lymphoma. <i>Journal of Cancer Research Updates</i> , 2014, 3, 129-133.	0.3	0
1196	Molecular epidemiology of Hepatitis C Virus (HCV) in liver disease patients in Sri Lanka. <i>Asian Journal of Medical Sciences</i> , 2014, 6, 1-5.	0.1	2
1197	Generation and Characterisation of HCV Genotype 1 Viruses Most Recent Common Ancestor. <i>Egyptian Journal of Medical Microbiology</i> , 2015, 24, 49-57.	0.2	0
1198	Computational Approaches for the Discovery of Novel Hepatitis C Virus NS3/4A and NS5B Inhibitors. <i>Advances in Chemical and Materials Engineering Book Series</i> , 2015, , 318-353.	0.3	0
1199	Peculiarity of Clinical Course of Childhood Hepatitis C Depending on the Viral Genotype. <i>Epidemiologiya i Vaktsinoprofilaktika</i> , 2015, 14, 49-55.	0.8	1
1200	Taxonomy and Classification of Viruses. , 0, , 1390-1404.		4
1201	HEPATITIS C VIRUS AND HEPATITIS C-INFECTION. <i>Brazilian Journal of Medicine and Human Health</i> , 2015, 3, 19-28.	0.0	0
1204	Hepatitis C Virus Genotypes and Their Evolution. , 2016, , 15-29.		0
1206	Tackling HCV-3 in Asia: Breakthroughs for Efficient and Cost-effective Treatment Strategies. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2016, 6, 35-42.	0.5	0
1207	Human MicroRNA-602 Inhibits Hepatitis C Virus Genotype 1b Infection and Promotes Tumor Suppressor Gene Expression in a Hepatoma Cell Line. <i>Journal of Virology & Antiviral Research</i> , 2016, 5, .	0.1	0
1208	Genotyping of Hepatitis C Virus (HCV) in Patients of Basra Province/Iraq. <i>International Journal of Innovative Research in Science, Engineering and Technology</i> , 2016, 5, 10363-10368.	0.4	1
1209	Synonymous Co-Variation across the E1/E2 Gene Junction of Hepatitis C Virus Defines Virion Fitness. <i>PLoS ONE</i> , 2016, 11, e0167089.	2.5	0
1210	The Role of MicroRNA in Hepatitis C Virus Replication. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 1, 125-30.	1.4	0
1211	The Prevalence of Hepatitis C Virus Genotypes in Mazandaran Province, Iran. <i>Jundishapur Journal of Microbiology</i> , 2017, In press, .	0.5	2
1212	Resistance to Cyclophilin Inhibitors. , 2017, , 59-85.		0

#	ARTICLE	IF	CITATIONS
1213	Hepatitis C Virus in the Renal Transplant Population: An Update With Focus on the New Era of Antiviral Regimens. <i>Experimental and Clinical Transplantation</i> , 2017, 15, 10-20.	0.5	0
1215	Diverse Genotypes of Hepatitis C Virus in Voluntary Blood Donors in Shanghai, China. <i>Hepatitis Monthly</i> , 2017, 17, .	0.2	2
1216	Distribution of HCV Genotypes and RNA Viral Load Along with Hemato-Biochemical Analysis of HCV Patients in Rahim Yar Khan, Okara and Toba Tek Singh Districts of Punjab, Pakistan. <i>Hepatitis Monthly</i> , 2017, 17, .	0.2	1
1217	Individual-psychological predictors of formation of dysadaptation states in doctors-interns. <i>ScienceRise: Medical Science</i> , 2017, .	0.0	0
1218	Study of the structure of hepatitis c virus, which circulate among the population of the region of Ukraine with an average degree of urbanization. <i>ScienceRise: Medical Science</i> , 2017, .	0.0	1
1219	Relation of Hepatitis C and Its Severity Assessed by PCR to the Presence and Severity of Coronary Artery Disease Assessed by Syntax Score. <i>The Egyptian Journal of Hospital Medicine</i> , 2018, 70, 1409-1415.	0.1	0
1220	Phylogenetic Analysis and Genotyping Distribution of Hepatitis C Virus Isolates Based on the 5'Untranslated Region among some Egyptian Populations. <i>Journal of Agricultural Chemistry and Biotechnology</i> , 2018, 9, 21-26.	0.1	0
1221	Epidemiology and Molecular Detection of HAV, HBV, and HCV in Patients with Acute Hepatitis Symptoms in Ahvaz. <i>Jundishapur Journal of Microbiology</i> , 2018, 11, .	0.5	0
1224	Chronic hepatitis C: modern condition of the problem. <i>Nephrology (Saint-Petersburg)</i> , 2019, 23, 36-46.	0.4	2
1225	Evolution, classification and genotypes of HCV: the clinical significance of determining HCV genotypes. <i>International Journal of Medical Science</i> , 2019, 6, 11-16.	0.1	0
1226	PROFILE OF HCV GENOTYPES AND HIV-SUBTYPES AMONG HIV-COINFECTED PATIENTS IN SOUTHERN BRAZIL. <i>Arquivos De Gastroenterologia</i> , 2019, 56, 344-350.	0.8	3
1228	Infection with hepatitis C virus in hemodialysis patients: An overview of the diagnosis and prevention rules within a hemodialysis center (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 109-116.	1.8	8
1229	Treatment of Chronic Hepatitis C with Different Genotypes. , 2008, , 130-147.		2
1231	Correlation of the 5'untranslated region (5'UTR) and non-structural 5B (NS5B) nucleotide sequences in hepatitis C virus subtyping. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2010, 1, 236-44.	0.4	6
1232	Overcoming hurdles in hepatitis C virus research: efficient production of infectious virus in cell culture. <i>International Journal of Biomedical Science</i> , 2008, 4, 82-8.	0.1	0
1233	Very high prevalence of hepatitis C virus genotype 6 variants in southern Vietnam: large-scale survey based on sequence determination. <i>Japanese Journal of Infectious Diseases</i> , 2011, 64, 537-9.	1.2	28
1234	Success of antiviral therapy in chronic hepatitis C infection relates to functional status of myeloid dendritic cells. <i>Indian Journal of Medical Research</i> , 2013, 138, 766-78.	1.0	4
1236	HCV infection treatment: a future full of hope. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2013, 6, 1-5.	0.6	65

#	ARTICLE	IF	CITATIONS
1237	Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study. <i>Hippokratia</i> , 2014, 18, 57-64.	0.3	5
1238	Molecular and contextual markers of hepatitis C virus and drug abuse. <i>Molecular Diagnosis and Therapy</i> , 2009, 13, 153-79.	3.8	3
1239	Genetic Diversity of Hepatitis C Virus Among Blood Donors and Patients with Clinical Hepatitis in Ibadan, Nigeria. <i>Archives of Basic and Applied Medicine</i> , 2018, 6, 79-85.	0.4	2
1240	Development of Preventive Vaccines for Hepatitis C Virus E1/E2 Protein. <i>Iranian Journal of Pathology</i> , 2018, 13, 113-124.	0.5	0
1241	Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance. <i>Antiviral Research</i> , 2022, 197, 105224.	4.1	4
1242	Virus-Like Particles Containing the E2 Core Domain of Hepatitis C Virus Generate Broadly Neutralizing Antibodies in Guinea Pigs. <i>Journal of Virology</i> , 2022, 96, JVI0167521.	3.4	8
1243	Repurposing Novel Antagonists for Targeting p7 Viroporin of HCV Using In Silico Approach. <i>Letters in Drug Design and Discovery</i> , 2022, 19, 969-981.	0.7	0
1244	The Human Liver-Expressed Lectin CD302 Restricts Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2022, 96, e0199521.	3.4	4
1245	Next-Generation Sequencing for Confronting Virus Pandemics. <i>Viruses</i> , 2022, 14, 600.	3.3	24
1253	Three type 6 hepatitis C virus subgroups among blood donors in the Yangon area of Myanmar are identified as subtypes 6m and 6n, and a novel subtype by sequence analysis of the core region. <i>Acta Medica Okayama</i> , 2006, 60, 345-9.	0.2	4
1254	Pegylated interferon treatment in HCV genotype 2 and 3 patients refractory to conventional interferon. <i>Journal of the College of Physicians and Surgeons-Pakistan: JCPSP</i> , 2012, 22, 615-6.	0.4	0
1256	Interferon-alfa: um interferente endócrino. , 2021, , 95-122.		0
1257	Hepatite C. , 2021, , 29-52.		0
1258	O vírus da Hepatite C e a Hepatite C. , 2021, , 53-76.		0
1259	Mapping Natural Polymorphisms of Hepatitis C virus NS3/4A Protease and Antiviral Resistance to Inhibitors in Worldwide Isolates. <i>Antiviral Therapy</i> , 2008, 13, 481-494.	1.0	63
1260	Pegylated Interferon- α 2b plus Ribavirin: An Efficacious and well-Tolerated Treatment Regimen for Patients with Hepatitis C virus Related Histologically Proven Cirrhosis. <i>Antiviral Therapy</i> , 2008, 13, 663-673.	1.0	35
1261	Very High Prevalence of Hepatitis C Virus Genotype 6 Variants in Southern Vietnam: Large-Scale Survey Based on Sequence Determination. <i>Japanese Journal of Infectious Diseases</i> , 2011, 64, 537-539.	1.2	41
1263	Genetic Diversity of Hepatitis C Virus and Resistance Associated Substitutions to Direct-Acting Antiviral Treatment in Colombia. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
1264	Genetic diversity of hepatitis C virus and resistance associated substitutions to direct-acting antiviral treatment in Colombia. <i>Virus Research</i> , 2022, 318, 198847.	2.2	0
1265	Epidemiology, risk factors, and pathogenesis associated with a superbug: A comprehensive literature review on hepatitis C virus infection. <i>SAGE Open Medicine</i> , 2022, 10, 205031212211059.	1.8	2
1266	A Hepatitis C virus genotype 1b post-transplant isolate with high replication efficiency in cell culture and its adaptation to infectious virus production in vitro and in vivo. <i>PLoS Pathogens</i> , 2022, 18, e1010472.	4.7	5
1267	The role of serum <i>Wisteria floribunda</i> agglutinin-positive Mac-2 binding protein in the assessment of fibrosis in children with chronic hepatitis C. <i>Scientific Reports</i> , 2022, 12, .	3.3	1
1268	Extrahepatic manifestations of chronic viral hepatitis C. <i>Vestnik of Russian Military Medical Academy</i> , 2022, 24, 341-352.	0.3	0
1269	A proposed disease classification system for duck viral hepatitis. <i>Poultry Science</i> , 2022, , 102042.	3.4	0
1270	Small molecule NS5B RdRp non-nucleoside inhibitors for the treatment of HCV infection: A medicinal chemistry perspective. <i>European Journal of Medicinal Chemistry</i> , 2022, 240, 114595.	5.5	4
1271	HCV 6a was expanding and became the predominant subtype among blood donors between 2004 and 2019 in Guangdong, China. <i>Virologica Sinica</i> , 2022, 37, 765-768.	3.0	1
1272	Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 0, 64, .	1.1	1
1273	Hepatitis C virus data analysis and prediction using machine learning. <i>Data and Knowledge Engineering</i> , 2022, 142, 102087.	3.4	8
1275	Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital. <i>Tropical Medicine and Infectious Disease</i> , 2023, 8, 92.	2.3	0
1276	The Role of Cytosolic Lipid Droplets in Hepatitis C Virus Replication, Assembly, and Release. <i>BioMed Research International</i> , 2023, 2023, 1-15.	1.9	4
1277	Sub-genotypes of hepatitis C virus in the Middle East and North Africa: Patterns of distribution and temporal changes. <i>Infection, Genetics and Evolution</i> , 2023, 109, 105412.	2.3	2
1279	Malignancy and viral infections in Sub-Saharan Africa: A review. <i>Frontiers in Virology</i> , 0, 3, .	1.4	1
1280	Virological characterization of treatment failures and retreatment outcomes in patients infected with "unusual" HCV genotype 1 subtypes. <i>Hepatology</i> , 2023, 78, 607-620.	7.3	3
1282	Computational identification of a multi-peptide vaccine candidate in E2 glycoprotein against diverse Hepatitis C virus genotypes. <i>Journal of Biomolecular Structure and Dynamics</i> , 0, , 1-18.	3.5	1
1283	Growth history of hepatitis C virus among HIV/HCV co-infected patients in Guizhou Province. <i>Frontiers in Genetics</i> , 0, 14, .	2.3	0
1284	Genomic analysis of circulating HIV and hepatitis C virus infections and coinfections in Cameroon: 2005–2006 and 2015–2016. <i>Frontiers in Tropical Diseases</i> , 0, 4, .	1.4	0

#	ARTICLE	IF	CITATIONS
1286	Genotype Distribution and Characteristics of Chronic Hepatitis C Infection in Estonia, Latvia, Lithuania, and Ukraine: The RESPOND-C Study. <i>Medicina (Lithuania)</i> , 2023, 59, 1577.	2.0	0
1287	Hepatitis C Virus Genotyping from anti-HCV Negative Sera in Blood Donors. <i>Journal of Pure and Applied Microbiology</i> , 2023, 17, 1926-1932.	0.9	0
1288	Metabolic, renal, and hematological changes in chronic hepatitis C patients achieving rapid virologic response after 12 weeks of direct-acting antiviral treatment: A prospective cohort study. <i>PLoS ONE</i> , 2023, 18, e0290235.	2.5	1
1289	HCV Phylogenetic Classification. , 0, , .		0
1290	Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral Agents. <i>Clinical Pharmacokinetics</i> , 2023, 62, 1365-1392.	3.5	0
1291	Chronic Hepatitis C and Oncohematological Diseases. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2023, 16, 46-53.	0.4	0
1292	Hepatitis C virus prevalence among men who have sex with men: a cross-sectional study in 12 Brazilian cities. <i>BMC Infectious Diseases</i> , 2023, 23, .	2.9	0
1293	Molecular testing in emerging infectious diseases. , 2024, , 175-198.		0
1294	Modulation of the replication of positive-sense RNA viruses by the natural plant metabolite xanthohumol and its derivatives. <i>Critical Reviews in Food Science and Nutrition</i> , 0, , 1-15.	10.3	0
1295	A novel candidate hepatitis C virus genotype 4 subtype identified by next generation sequencing full-genome characterization in a patient from Saudi Arabia. <i>Frontiers in Microbiology</i> , 0, 14, .	3.5	0
1296	Optimizing HCV Disease Prediction in Egypt: The hyOPTGB Framework. <i>Diagnostics</i> , 2023, 13, 3439.	2.6	0
1297	Genetic history of hepatitis C virus genotype 6 in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2023, , .	1.7	0
1298	NeTaGFT: A similarity network-based method for trait analysis. <i>Methods in Ecology and Evolution</i> , 0, , .	5.2	0
1299	HCV Genotype Distribution and Clinical Characteristics of HCV Mono-Infected and HCV/HIV Co-Infected Patients in Liangshan Prefecture, Sichuan Province, China. <i>Journal of the International Association of Providers of AIDS Care</i> , 2023, 22, .	1.5	0
1300	A panel of hepatitis C virus glycoproteins for the characterization of antibody responses using antibodies with diverse recognition and neutralization patterns. <i>Virus Research</i> , 2024, 341, 199308.	2.2	0
1301	Machine learning-based approach KEVOLVE efficiently identifies SARS-CoV-2 variant-specific genomic signatures. <i>PLoS ONE</i> , 2024, 19, e0296627.	2.5	0
1302	Distribui�o dos gen�tipos do HCV em pacientes das regi�es de Botucatu, Bauru e Assis, SP, Brasil. <i>Revista Do Instituto Adolfo Lutz</i> , 2006, 65, 137-140.	0.1	0